var title_f23_24_23936="Dense RBCs in beta thalassemia";
var content_f23_24_23936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dense red cells in beta thalassemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Analysis of the density distribution of normal erythrocytes (A), erythrocytes from a nonsplenectomized individual with beta-thalassemia intermedia (B), erythrocytes from a splenectomized individual with beta thalassemia intermedia (C), and HbH erythrocytes (D) on discontinuous Stractan density gradients. The more dense cells are at the bottom of the gradient; dense populations are present only in the nonsplenectomized and splenectomized subjects with beta thalassemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Schrier, SL, Rachmilevitz, E, Mohandas, N. Cellular and membrane properties of alpha and beta thalassemic erythrocytes are different: Implication for differences in clinical manifestations. Blood 1989; 6:2194. Copyright &copy; 1989 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23936=[""].join("\n");
var outline_f23_24_23936=null;
var title_f23_24_23937="Frozen fingers in NSF";
var content_f23_24_23937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Picture showing thickened skin in hands of patient with nephrogenic system fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 364px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFsAZEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwL4r/APJUvGP/AGGbz/0e9crXVfFf/kqXjH/sM3n/AKPeuVoAKKKKACiiigAooooAKKKKACiiigAooooAKK3fCHhLXfGGpGx8OabPfTgZfYAFjHqzHAUfU16iv7M3j82/mEaQHxnyjdnd9M7cfrQOzPEaK6/xt8N/FngoeZ4i0ae2ti20XKESRE9hvUkD6HFcjQISiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA6r4r/8lS8Y/wDYZvP/AEe9crXVfFf/AJKl4x/7DN5/6PeuVoAKKKKACiiigAooooAK7D4b/D3XPH+qG10aFUt4iPtF3NkRQg+p7n0Uc1k+DfD914q8T6dotjkTXcoQtjIRerMfoMmv0H8DeFtO8K+HrbSdIiENtCMA/wATt3dvVj1NZ1KnIvM0hBNcz2PIfDn7LvhiGBTrerapfXGPm8nbAmfYYY/rVLxh+yzpTWU0vhTWbu3uwMpDfbZI2PpuUAr9cGvpKJSgADbhjqaWdgI2yccdax9tJRuwersj8yvEmhal4a1q50rWrV7W+t22ujd/Qg9CD1BFS+EPDt94r8RWej6Wm64uXxuI+WNf4nb2A5r7V+JvgDQPHtq8eqqYb+NSLa/iH7yLrwf7y5/hP4Yqh8BPhKvgTT7u71J4bjWbtynnR8qkIPyhc8/Nwx/AdqpYmLhzdTWWHcJe9segfDjwlpXgvw1baVokAREAM0zAb55Mcu3ufTsOK6cz4Y8Hb60yFY41Hl8DpxUcrpIsiRMGZfvqOSDXK6kt76k2UpeRFqwtr2xmtb23juLWdCjxyKGR1PUMD2r44+NvwRuPDJutd8KI91oO7fLbDLS2YP8A6FH/ALXUd/WvrC93QRA+Z8wPK4ODWVJqTRSqe5yMf0qYYmUJanbHBKpH3T88aDX1D8U/ganiTV7LU/Asdvay3kwS9tCdsUef+WyDsOu5R9R3r1DwB8C/BPhe1RLzT4ta1ML+9uL5N4J/2UPygfmfevQVWDSdzgnRlBtSPg6iv0c1f4aeCtWtzDd+F9IIxgMlqsbD6MoBH514343/AGbPDsoY+H7660qf+FZG8+E+xB+YfXJo9rEUabnpE+R6K7n4hfC7xL4FUT6rbRz6czbEvrVt8WewbgFT7ED2zXDVonfVENNOzCp7K0uL6dYLK3muJ2+7HChdj9AK9r/Zn+Fun+N7+91jxHGZ9IsHEaWwYr58uM4bHO0DqB1yPevrqwtNG8O2y2+i6dZ2MSjG23hWMfTgVnOpGG5cKbnoj5F+G37OXiTxPAl7r8n9gWDH5UmjLXDj1CcbR/vH8K+gvCn7PvgHQrdVudLbVrkD5p79y+T7IMKPyrvZ9djiTIIJqW01uKQfOwBrJYmJq8NVSukcxq/wb+H+qWrQTeF9OhBGA9rH5Lj6MuK8v1v9lTQp7xZNH16/srcuC8M0azYXuFbj9c19DxXsTgEN1qdXB6Voq0ZbMxaktzyvwj8BvAXh1FLaR/alyAMz6ifNz9F4UflXQX/wq8Bagp+0eFNI57x24jP5rg122aDVXfcnmZ5XL8APhtIxb/hH9uTnC3UwH/oVV7r9nb4cTx7V0eeA/wB6K8lz+rEV65TSw9qHNLcfMzwO/wD2WvBs7lrTUNatR/dEyOP1SmWX7K/hCGUNdarrdwn9zzI0z+ITNe+CX5SV5FVH1DllCn61m68Y7lRjKWyPF9R/Zd8EzwsLO71m0kPRhOrgfgV/rXi3xI/Z18TeF4pb3Q3GvacgLN5KbZ41Hcx5O7/gJP0r7Zt7lJUG08+9SMeOKftk1dCaadpI/LUggkEYI6g0lfVv7T3wjW6gm8X+GbQLdRjdqFrCmPNX/nsoH8Q/i9Rz2OflKtIyUldClGwUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFAHVfFf/kqXjH/sM3n/AKPeuVrqviv/AMlS8Y/9hm8/9HvXK0AFFFFABXReD/BPiPxjcPF4a0m5vtnDyIAsaf7znCj86d8O/Ctx4z8X2Gi2zeWJ2zNLj/VRjlm/L9SK/QXwjpGneG9BtNJ0eGO1s4Fwqr1PqxPdj1JrOpVVPc0jTclzHyCv7NHxAa280ppSvjPlG7+b6Zxj9a4HxR8OPF/heVk1rw/fwoP+WyR+bER/vrkfrX6Hs7l1CTBiRux7fhWVr+tJpthc3czkJbxlyBxnHQf0rH6zbdGkaLkfOP7KHhWG1trvxXqAzPcFrSwjClnKg/vGUDnrhfwNfUljuWPc8DxnGRv+9j8M/lnNeWaD4a8RazG19cX76ZFdfvNkA2OQeecYwPb+taF74G1aGKP7Jrl9I8MgljDMfvjvmsZ1OaXM0dHsfd5HJI6e/wDFFrF4iOiWpuri/VFlaOGH5VRhkMWbC457E1a/taC/GLeThSVYMpDAjqCD3rybXV1GUFdfUJe28nmWd7FGC8HPKsOjxnnI9zgdqtXN68vhjSxpGrwPdJq9v9veEFolLqwZRwCVJGcdcn6Vi0qmkWaxoKNuY66wRrrWlts5By7n/ZHJ/mBXa7lOAgAA4xXK+H4Tb/a5+XeacxRuwIzEp4PPrz+VdVAgADNjOMj2rOMWtAxk+Zp9CwiNtIJIz3qO7wsJwRuPfpVnIVc5GKxtWugrndyg7e9dNW1ONjhpRc5mXdlTLIWI6dK4jW7xIJXkzgYwM1vaneBBI544ODXml2k3iPxFZ6Jbuw+1yYldeqRLy5/Lge5FcUFzOx78I+zjqeufDNHn0hdQlBAm/wBTn+56/j/LFddJCHYNjkHNR2ltHaWsVtAgjijQKqqOFA4AqSSQRKfmIrrjZKzPDrVXVqOSG3VwI1wOD61zOrXKOpYk5XvVq9upZN4WPaoOATwDXNa5ciKA8YB6nPWs51G2d+Focur3ItSmtNS0may1GJJ7C6QwzxsMhlP9e4PYivhfxVpLaD4k1PSnJb7JcPEGPVlB4P4jBr681PUBFpQwcljmvk/4g6jHq3jXV72EgpJOQCO+0Bc/jiu3C3sznx6jo+p7J+yz4wj0qDV9Flfa7yC6jBPUY2tj6YWveLvXorg5VufrXwZpt/daZfRXlhM0NxEcq6n9Pce1fWfwp03xD400SC/uNNfTIXHM1yCqy8fejX7zKfwHuaWIpOXvI1wOIpRVqm66nWz3xcgowwaki1HyymXHXFb8Pw1h2D7Rq90z9/LRUH65qtdfCyCZjs13UIx2+SM/0rk9hI73mNDa/wCDJra/bIKNWxZ6qd2C341Ss/BK2yRxHVrqbHVmjQH9K6C20DT4lwYnkP8AedySf1ojSnfQ5K2Jw8lrr8iKXVwqg54pp107cbQT61audDsJIyojZD2KOQRXI39pPpkhMu6S3B/1mMFR7j+v8qJ88OpnQhh62i38zq7PWElGGBDVeWdZDjI9TmuHiugSGVsN2IrYsrpWmjeQthfvLjrUKq9mFbBKOsTpEQKuVH3iSce9Zmo2xIMkB+YdR61qwyLImVpTGCOMV0unzL3Tz4VHTlcwdOmVnBbcPUe9b6FWXNY+qWJQ+bbDEvcdA1N06/JBWQlSDgqe3tWUZOlK0kdNWHto+0ga11CJY9v86+X/AIs/s7y6nr0uoeDJbK0e4BkexmYxoz5/5ZEAgZ/unA9K+o0kDLx19Khlt2uI3WYIO6Feq10xk780Dmi18Mtj82vF3g/X/B98LXxHpdxYyN9xnXKSf7rj5W/A1gV+l+q6La+I9Hn0nxJZW15E4w0cgyrDsw7g+45FfF3xz+Dd78P7t9R03fd+HJXwknV7Ynoknt2Dd/rXRCopeRMoW2PIaKKK0MwooooAKKKKACiiigAooooA6r4r/wDJUvGP/YZvP/R71ytdV8V/+SpeMf8AsM3n/o965WgAooq5pGnz6tqtpp9mu64upVhjHuxxQCVz6Z/ZI8KeTpGoeI7hMSXj/ZrfI/5Zqcsfxbj/AIDX03DaxCLG0HHfFcx4L0OHQ9BsdKsgFgs4UiB6dByfqTk/jTvGPiaDw2tvDLbG6M4yVWYIwAPXp0rzpy9pNvods4uKUEy/4hlbTdMdoSWlzlcHGAPSvLLa4vfEHiO1068uDNaySh5dx/gU7iPxwB+Ndx/aWk+JNONxJfjTdgKtFcYDfUc8jtkelc9p2piW/wDsHg+0jEshYNeONzEDq2fTkDA9etZTfLJKx2UNYWW/fb8T1hZIoIgZikKj++QKo3WuaTFIEk1O0V/QyA/1rk5PBizosms6lc3c2Nzb22r9AB/9ese88KWSyr9lBVRz1zmnOvJK3KiKOCpVHrU+5f5nSeILWx1iE/Zbu0mPYJMN1eParLcaXcXmg2SvHdanNAkEqcNDKr5RgOh5756ZrsLjwmrozLMFK98/MKp+B9HvbvxQ11qL/abfTSVtJJRkiVhg8nrtX17kVjCb5rnZKjGEbc10j0nQ7EQW8EBkknEEYj8yRi7OQMFiT1J65966GALs3gjb0xiqOn7YsKD8i/L0q286YZMAKO9a07L3meTXblKyI7+5aJM5AGK5HULxmk25Bz6VrahI0oKqwxzg1ykxkG9punOCPT2rCtJydz08DQildnPeM9RMFrsVgWY8CtD4H6M0kl5r9wMtP/o9vn/nmp+Zvxb/ANBrivESvrWt2ml2Ls89zIIgwH3F5LsfoK9/8P6fDpml21paoFihRY1UdgBWlOPKvUWNq2i0jWOMZNUr2dUGJMYP61cLgAhu1c1rtyfMccjA4xzzWtWVloeXhqXtJ2KOrXgGWQ7QvOO1cR4lvxPBheAa3NSmbyWZ8gEYNcPqdwEd3lcYiyxJ6ADkf41hBOUj3uWNKB558Y/E/wDYulpp1tJ/ptwpAx/yzXoW+vYV4Xo+l32s6jBp+k2st3eTNtjhiXLMf896veMNbk8Q+IbvUHJ2u22MHsg6f4/jXv37KjabaeHNXvBEg1drrymnPLCEICFHoCc/X8K9dL2UPQ8GTeJqmj8HfgMmi6hHq/jlba6uYwGg09T5kcT/AN6Q9GI7KMj1zX0lDcIsYwwFef3OvqhI39Tyc9ar/wDCUogwzcg+tcc6spM7lglayZ6S96qyAZ4xUguFEZbdk/WvPo/EEciKS3XvWpbaqrR43A/jWXM0TLBJLQ6qK5UgMcFj6US3YU5yMD9a5aPUCFODxmoZdQcOByw9BUurZFLAts6k3xQqXIC5xzU80Uc8WPlfd+XPasWyvEliA2445zya37UKIAc5OO1OPvaHLWh7LpZnBeIdIl0hvtNqha26soyTH7+4/l9KisL4Sqjq+3HOM9a768AeJssuBzyOleeeIdDn02Q3+nIWs25liXnyj6j/AGf5fTpjOFtj0MLifarlqbnVaXqO08jINbttdpN0OD6V5rpt95qgq3pnnpXRWF4q7s8Ad/WilVcXYjFYJP3kdgSJEPcVg6xYyg+bB98en8Q9KnsLt1l+b/VkZzWikqT7lO0nGcZzXVJxqx13PPjz4ed1sZ2i3IZDuY7vftWujqQSGrIvNMKP59o3P8S4+8P8altLtTHllOR1GPu/WphOVJ8rHVhGp78C5dIzgNGcOvIP9Kq6jZQatps1rf28UkUqFJYZVDKwPYg9RT49RhlX92TjGc+1MmuMYeIjjv1z7Vbmr3TM4wmtGj4u+OPwXvfCM8+teH4HufDrEs6p8zWhz0I6lPft39T4rX6dyrFdQtuTzI3G142wR7givlL46/Ax7FrrxB4Lti1ouZbnTkGWjHd4x3Hqvbt6DppV1L3ZbinTvqj5xooFFdBgFFFFABRRRQAUUUUAdV8V/wDkqXjH/sM3n/o965Wuq+K//JUvGP8A2Gbz/wBHvXK0AFexfsweH/7U8eSanKgaHS4TIuRn943yr+Q3GvHa+xf2cPC7aF4Bt7qZNt1qbfanzwQh4Qflz+NZV58sGzpwsOaon2PY7GRVYIyKMjOWOFzXL/EuW9h+zPp888S4YM9q+C2OgOc8DrkCumCyRRkn5WXBFJrDxXRiO0bCuc46V5fNZHeoqVRNq6PnbxZqF7Jak3UJnfGA107SsR6ZOK9f+HeknTNIt5LpEF7KgMiLwU77OOw/nSJ4ZttW1iC4eKNrO3YSAY4kcdPwB5PvXc6dYrEhwBknP1pLXY1q1IU4tdR7M0pVXQqAM5xkZ9/SoWs0kdioyfQDtWiIXU4yCmOg61JHEVYufwFaezcnqed7bl+EzY9LVwfOJA9cAHFCadHFJ+6AQEn5f/r1rMRjnGPelUZwSOKr2KbsiPrE+rKltbMrHoE69ap6sm2NjFhSOeDya2GwMmqF2UJZSGyBn7tFWCjGw6U253ZyN7NIhyucHCnJrmvE2oCz0qWTBLYPbkntXdXlqkkoVtoJ5wx61k6n4RTW4FzI6x7wWUcEAf1rkUW3Y9mOIhGGuhynwQ0FriG48RX0Mq3dxI8UJk/hhDcbRjgsQcnuAK9miTaOevaqumWSWdtFDEgVI1CjFXmHy89q7qcG/ePFxFX2ktNjIv7vyy6omXxkk1zl5KWZmZxv4z3zXQ6uYpAAy5A5NctqzBeIEAjY9AOlc1Q9PBRTS0MTXbndGQdvPYV4r8aPEA0zw49nbNi4vmMQIPITHzH8uPxr03W5PIVpcgBPfrXFX3g3SvEc4udfhklJQhGSRgUHsAcda1w1ovmkbYxSlHlgfMY9K6XwR4rvPCOqPLCPMt5cLPDn7wHQg+orY+J/ge18JS2s2nX0txa3DsoSZAHjIAPUHDDn2rgmIJyBj/GvUTUldHgNSpy7NH0XpXjiz1tA9ncZYDLRNw6/Uf1q5LrCbSGJ96+aY3eNw8bMjjoynBFTS3l1MMS3M7j0aQms3SXQ6446SWqPoGPx7plncJaXeoRKxOAc5A/3iOB+NdlpuvDCukyvG3KsrZB/GvkSrthql/p//HjeTwDriNyB+XSplQT2Kjj5J+8j7ZsdUWULufDfWtu3lSVMDgj04zXxz4c+JuuaXcx/bJVvbXcN6OoDY74Ixz9a+jfDXiKHULO3vLScS20wDK4/r6EdxXHWoOGp3UMVGrsd9b3cUUpAIVx1JNb+n3hlUbnJHqp4FcbC8TfvUG9xz+Na9vefdfcFXHIArmT5Toq0lUjpudpblZbcgjcP50bOCrR/Tb6VQ0y4DgJCcHHUdK0FuSkpRsADoSMZroTTSueLOEoSaRxniHw+1msl/pURwPmltwOg6lkH8xWdp940ifIykkcg4NekrNHKwKkHPSuY1nwoJLprzR5Ut5WOZIWH7tz6jH3T+lZTpJ6xZ3YfHW9yt95Rsb2SGUs+456j1rchuDwVZV4wMjkVjRWWoAD7RYzpIP4htcfoelakdpO6jcvIHH/6qyipJ2NK/s5apo27Z5GJVhgBeuOCabJYh5NwO1SOeKZp4lRGEsm4+/arxl2qDtZs8fKM1201GS988mTcJe6U/sEQJIJ9+2T60i2ixn7zH09q0Tg4yKaR24PsauVFdCfbS6sqKhYllU5x3GM0skW5RmMN6g8YqyCPTBqOSVAdpJz6AZNTyRirtiU23oeA/GX9nuz8RiXV/ByQadrBJeW1J2w3B9uyN79D39a+SPEOhap4d1SXTtcsZ7K8iOGjlXH4g9CPccV+mBukVsOcgdT6VkeMPCGgeNdIax1+wivICDsY8PGfVGHKmuinVvoEk95H5qUV6b8bfhVefDnVkeGR7vRLliILhl+ZD/zzfHGfQ968yrdNPVGbTTswooopiCiiigDqviv/AMlS8Y/9hm8/9HvXK11XxX/5Kl4x/wCwzef+j3rlaAOj+Hvhqbxd4x0zRoVYrPKDMwH3Ixyx/IfnX6EaJpUUEEahQkUSBEjA4CgYH6V4N+y54Oi0fw2/iO9iBvtSGIcjmOAH/wBmIz9AK+gbS+jBIbArixE1KXL2O6nTnCneO7LCx+ZIyDgD0FRSaTahxIVUsPXp+VW45iCSSAh6ZqlqF8iHhwE9O9c8uVLUUHUcrR0FGxWCRjAPOcVZSSNMuzc9MisRrwMN5fCntnrQmoMo4UKnrjJ/+tURlY3eHlJHRyESIVDsD6r1p2/7obgntWVZXySdAxb+8x/SrMl4IogZGUN3+taKr1OSVGSfLYsn5VLuPmzwKQTFkBAAPfnpWFdXzySH955akdxkn6Cqzywhcym8mPv8qj8sVHtLPQ3jhG1qdDLLhSfMQem5sc1jNfNJJIqFiqtg8iqBmgL7lREPqTub/GpEkDkqd7xhhuDfLn2pOpzaHTDDKC11NeC1S5kjlePLL0J7ZrYhi2emO2BVXTnElr+6whz0NXd3FdNCEV7zPNrTk3yvoKRx1xVe5mRF+Y4PanyygDIyQDzisXWZC0beU4yOeegqqtRbIKNLnkkyrdXZedlC47hieD9K5/UGJkfIymRtA6++atwxFXLOxfeec9M/0qrqTLEuEcBj39q4Z6nu0oxpuyOF16FJLiK3DMweTe6+g9KtmFI4wuMBgBn6VBHDv1ed3bdgcfiauXcZ8gEjj61tHRJGc2220fOfx71AT+ILKyQ5WCIyED1c/wCCj868vro/iHdSXfjXV3lyDHOYQD2CfKP5ZrnK9OC5YpHhVJc02zT8OaJqHiPWrXStHt2uL64baiDgepJPQADJJNfTnhX9lnT306KXxFr1zLdsuWjsQqxqfQMwJP1wK8h/Z91lNJ8XXiEIs11aGOOQ/eXDBiAfcD9K+r/DmomZBiQ5PPWuevWcGkkdeGwvtYOaep4b42/ZonsIXm8Oas02OVhvEA3fR1/wrwTX9C1Pw/fNZ6zZTWk46CReG91PQj6V+kGj3XniSGYq3J+U1yPxH8B6f4gsZYrq0jmgfkBhyp9QeoPuKUazSu9UN0ISl7N+7L8Gfn1XZfDrxpP4XvvKnLS6XM2ZY+pQ/wB9ff1HetH4kfDW98Kzyz2YkudPByTjLxD39R7155XReNReRyyjOhPXRn2VourR3FvFPbzLLbSqGSRDkMD0NdLYXCBsk5U9q+UPhh47bw5N/Z+pOz6TK2QepgY9wPT1H4/X6Q0e5jnjSS3lVlYBkYHKsCOCDXnV6Liz28LilUj5noek6jHCSVDEjoB0rrLK7inySAOODXmVhdPERvBLA9Aa6TT7yVkG5jsPv0rGnUcGLFYWNRc0TrJGgUgIF+Qdh2qeNgy5GMisWJZEzjDoR2PNaFpKikKflJHTPWulTu7s8qpSstNS5juOlATkkd6C/OByfSnBgeARWyUXoc2ozyEDbgvNIY2DEq5AI6VIzAdabvBBI5x6U5Rpod2V2kKAeZ16Cq15ewJHl3weuTwKbdyCTJ+UqOqsATWLKkfm+YkKMe3Yf4VxSm1ojuo0FLWRo2+qiYKrSRZzwVfk/hU/2ppHK/KWHUf1rKaSbaRKYVyenXj8utZd3MySLIjbT0O1uP8A9dS5s6Y4aM3pob9zcLKSVOGBxkNnJ/p9KgsdSaC/COQEc7SD2+lUbC58yDa25mbqTwfxqunN+XIBwBjJ9+alTe6NFQjZwkhPilodj4o8L6jpV3sMdwmFJ/5Zv/C/tg4P518Aa7pN5oesXemalEYru1kMcin1Hcex61+g2r3KG3cKpDr8u0jr9K+ZP2pdFtxd6L4gtVCvcobW4x3ZOUP1wSPwruwtW7cWcWJoctNS7HgtFFFdp54UUUUAdV8V/wDkqXjH/sM3n/o96wdIsJdU1WzsLcEy3MqxKB6k4re+K/8AyVLxj/2Gbz/0e9a3wJgjm+JmmPKgYQh5QD6hTg/rSbsrlQXNJI+zdGsY9J8P2djbjCW8KxBAP7ox+FSwOVl3OQCeig5xSQ3ubZABlcYyo4FUZ1Pm+dD84Xjkf0rxZybdz6CnDozbQyzFmZwYx0AyM1k6lNLvZEGewBNMS/LIwzgeoOKkkl+Xgru7YAyfeolK6NIU3F3ZRitrlYxhtuf7xyT+FW7a3nx8rswHVix/XtSRsEjAblj1BOamXzpD8k3ygZxjOKVzVt2LFncywNtkKkAYUDt/n3qeV2lVg4B3dgec1UaF3RVlZZEbDHINN8wo5XkgcUXMORN3W5bbMRXzUaQY52j5vwNV7gxyMB5M3X+MYH5ZpIrpfuuG3fWqFxdK8zkbTj7uG5I96dyowaZoQhIY+NijvjAH6darF3luseaFjXlh0/Ae9UnLMRxn6c4/GrtrE+xTkoinJJ5pMtJR1Z0NtfGK2UEiIDhWqy1623dnjqWDZH/6q59XBAV9xQ9Pep/OZWxG3A7Z5FaxlZHFLDxbvYvTX4y3zncO4OcfhWdNelj+85yeGH9fSqF/ciMYkQdeOf5GqkDFzvSYD2f7w/EUuds6aeHjFXNlpsJlFzXM6vPIsrPCu5clGyen0q5c37RjbkHHHFc3rF7tXEZ5JJP41KvJj0gR6efNunbHfB5960r4YhAxnPp2rI0NmWHeTnexNadxMdnXg1rJ20M4q58lfFK3Nv4/1ldu0NMJBxjO5Qc/rXK16P8AHqxNr43W4xhLu2Rx9Vyp/kK83r1oO8UzwKq5ZtE9ldTWN5DdWrmOeJg6MOxFfUvw/wDF8epaPbXcD43DDpn7jjqP89sV8p11fw68RSaHrkMbsxsbmRUlUfwnOAw9x/KpqQU1Y2w1f2Utdj7k8M6gbrbIy7cdSe+a66KXzsRkbkYc5ryzQr1ooIwT0UA13Wg3vzKZCSOnNebGfLLlZ6OJoOUfaIw/G/hqK5jcBN28ccZr47+K/geTw7qEl5Zx/wCgu3zqo4jJ9P8AZP6Gvv24SK4jw5DCvI/iD4XiurSaOSNZEYFSCMgg9q3jP2crrYyhbFU+SXxI+Gq9B+GXxAl8NTpZaizyaS569WgJ7j1HqPxHvzPjHRH8P69cWTA+WDuiJ7qf8OlYldrSmtTzk5Up6bo+6PD9xFdRLuwQyghj6V0URSHkTAj3rxD4LeKBrPhiG3d/9NsAIJfcAfI34gY+oNelWuogFlYgkc8mvIqwcZWPoKM1Vgmd1YXyyJlW2n+9jrVyG7ZWO4/KBkYFcbpmpgOdi5DHn1FbcN4hPYsfekp23M6uHV3ZHRC9U/KmQW6mg3ka5WBst3IOce5rn2ucRFc5yf4etU2vHVDufyx/dU8n6ntVuZjHBJnVPeGRdpYbgOT0xUCXhBKhjgdx1Nc3Z3EryLgEIe3r7/8A1614ZwRtYA55OKjmuOeGVPQZPeyNKNpIUchhzmqE91IFLKeT/dGB+tO1i+ht4JJPLyqL0XrWZY3n2+2jlVSEbJAJ7A4qJHXSo+7zWLUTGSdTMG3E5CICB+J6/gMU6+hMqqMABWB44wM9u1MMoTH3gv8AsjP5+tJc3YaIAjHGQCOSaVylF3CFQzjzC67GyCDgGo9RuvKki8vh8g89KHZ2RNmC56qQKq3UPnZiYsJAPvdD9Km+poo3epc1KcvZI7IFZ+OOa81+K2kxeI/hnqMUAL3FsPtUJHGSnJ4/3c13zzD7O0MvHG5N/X6fSsyKeKa1bzFLrzuTpx3HHtW1KXJJMxqU1ODifDdFbfjTR20HxTqWnH7sMx2H1Q8qfyIrEr2j5pqzswooooEdV8V/+SpeMf8AsM3n/o963PgF/wAlEgPpbyf0rE+K/wDyVLxj/wBhm8/9HvXR/s926TePN7E7o4GIUeh4JzUy+F+hpR/iR9T6xiuMIq5yCM9iakY/IQztg/rVaSKN4FVEAdDx7DvSRNGSyDduHXPHNeFJn00IqwkUSs2+OJuOoJORVmTYQHcKdnPPanwt5WA2Cp46HGPrTwq+bIDwnYYxUFXGt5ZYEkY/vdqltJi02Aq7RwTiq5UGQBSpA4x6/WpGdljBdSrgADjgUJhJXVjTfMgH7xM988H8aqSyDcYtnzjjfioIpQZkZ2DgAjA+6KLq5TcrRNn1xyPzqubqZRptOxBPlI2ZkZuOnesyEQOC2za54HJOfr1q3IJZyxSYYxnBGRn60xbZbdAwIZ88At0P4UXsb27lu0xCMsUUe3FaEckeFVTkHmqlnGCjHKZblt2M0EjDA9AcDBzRczaUmWpJAhB3LgHjiqdzdHJYH8BxmqsrMHB3BQPrVK8knkB+ZRx1z2pJtlqCjqyW4uJWBJzs9DyDVQ3WCQgVW+lQqkqLl24PTB6VWvLpIIihOS3Ut1NaKPQzqS7DLu93Arv5HfFYF7OzOFzk+1QX16glKR/ic8UujK11qK85WL94x9+36/yreMeXU5nJvQ6axh8m2RD0UYz71HcyYHsKlZ9iADtWL4i1GO2tmlldUUDJJ4AwMkms4pykaNqEbnifx9u1uPEunxqwLxWvze2XOK8vrZ8Yawdd8RXl9z5bttjH+wowP8fxrGr2ILlikfPVJc03IKUEqQVOCDkUlFUQfZHgHUU1fR9Pu1+7NCkh9iQM/rmvTLBo1jCk/jXz78CtUD+DLZC4L28jwEegzuH6MK9n03UEKKoJOR615VePLNn0FB+0pI6uK8MXD9qpaptvYmQgdOKznucsELZ9KUSYXljWHtGtDRYdRfMtzyD4pfD611y2LsgiuVyY5kHK+2O4r5p17RrzQ79rW/j2sOVcfdceoNfdl1ALxCrEA4OCRmvLfiF4NtNUsJLe5jwxyUcD5kb1FdmHxFtHsceLwyn7y3PBvhR4jHh3xXEZyRaXgFvLzgLkjax+h/QmvpwR+cVKcMOuDjNfIGuaVc6NqMtneJh0PDdnHYivfPhV4vj1fw9Bb3E4Op2oEUqM3zOBwrj1yMA+/wBa1xMLrnRhgqrhLkZ6pal0Hmxg46H/AOtV6K4fGc/KOtc2mpGKZUPAbsOxq22ohAATnNcEotnq8x0KXG/kMfoKl3W4y8iszDplsD8q5Z9Sy4wRu9Ohp5u5p1ZSPzpcrHzHT/b0IPlNz64/Sn/2h5ScuBk1g2W3q8mQBjgVpwqN6seW/hBqWaKzLrXWIj3J6P2H9a5g65LDrAtI4Pl3KjOTk8+groZbgQsDIQPc9BWRHNbC7MqOjSg4EiqCy+wPamrtHRTcUnpubKXSIjIzI79SSMYqMJ56s5bBUdz71XtcyyGXYDwVz68UrvIkfl4J5645OKgzla+ha0wj7Q4cAbQdppZLjzFcSBQ6nPygZFUI2eNS7fM2cgA1PE25HMQG7B5IzilILa3K9wFLEgMvl/Mo/rQId8DGQlXbAwBye9WjKlxIVyQMfN24ParFjCu6SLOVjHGT1HtVXIn7ruz50/aX8LtDd2XiK3X9zIi2sw5JDAcH8RXhdfc3xC8P23iPwdqelyfemjJiLfwuvII/EV8OzwvbzyQyjbJGxRh6EHBr1sNU56eu6PBx9Lkqcy2ZHRRRXQcJ1XxX/wCSpeMf+wzef+j3rvf2a4Ld9e1CdfN+1Q253Zxs2lgBg9c9a4L4r/8AJUvGP/YZvP8A0e9etfszaURoutakBh5plgUnptRcn9XH5VnWly02zowseaqj3uEeZArM20Yz15FVzJiby2jC+hYfKfpVm1iH2cBzkqOvanQxv5gV2Vg3TNeEz6ROyCGAL8+xsqN3op/CltXa7USyZUnqvPFTIrrvDkiIjAUryPxoQmEkrG+xe696RKbIZ4BErsyuq9tpyc+v0qRsuVABaNRyQen5UjSfa4yrYTnDd80/LJJsCttxwSODQNt9dwjETnbtfaQRkGqItXik+Zo1hXpGq4q5czJHACy7GHfHBqm08rNuY724AQjOfxoCN7j40hklAQeW4PQdxV9reNWRdzSEgfexxWfGW8z95GF7heP51alViS5YKdv3MdP1qugp7pXLCnylIRwvHJU8Y/OszUSjyfunHmMOig81ZDouVlC46nrzWfLMFcSxuEjA9MVLKpx1uUbgyojFgW29een1zUE1yTGPLAz3B7CrV3IGAVerYY5Hasu8VZJNpzGAc5Bqo2Kk+4yS6VwCwwyd84rB1e83gooBLHGe9XNWWKAZ80tnnnvXL3dyxY46etdEIanNUmrENy4iYc5JFdf4etGtLHM2FnkPmPk9Bjgfl/Oua0WAT6gksygohzg967RWB3bs59auo7KxjDV3ElBYli3AB4rxb44a48FvBpUMpEk5Ly4/uDgD8T/KvXNSu/LgdiVVAud1fKvi3V21vX7m8LExE7IgeyDgf4/jW2Ehd8xzY6raPL3Maiiiu88kKKKKAO3+FnilfD+qyW92+2xu8Bm7RuOjfTsf/rV9FaXqiHa+4Y4IwetfH1d14E8dT6K0dlqDNJYdEfq0P+K+3bt6VjVpc+p2YbEul7r2PqK21dTKGbO0dT6VvW90tzExHI9q8z0fUUmiWWOQPG43qy8gj2rrtGv0OEwwLYwe1eXUpcrPep1FNXOjB+uV6g1W1C1W+gIAG70x1qYMJAyeZuYdwMfhUtuNjkbSe/tWSvF6DmlJHhnxW8F/2jYv5aBbqLLwseOfT6GvOvgbdRWni+6trpAs09syRluoZSGI/IH8q+qdb06PU4XAXnHOe34155qvh6K1uIboQRmWBgyNsGV+h+ld1OunBxZ5tTDe+prcn879+cdas/bMrtYDcf4sVmTFVO5CNp5wTUC3Azgk59xUWNrmqro43EYOeDjrVm03SthT09axgztyDzVq1k2vuDlT3qWVFnS2vyndIVAzye/5VoQXEYGUYjb1I4rm0uwSCRkHsTV03CybQFHH8PpWLR0RZp30guYWj6q69jyBXB6bYT23iiYPNIxDGRtxJOwj/Gu4ttiEOcB+nPas251i1k1UQlHLBtjFQOfr7VcXZWR0QV3texs2t193rEo7f0pbxVRjvdgARzgc/j6UyTyiFVPujoT396kEaXACSfczkA96wZL0dyKCXMjYjIVQMn3q7ZzgXHzgKSMMPXNOuLZI0HkqU6HOapyQMSCCQFPXpmi/QFZo0XUR+XIcDzOMYxjn1pkE3l3S7G2iQFQWHr2o2SSwKrMz7c9Rj3pkRRSTNGwYgLx0PvUoe6saV9tdzFGC6DBOR1r41+NWhPofxA1AbQILw/a4iBxhuo/Bsivse2kVrdi2WfgAd/f/ABrxX9oPww2r+HU1W2Um600GUqO8J+8PqCAfzrtwdTlnZ9TzcdS56Wm8T5n5oo4or1TwTqviv/yVLxl/2Gbz/wBHvX0l8FdNOl/D3Rogv7yaI3T8dTIxIz/wHbXzr8RrR7/4xeJ7OL/WXGvXUS/VrhgP519e6VaLaqkFvtSGBFhUY6BQFH6CuTGStCx6GXQvU5jRjZw2V5UEKM9qkZlGEbaN2QQwxn0/WgpiVtpO1jxxUixtLKPNB/H29DXks9u6GPGwdJFV8YwyE/rVqWUPbpiM5AIYk9qZaqCzNCuFX5cUNOx3b0AG0BkFCaS1JerXkVPMfzQq4UN0OOOKsWofc5IKqeCQOtOXyQyMD2wPUU9odiEMdgPO7dSHKS2FmK7dqRArgj5ucms6VFjLFXjJHUZIAH4Ut8qo675Dt9MYzVdwoVW2ksB82MjI9aYRVldDVOXK7yNw4O3gVetyInIJJz6tuFVLRVaYsCFHQ5q9KFtYRv8ALO7+JRz9aLDbvoV764iY7FDDIznGBWPdEodzqD6e1Tz+a8xCFMdhwM1lybGDtKHjYNwHP3j6jFJalr3VZEVzcZJ3AsSOOelZVxcgKzEkAZqxqTkSJ5a4jXqc8t+FZV9LuhHyx7ycFTzxWsUZynZGbqF00+SWBGcCs+RXIJwck1PwzYCgKO1SwIZZdqfSuqOhxzdzV0S2KQKXIDtzW2RiMHdx0xWbaDYgUHk8VfLggqTn8eeKxk7s0grLU89+LWrNpXhKZIW2y3BFuoPYHOf0Br54r1n4/wB8H1LS7JD9yNp2+rHA/ka8mr1KEeWCPFxU+ao/IKKKK1OcKKKKACiiigDvPhz4zOjzpp+pP/xL2PySH/lif/if5V7xpl8u6Py5SqsOCDxXyXXpHwx8YfZJYtJ1OT9wTtt5WP3Tn7p9vQ9qwrUVNXO3C4l03Z7H05bTb4w8bAuOc+vtV61mMjrLv2beGHrXEaVfukhxJ6AKeortbB4pI1IADn17mvLnDl0PchUUldFuTk8Nj6HtWXrUYeAlQGHQjFaIPJXC59hiqsxUbk65HANZKVimkziSsccjQuv3TlCR29PwqrcxRBtytjPGK3NVsyTmP7w7kVz1wDuIZVGK6Yyvqcso2YillbauTj1pEmcNhwPcjvTEMu9cKCvcjvVyCAFwAwIP96quRtqOiKyvjbkLycdquQBbcg/NlugzVWa3ETBxIx3HOMdKnt3bYWk+bBx1qHE0jM2reRDGu98Y6ZqGSKB7gtsQuxwGA5qip+far5yM1YsopIrtSzbRjIB6GovZWOiM+XVMvBmiGH4UdT2xWraS7UCSlduNwU8k571RuJh5g88KwPIUdPyqSH94cDoOScdB/Ss2hublqy9eXBMIGU2jqo7U5oWFm84YLJnjngCqTJIkZ8xSQe/UVL5jzOIk6AjI61G25aXYtWc8kdp5EzFnPKn2z0p5j3RKQD8oxknv2OaqLbzrJGS212B247ipiZ9wQ4EQBJ3Z6/1py7lxt0J4X8m4i5Cvk9e5wf8A69VNZiWe3kDxecrArImOCCCCPfilaYyS8n956/pRFM5DxN8ygcHsce/51UX1RE4njf8AwpLw5/z/AF//AN8f/Wor2X7OPRv++aK6/rVTucP1Sj2PnbRdJ/tX9pzXty7o7TWb67f/AIBM5H/jxWvo+xVwFIIUqNx/GvNvhjoq/wDCy/iXrUgO5tburOLjsJnZv5rXq8UZRhIBxjB9RTxs7y5exll0OWnzdySIsykqRnqDnANWGjkLqUYgYwSDVb5mLbOAfuk1PbNhDvViq4GOvPvXAd0u5MR5EDGQncMnA71RjnBY70KMTwp7j1+laCyLIpdYjG44IJ7VnzMp2nhQOOmaGTT1vcsBADuCncOmP4aJ4hJCCV3nOT83K/jUEReNJHz8h4xnHFQvtMx8skK59M/lTSuNpp7kM7vIQVK8MDtDcn/61QSGWSRlZQq8fdXOPercwRcIwbcTjIyT/n61TvfNtbrA/exYJL9MUzSKuRwRKHdscK3Jbrn6Uty7uSPMUqOgBzVae4coxk4HQjp+tV5J2DEo+1R1wPvVNjTYZPNtcgv83QccfWs/UJ03cMC3QnrinXL/AClyuWPvWXNIZCEbI57VcUQ5WHXM48voATxx3rGuiTNsVui4PerE7KZyOv0qNVaRuQAS3GB1raKSOWbbKrwk9QP64q3py+UynHfPSmeXgjL5YnIUelWF+V12DDgYBq7kKNzV2Fk3BwrDII6YqlLIV27WPyk/Uj1pWk8uFemc46cn1NcR8TfFK6JpZS2AF9cgxxnuo7t+GfzxTpwcpWJqzVONzyf4kar/AGx4vvpkbdFERAh9QvB/XNcxS9aSvUSsrHhN3d2FFFFMQUUUUAFFFFABSikooA9s+FHihtRtDZ3su66tgBubq6dAfw6H8K9s0aYgoGJYAcnsK+N9B1SXRtVgvYBuKHDKejKeor6d8J+JY59OhubOUNDMnynv6EH3FcuIp31R6WErv4WeprteILxt6gY6Gs65WNJ1V2xn25xWXa6nmMbCzkD8aui6Jj27RMT94EYI9s15soanqwldEN+qTQAQOEOTuLCuW1GzLSO5cL6jGfyrqr+OOO3Hllmc84YcL9ax5lmcP5aeYqrzjpTi7EtXWhzQj2ZIfcvTANWbcDywz8DtUgjkYlJ0VVOTuznNSKscIACM4I6DqK0vczkrEnlkoMsMY4B71AMlzGDgnr6VcVSVAYFRjHFOVXA4XI7GlchFdLaUKu1uc/w9q0rV5Adk+CTwpPaoU3u2ed3oM5qzANpDOxOOxpPU1T7lhCANrsAF7Acmp45SyMkaA46AHj8c1Viuoizqm1gOm096IVnSTDgjOOGXAH1rKxrzXLcM3mLtMhIHBGOQf8Kkt3IJdCQ+Dj/D61IFjKgRDMnVinf2qN4JIgpH3Mcgev8AWoN46oWC4l4kk+VucZ6j6VJBIX+WZcluQ56L6cVFbq5kGTlwc89MZ6fWp4wgcykZySoPv/hTshtsYJmjugVUnB7jAqxa4iMphG5iNmOuPrVcgHy/JTjkbvSrccsdtHFbAAFvn3kYznjJ7mjYmWpX23Xv+Qoq5/Zaf89h+YopaiuiPStJOl3WrqoBefVb27b3Mlw7D/x3bW1GrdDn3IGabqI26teEt1nbAH+8ad5bTqQpKgEHOetbVpc02zmox5aaIpNrHABbPYHGKsqrRWqo2MZz81VZy0UmCoO3ntzk1LbhrgHCqyIepzmsbGstr9CYOZA23cF29uAT6VHNBuK7o1DBeueRUyIqA4CfMxbC8VC90UzGql37qw+7+IoITd/dGE7IH3jgduvFRQgOQXO5FPAB6fWiTfvBTIyMc9B9amhZuQ7qqqBk42/hTL8yVpHdiAco3C5Bz/8AXrFvbfy/nfI6nb0zWmm3ziVYYA6buTWdeTlwU3nPo3A/D1pNlU466GPdWsZyANidTtPf6VVlCom1Hyx5LMeK0JGaSBsB1wCAMcY9azkT5dzLIpbAyvenc1ZQu3AfIG8DHbiqUm59reV8xHyjFat5bok+7eWZTu28gY/GqywlkLL93JwQc5NUmYS1Rmyx+QWZwORntUYcNggL/vdauyKZCy7S2f71UzaFArPy27oPWtEYMjck8FPlHJb1NSxx4kxnDevpTmic7A3Azzz2H+NEvyB2LYYjPNUJFPV7mO3tpJpZFWKMFskY2gdfwr5x8V65Nr+sS3cpIjHyxL/dXPH4nrXffGTxC2I9HgkxvHmT49P4V/Hr+VeUV6NCnyq7PJxdbnlyrZBRRRW5yBRRRQAUUUUAFFFFABRRRQAV1/gPxa+gzm2umLafIcnuYm9R7eorkKKLX3Gm4u6PpvQdbiuYopre5WSNuVZDkH2/+tXZWmpbkBBByec/zr5F0PWbzRrgy2U7R5+8mNyv7Ef161674N8dW2rFIHb7Lef88nOQ/wDun+h5rkq4e+qPSw+L6SPZpLyN5N7yne3b1oVj5TCMhieSuMVztteK8YD5/wA981oQSklHRsP0C56muCULHpxmpLQme03/AL1o2SU/hiolEbTeUuNxXO7HHp1FbImR41BdEl6EHjcahV2eQIFQBSdx6YpbEyuzOztbyl2M/XaOtTSKrxJG27c3RgelW/J2zO5OQcEcA8fWo0CMQEX5jz0wcfhTRBX+zSgKq7j79T/OrcMBcgSxlnHJIBzTbdRcOQCB23Er/jViC12y4MirnqAx5/Knzdh2fUgMbROXihKY6kjH86fCrzy75ZCc8bQcmr8NonnkuYyAOhYD+lXEiCgsskaIeMhNx/Pj+dZM0TsVNqFT5RAOQcYyOPXt/Oh55Gjc7T16D0+v+FW4kigikZnZiTxu4H6ZqBnjxgYZXPGCev0qGjaLI7fyxE28fN3cjof88VJtDq2FwBk4AxzRPsCkOoVjgtuHalctIsYSNxH078igpspLLkGJQME42gcCtvT4Fe0YyOvmDB+Ycj2/+tVa3hhgWOWWNQeeT1Bq0qQSXCrJkkKW2dQp65Pv9ae5MmTb19T+Qopnmr/f/wDH/wD61FQVbyNDUXQ6pdqy5AlfJx7mjgwLhW4ORggU3U2I1K8A6GV+/wDtGmxshTO3kVpN+8znjH3ERzYJzKxGTwacZJYnxFnHqOMfWhQJy6AE+6jOKm2yA7FdimMhSMZqCm+hXjuXluTDJHtYc7143fhVo5MZCcHtubHH+fpVGSKQy4khKBsgbHxT7eIBxvdicZUEc/kKaCSXQslvKLMVlVcYLsPl+vFUpH3gyRusiAcYPX8qtyytFIEhIl3cEZAK/wBarOygjy0jRcksy9/rjqabCCsMtCwQyMQjtyFYYJPp/kVlahcPKjM8aF29iD+Xar81y6sEAy4BOcCsKfUHE4DRELjJzxyaRtHR3JZcyMnzeXjJKg7gfbimKsccSl0weuFJ4/DFQStnayOfu4ZNwOfqOKbJKvl5beGAzgDOB7g0A2SXDGReWwCPvYGTWVIJXWSJmZAAQATj8qtB5ZIRtIwepA/+vVW4lYyDkNtGDkY/rVJGUiFeV/dJzx9+owWOSw+Y9d3UY71ZthE7HcxBYd/WqssybWKN/EM5HWtEjLdkdtGcsSCWHccgVjeMNUi0XR7i9nwfLXI9WJ6D8a1rm58jfggLjFeJ/GDxINRuIdNtpAYoWLSgH+LHAP0rpw9NylrscuJrezhpucBql9NqV/PeXLFpZmLHnOPaqtFFekeKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFKpKsGUkEHII6ikooA9F8HfEGS2EdnrjtJFnCXPVl/3h3+vWvYdK1OKVInjkjaM/MrqQQR65r5ZrofCvie70GYKMzWTH54Senuvof51jUpKZ10MU6ej2Pqe2killKOQ5b5seh9avWhUSMQxL7cHJzjFed+F/Eltf2i3FnKJEPXPVT6Edq6y31EnDDnPJHavOqU3FnrQqqa0NTzmDsHLKudpAHH1p0UZ89pN+D0BAqobokKsJzgZOef51Y0+6dwftGN4Y4GOB6VnZlmpG0UTAEqXJwuR1PpVox7tmNw55O7pWZL5czIZBGwU5UZwc+oqdNRj+0eRglgM9On40g9C8Y/Kkdgpdh23Z/oKjV2nhLkPEQ3yjp+uc01pixPKY6YJ5P4CnomZcKeCOTtHB/HFQzRaEah5Ac7HJbIblv50mJBOfMVYwOVbjn6Y4qWNV8xshmJ6nd0/LH8zSTtGiFvLDHsTn/P50FX1ASCUkLkADO9hxn/PpmnXl5bRwqgYyEfeCk8n/AArMnlZmUMT7r0GPc9ailR5nSMFiMfcX5cD3pWGaMcnnlZJCEB6If581auZCnEW5VbjHVmNQ2sKQlN4VpBj5R8238qkllSGQJMdzbs4B6fj3P04/nSZS1ZD5Vx/zwT8//r0Vc89v+fd/++jRSsXzM1tTvFGqXabN375wfzNQLufqdpxwAOPpVuezB1K9lK5driTAyB/EaSbzLcGR43OOwAJq6i95nNCUVFJb2IUWOOYBpDvPBxx+lWgoKjbdFR2wB/KqZmibmZZFbsGTaTUhhZlDBwoIPDDI/GoHJdyZ0VGdDNDu47FHP5GoJJXQjbLGWBxhwMj8eP61BNDCUxKr/LzujxtI9qheZUQgGOSPAAbft/A9qYKJPdOrSK9xGVfHL7Dz7d6oy3kY27tvy8YPp+NOe6ZMgkJGFyABxj8CQazZNQUp8zL6YbC4Hvnig0irIdJdRPISGUj2wKypMSTEEjg+ob/69Ou3jZAYRHvzyUHP5rxVXY5DeXGRj+J8Mc/UVSQ72LUMAG7YQ67sE7uM+4qUZCujMp56Nzx+FZTTEKokReDkgPn8u9OlvSrKNgLN6jP69aLEtjriSOM5PmY3dxkVmyzqZSpkyo53DoalvpGfKkkqCM81T3IWZQAPlq4ozkyWS4yp8sYbpwOarSyBYxg4I4IpfmEvDA4GM1i6tex2kMsszhIkBdmPYDqa2jG7MZTSRy/xL8TPpWnpBbOBezkhD12KOrfXsPx9K8XmkeaVpJWLOxyxPc1o+JNWk1vWJ7yQEKx2xp/dQdB/nuay69OnDkjY8OtVdSdwoooqzIKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClpKKANHQ9Xu9FvVubN8dA6H7rj0I/wA4r23wl4qt9Ytt9u2HUDzYXPzIf6j3rwIVY0+9uNPu0ubOVopkPDDv7H1FROCktTalWlTemx9T297vVQTx6jt7VdhuSG+RjjPQnNeW+C/GFtq0axS7Yr8D5oifve6+o9uo/Wu4t7wt91STnHBrinTcdD1KdZTV0dG95gBfl354wOlWUdpCC5AycnA61hJO7Njqwq/DIGHJwx7Z4rncbG/OuhrR3Gwk5XOMVZt77aVKlCCfu4AzWG0oynQDPPOM1NG7vuwduOm08fU1DiXzXRueeyvlQgXOdobgj/PvUTTNJGd6KxJzg5AH68/jWWGCgNIQ7Ke2Tj8a0LRUuXCsMDrheSR70rFXEgmRW2yMSvcKMfyq4jecStnCYwcZYjge/NNVIhJ+5Qyk/KFHJ9s+n6Vet4JngzdyRqo5Cxj/ADn/AD1pMpdwt0NsyrBtmuXX52HG0fXoP5/yqxBYlm8xlB5zktgCrA8pEAiiGcfxHsKZHcyy/MMLx1qGVrYm8pf70X/fJ/xoqHDei/nRS1C3ma13Jt1G6VTu/fPxjH8R70SFZgCq/N/sNjNJfIw1S5wcEzMQMcnk1JEo3EyK/HBbn/Grl8TOfRRTXYqRwyFGaN8YGNky9++GHFMnEsSgNviB+XcvzL+OD/hV64h3j9xcTIFOfu7uKiEc0cYCmObBB67SR+NRYanfUrfMI0Dxbk5JaIlwD/Os66WC5kV1bCY6ooU1rTKgk3SxS5zwpX+TDimmRJcDczBRgFlVwP60y4ytqjFkjKKREBIq8qSVJ+n+cVnymIu3mMVZT/ENv4ZOTW9cQqHLER5A5ZS2D/PH4is1ohIRlY5GHR4yGP5dM/hQap31KE8A2DcqoBznAGPxHNVJIGGGyR3OSefof/11c+yiGZ2RXcPk+W42HP06fpTLl/LXiIrx06/pTGzHuck8odw4AZQfxzVC5BYKxGGHYHHFaN45C4Rhg9VK8Vj3GNzAHk9R2q4oyk7DVJ4wpPOORkCq9w4QHDKefypwlCZBUHjqD0rMnuA8RIyoyQNw/WtYxMJSsTXd15akbs4HOa8l+J/iIzy/2VbtwCGuCPXsv9T+FdP408SJo2n/ACEPeTAiFT2/2j7D9TXjEjtJI8kjFnYlmYnJJPU130adtWebiq1/dQyiiiug4QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAcjMjq6MVZTkMpwQfavRPCfj508u11pzjotyBn/vsf1rzoUlJxTVmVCbg7o+mLDVVmEcsTJKjjIZTkH3BFbEU6vHnhW65r5i0TXNQ0aYPYzsqZy0Z5RvqP61654O8b2erMsUp+zX3/ADyY5D/7p7/TrXNUovdHdSxClvoz0mOUnDk5UD1zV23CyAEsAD15rGicMADgA8/Q1ZiLxrujk3AdmGM1yuJ1xnY6COGF41y5cZ/h4/XrV2OJAMspXAwAoIyPrxWFZXKgZO6J+mAMBq2LW/dsbWfPTk8frWMotG8JXLsbMqbY1XYevAwKltshHYEgE9M5zVVwsr/PKAB/CBtrQxGkasieYxGB3A/TH41kzdMe27h2/doOvQ5/KpVYsv7hQiEfM55z9KiVowN7qJnz03bsfWnNJJLKXYfu15xnAH5Uhsfs/wCm81FVvN/3P+/bf/FUUh6nW6gIje3AKq7eYx2yc9z+VRozJGAu+PtncWU/1/nUNzuXULx3ZAPPcA+24/lTMqR5gmZODz2/Pgf56VpP4mccY+6hfNcMpOHA+8V4/l/gKja6VowykMW9Oc1BPM7RlvKZ2HQqCG/CoxNKg3S5bsC8ZX8zx/M1mbqCLgmKg4LIOMqeR/8AXqtKqSsXdIiexXjP54pjX4Vv3hO49xnj6ZzU0c6lWZZo3x1Iwp//AF/jT3HZx1sRll2qy3EkTdwXyP8Ax4VTaPfKJJZopFHYhef51cnuUwYxOysw+6cEn8+f1qq7N5flqCM9WwV+nB4/WgpXRHdAHhThO4c7hn2ByKyLqMswKMoY9SoIH5DPNXpoEIUrIGfPJXH9KilgVM7o+vJwMc+uTTHexg3kU0kpB2OmflOMHNZ89i5YMYwqn7xAxmtuRUwSVO0npzxWdfztHGwyDGB0yOv4VpEymzndS2Qgrgbh2zXK6/qsOm2El1dOVjUYwOrHsB71r38/nSuzMoVeSf8APavEfHPiH+3NS2wM32OAlYwT98/3q76NO55uIrcqMjWNRm1bUZru4PzOflXPCL2UewqjRRXYeZuFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFKCQQQSCOQRSUUAek+BPiBJaPHZa3KWi+7Hct1X2f1HvXtFldpMgJIKtjHf8AKvk6vRfht40NhJHpuqSE25OIZXP3D/dJ9PQ9vpWFWkpao6aNaztI97itwzbgwA7Z6H8a1YGkiCkgMueGyCD+FYFleFwGDcY6Vs29wTjuoHGOlcMkelCXU1Y1R8MWjDqc42nIq6I/MAG78hxWRa3QJxk4+mcH+Yq3HKeQu1gf7xzXO0dcZE5dozsHBH8T4A/Kno6spaSYuy9Tjai/nTVlUpgbVI/2cgVGzqxYMVZfVh39vWo2NNxftMf/AD2P5mik8sf5jWindhynS6hcPJq1ymR8kzgDpxuPrVSWY+ZsRWjJOGBJTP1PIq1qe2XU7xdsZxM4/U/hUKIkOzy2Zu+0jhfxz/KnPWTMqbXKvQcgil2pMsZPfp+hXj9DUMsFtIqJAXPbKFX/AD7/AKVpSxZI4Vs/38Y/I/4iqzbJEIkTjPJU5H65x+dS1YIu+qKaQhOFw2Tz+7IP6H+lLGXMgAmUHPAPH9ePyq1EFOAofP8AsuDn8OlR3M7DCuY+nIZNpP5rj9aRetyG4WWVhHMWOehILD8uKfFBbwoMIyFf7rMgP4ciqkku5vkiDDrnYGB9uDUMkxV2CIo4ySEIxTuXbSxZniJJI3Y92DD9RWZc78NsfgdmX/CpvtBMe9xu9ccVWubgsBkuM9iRTQnoZ9wWBJkX3yeP51zeu3p2kA8Ed+v51uandJFEcBQ5/E/nXC67fR29pcXdwcJCjSNn0FdVGN2cVadjz74m+Ifsls2kWjEXEygzsP4UP8P1P8vrXllWNQu5b++nu7ht0szl2P17VXr04x5VY8Wc3N3YUUUVRAUUUUAFFFFABRS9qSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPTfh546aBotO1ibCfdhuGPT/Zb+hr2ixvF2qQ2QO4r5KrvfAXjqfSpI7HU5DJY9EkY8xe3uP5VhVpc2qOqjX5fdkfRcd2j4OefUVbilBO5s+zKTXLWF/Dexxy27oQwDKy8hh/KteGRlIySCePWuGUD04VDbhQPhyxY+hfpV+BG83ARVHruGSKybZ92QwXPqua1rIgKNhEh98cH9awkjqjK5a8pf+eSfnRVjJ/55iiosVzmjqJzqd2scTkedISy7SQdxzwTUP2Muyuzh8cADgk/Tr+lYB8c6fca9rlpqDLp8lnezQqZnG2ZVkZdwPUHI6e9aum+INI1MyQ2epQXLLy0acsv58/lW1SlKLd0c1Komlys1IzhzG0ihFHKtgkH8Qf6Uhhx80TBDn/WBVP8iKUyxyxAKST1/ebs/hTuGwAJH44w/IP6msTTVakLpIGA2uwI5dVH6/8A66j8raSrNLGp/hIGG/LNaBWJ4iBIvpkrtI/GoT+7UKrAAEAlTyT9KVgU76GfJbBRsEkbHPHPI/QGqVwjqjK3lnHr8v8AOtK6Db2zIQcegOKyrtpchYweD94H+lI3jqU5mYLlsqPQHPFZ15M0Kndkn0Jxn8BWtdNGEw5+b3XrXL6jIC7427s4GK1gtTKpLQyb66eebaeB1OBjAryj4w6wIraHSLd8vKfMmx/dHQH6nn8K9F8QanBpGmXN9cvlIlJ68sfQfU4r5u1bUJ9U1G4vbpszTMWPt6AewFejh4dTyMVUt7q6lOiiius4AooooAKKKKACiiigBe1JS0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHV+CfGFz4enWJ8y2DNlk6lPdf8K980XWrbVbWKa2lWSJxwwOR9P/AK1fLOTXafDPxA2map9imci3uSNuTwsnb8+n5VlVpqSv1OijWcHZ7H0dDOUKkDcR0z/Q1s2t2pYGQKffvXIabfrNFng/zH1FasE3AJHyivOnA9WnO51f2y3/AMg/40Vz/wBpb++P++f/AK9FZcrNudHmPjmbb4+8USeekcSajcAjaM5EjZ5rm4TPdTNdLO0cW7MZQ7GPuD2rY+IrSz+PvEUMSRtAup3LSHgEfvmyPc81x+qXojk8uAFUA2kqen+Fe+9j51Stqj0yw+JWsWlxDGbuOfaoURMgIfHGWPUH3rsdF+LlkdTitNYtfsizNsWeNiyhj03DHT3FeFaUjCCS5URqST8zjtWhaqIx5lzGPOYBlzzgVhPC05rY6oYupF6u59UwalazSKv2qOV26IXBz9PWrodAjEqUx8owSP5gV8k3N1NaWu/evmtxlDnn2rrfD3j/AMQ6PbBL++FwCdypMC2AB03eneuOeAa+F3OuGOjL4lY+gLmUbCqqrHoSDiqV0u0bY8cnr1rhNH+KNjd2sf8AaZZZiSr+UpZQB0PrzXWx6jbXNrFc20qSQyDKSKeGH1rinRnTfvI74VoSXusq3jnac8DucYNcxfSHcxXGz8h+FbGpXu8HaQ2a83+I3iRNB0aV0Obp/ktwe7euPQdfwFa0oOTsYV6iirs86+L3iMXl8uj2jZhtjumI/ik/u/hn8/pXnFOkdpJHkkYtIxLMx6knqabXqxioqyPDnJzd2FFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSqSrBlOCDkGkp8UbSyBIwWY9hQB7B4H8S/arWL7QxScABuevYGvRbe9GxWZscdRz+deIaPYMkKLE0g2jAIGD9fpXVJrF9b20UEhHmKMbip+b6+lYzoOT0OmlX5dz077ev8Az0j/ADory/8AtK5/5+F/790Vn9VZv9aRZ+Iz/ZPHfiYQ+YZJdWufl75MzcisV7EwQ+b5iJK38H3t+e2RxWn8TLqN/iL4mhMJkcancjjrjzWyBVK2vJGtPs7wpCA4fZtAORn2z3ru3PPGpEjFYhu6Y+b7v+cUTNJcXXlyIzRwHIAPDt2/Sm+cTFM1ygKfdjYHjgVAjeRb75JiJHwSMdapgSRLFLPJLJFiPGEKjPIPNZl1e/aHIkdljUkABuffNW755o7VYg26JjhHHGOmefx7VQVXUHe8aBemVyD+NSwNfSpEtrEmWTg9uB/+ur+l6ldW1kXF1JHFGWKqrkbQT149+aySpXTkSOIsXwCxHJz9anluJJJI444cAD5xnAGKLJ7lKTWx3Wi+MDKv2e93tJ0E+fvD3ryH4k63JrPiSblhbW5McQIxn1b8SPyArcnunhMgOAW447Guf8WK15a21+EPy5iduOeePf1rL2UYvmRc6spqzOYooopmQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABW94YQfvnZeGOzd6cVg1o6Jc+TeLE5JhlO1hnGD601uB2wk2qihSIoxyCeretNjmaOVWjV8YOXXv7VHAQzp3+XkdjR5iJGnmblcnAAPI/xqwHfbZfX/xwf4UUvkr/AHJPy/8ArUUWC5p/EeMt8SfFKefGpbVrogjqP3zcVS82KOzLSblZgB1/Ctz4jqD4/wDE6FI1kGq3LKw5Y/vm6VmSR7IIt0YbLZZepNNICK5G2KCHG6BiCNvJ4pZZT5ymOMBIyS2R3/8ArVDEwmvGIkCRIvKjkZ/wqMyKIpJYpGJJIweQR06UwKl46TljuYohICxnsaIY5ESNFjBBI2uwAIPvUEbTq6nMYQk/MRz+VW7cI0qrNJuVTklT1PpmpAvy7hNGjTAuAWw3HP8A+uq8ci5mlZj5mNuB9P8A9VLcSRGRjGuGVchm7k1BvnFoilQrHJG48kHrTAp3jgEIN2MfxHnNWZ43uNGkjlCN8jFF3Y6VWvWXzVEnRsDPTFXW2mAJDG+5kOGJwefWktwPPx0opSpUlWGCDgj3pKzAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAp8TbJUbJG1gcimUUAdzFMJCJQ25XyQcdvWnsC82NyhSO/as3SpGksITKeMYB9gcCtDzdybiQQpGcjqK0uBNsm/wCei/pRUPmp6r+VFO4XOr+IlyG+IXidM7Qmq3RY5/6asOK54XP+suAxaNRtPHI+lb3xNbZ488VPHCZMandAseg/et+dcvdwL9mU2nJfiRORk/T1ouA+2kR7eRlTcXyceg/+vUt85uIsKCpQfNgc+tQMk0MCrsRApG4Z5qncXEisPL3Fj1x0/H1FK4FmJIQfM8iTAGHBy1T2SESsYrc9QcnjbTVEkkSETDIIHAI61Zhi2GRmuZNijABAGT1ycUwIJZGEe14wokbI56H2ptwFMi4k3bV4Y9PwFMKfvIQcyxcYByefSi5ypkB2qgIwP7vsKQENusrlmWJWAblj05zxz3/wq9IzbvMaUMq4LAdqoWYDzgGSQr2A6ce1W0fzleFI1TcCAxGN3ahAcG7bnZueSTzTaMY4orMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDf0O6zamAuA6NlVI6rWxG/DAhMdCp6YNcZBM8EokjOGH6+1dXDOrGOTAkRxgjP5VaYFjypvQUUzzV9R+f/wBaigWp6t8RNElm8Z+IJ4ZRKIdQuJZAmdozISEz/ewea8+vZGGpgwIZCvJwAMe/1r1XxBcOviLxNGPuyare7uv8MpA/lXk1kzYllz88jfMfXNNPocmHqSlOUZPYgbzPNedWHkxkFgemT/PGahaPbC0qKzySdFA4QE1YMSJuiA/duVJX6k5/lVqXAvIkUBUyQFA4H0p2OwoXNsyXNusLO6sMsi+3f6U6V3dWEUAWMfewRwPSnyFlv54kYqudox1H0qKGQrN5IwU35Oe+etADIN6tI6OFjHqefrioyyuRGPmKk5JGasXltHCAEzjOQD2rPl/dSOU4Oc0hFy0WV7jEYUDAHB/Sn6hKUtZpMqQkbHAPGcGpNPQSRmTJUt1C8A1T1RA9jdhs48osPY5o2QzjBRRRWYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWzobl45Iz/B938axq09BkK3TphSGXPI54poDcwf7popd3sKKoVj//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin of the hands of this patient with nephrogenic systemic fibrosis are so thickened that flexibility is lost. The fingers are \"frozen\" in place by excess collagen in the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Shawn E Cowper, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23937=[""].join("\n");
var outline_f23_24_23937=null;
var title_f23_24_23938="Ultrasound normal fetal brain transventricular view";
var content_f23_24_23938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Transventricular plane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23938=[""].join("\n");
var outline_f23_24_23938=null;
var title_f23_24_23939="Local anesthetic block of the lateral femoral cutaneous nerve";
var content_f23_24_23939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Local anesthetic block of the lateral femoral cutaneous nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A local anesthetic block is placed over the lateral femoral cutaneous nerve to distinguish meralgia paresthetica from referred pain from the lumbosacral roots. The patient is placed in a supine position. A 1.5 in (4 cm), 22-gauge needle is inserted perpendicular to the skin, 2.5 cm (1 in)&nbsp;medial and 2.5 cm (1 in) inferior to the anterior superior iliac spine. The depth of injection is&nbsp;1.3 to 3.8 cm (0.5 to 1.5&nbsp;in) to the subcutaneous fat/fascial interface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23939=[""].join("\n");
var outline_f23_24_23939=null;
var title_f23_24_23940="Antihemophilic factor concentrates (human): Patient drug information";
var content_f23_24_23940=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Antihemophilic factor concentrates (human): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"     see \"Antihemophilic factor concentrates (human): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/35/14902?source=see_link\">",
"     see \"Antihemophilic factor concentrates (human): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hemofil M;",
"     </li>",
"     <li>",
"      Kote&reg;-DVI;",
"     </li>",
"     <li>",
"      Monoclate-P&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hemofil M",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is made from human plasma (part of the blood) and may have viruses that may cause disease. This drug is screened, tested, and treated to lower the chance that it carries an infection. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hemophilia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701530",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to antihemophilic factor, mice, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to latex, talk with your doctor. Some products are found in latex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given to you in a doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is given at home, store unopened vials in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Or store unopened Hemofil&reg;M at room temperature. Throw away any unused vials after 1 year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699229",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Or store unopened Koate&reg;-DVI and Monoclate-P&reg; at room temperature. Throw away any unused vials after 6 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11467 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23940=[""].join("\n");
var outline_f23_24_23940=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135729\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135730\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025891\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025893\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025892\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025896\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025897\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025899\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025895\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025900\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025901\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=related_link\">",
"      Antihemophilic factor concentrates (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/35/14902?source=related_link\">",
"      Antihemophilic factor concentrates (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_24_23941="Foregut formation";
var content_f23_24_23941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Foregut formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 457px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Formation of a ventral mesentery in the foregut region. The accessory organs of digestion (liver, pancreas, and gallbladder) derive from the foregut only. Like the gut tube, they rest in a \"sling\" of mesoderm, but because the gut tube already occupies the dorsal mesentery, these organs need a mesentery of their own. The ventral mesentery appears to form from thinning of the overlying mesoderm of the septum transversum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sadler TW. Langman's Medical Embryology, 9th Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23941=[""].join("\n");
var outline_f23_24_23941=null;
var title_f23_24_23942="Hydralazine plus nitrate therapy in patients with heart failure due to systolic dysfunction";
var content_f23_24_23942=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hydralazine plus nitrate therapy in patients with heart failure due to systolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23942/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23942/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23942/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23942/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23942/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23942/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/24/23942/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     Hydralazine",
"    </a>",
"    plus nitrate therapy provides symptomatic and mortality benefit in selected patients with heart failure (HF) due to systolic dysfunction.",
"   </p>",
"   <p>",
"    Data supporting the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus nitrates in patients with HF due to systolic dysfunction and recommendations for their use will be presented here. An overview of the treatment of HF due to systolic dysfunction (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    ), is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hemodynamic rationale for the combined use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and nitrate is to reduce cardiac preload and afterload by achieving both venous and arterial vasodilation. Hydralazine is an arterial vasodilator and nitrates are predominantly venodilators. These effects can reduce intracardiac filling pressures which may reduce adverse cardiac remodeling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=see_link\">",
"     \"Cardiac remodeling: Basic aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has also been hypothesized that combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and nitrate therapy enhances nitric oxide bioavailability since nitrates serve as nitric oxide donors and hydralazine is an antioxidant that reduces consumption of nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It has been postulated that this protective mechanism can be recruited even in the presence of neurohormonal blockade (eg, use of angiotensin converting enzyme [ACE] inhibitors).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVIDENCE OF BENEFIT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     V-HeFT trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The V-HeFT I and II trials were performed in men with predominantly NYHA class II or III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) and left ventricular (LV) enlargement or systolic dysfunction (LV ejection fraction &lt;45 percent). These trials found that the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    (40 mg three or four times daily) produced modest benefit in patients with HF compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/3\">",
"     3",
"    </a>",
"    ] and was less effective than ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the V-HeFT I, 642 men with HF were randomly assigned to placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    (20 mg per day), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    (titrated to 100 mg three times daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    (160 mg per day) added to a diuretic and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/3\">",
"     3",
"    </a>",
"    ]. No patients were treated with a beta-blocker or an ACE inhibitor. Mortality was not different between the placebo and prazosin groups. With hydralazine plus isosorbide dinitrate there was reduction in all-cause mortality at 2 years (26 percent versus 34 percent with placebo) and there was a trend toward reduction in mortality during the overall period of follow-up (mean 2.3 years). Post-hoc analysis found that blacks, but not whites, had a significant reduction in mortality with hydralazine plus isosorbide dinitrate compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/5\">",
"     5",
"    </a>",
"    ]. However no significant interaction between race and treatment was found (P=0.11).",
"   </p>",
"   <p>",
"    The efficacy of ACE inhibitors compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    was evaluated in the V-HeFT II trial of 804 men [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Patients were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (20 mg per day) or hydralazine (300 mg per day) plus isosorbide dinitrate (160 mg per day). No patients were treated with a beta-blocker. The mortality rate was lower with enalapril (18 versus 25 percent with",
"    <span class=\"nowrap\">",
"     hydralazine/nitrate)",
"    </span>",
"    at two years and there was a trend toward reduction in mortality with enalapril during the overall period of follow-up (mean 2.5 years). On post hoc analysis, the mortality benefit with enalapril was seen only in white patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/5\">",
"     5",
"    </a>",
"    ]. However no significant interaction between race and treatment was found (P=0.09).",
"   </p>",
"   <p>",
"    Compliance with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    has generally been poor because of the large number of tablets required and the high incidence of adverse reactions. However, the V-HeFT trials did find a mortality benefit from the hydralazine-nitrate combination. ACE inhibitor therapy produced a greater mortality benefit than hydralazine plus nitrate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     In addition to ACE inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and nitrates to standard HF therapy also appears to be beneficial. This was demonstrated in the African-American Heart Failure (A-HeFT) Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In this trial, 1050 patients with NYHA class III to IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) who identified themselves as black (of African descent) were randomly assigned to receive either placebo or a fixed-dose combination of hydralazine (37.5 to 75 mg orally three times daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    (20 to 40 mg orally three times daily). All patients were receiving other HF therapy, including ACE inhibitors in 70 percent, ARBs in 17 percent, beta blockers in 74 percent, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    in 39 percent.",
"   </p>",
"   <p>",
"    The trial was terminated early because of a significantly lower mortality rate in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus nitrate arm (6.2 versus 10.2 percent with placebo at a mean of 10 months). Active therapy was also associated with a significantly lower rate of first hospitalizations for HF and a significantly greater improvement in quality of life.",
"   </p>",
"   <p>",
"    At six months, the blood pressure had fallen by a mean of",
"    <span class=\"nowrap\">",
"     1.9/2.4",
"    </span>",
"    mmHg in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus nitrate arm compared to a small increase of",
"    <span class=\"nowrap\">",
"     1.2/0.8",
"    </span>",
"    mmHg, raising the possibility that at least some of the benefit may have been due to blood pressure reduction. The following observations support a specific benefit from drug therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a post hoc subgroup analysis from A-HeFT,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      plus isosorbide did not lower blood pressure in patients whose baseline systolic blood pressure was below the mean (126 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/7\">",
"       7",
"      </a>",
"      ]. However, these patients received the same relative risk reduction as patients with higher baseline blood pressure, whose blood pressure was reduced with isosorbide and hydralazine.",
"     </li>",
"     <li>",
"      In different trials of patients with HF,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      lowered blood pressure compared to placebo but did not improve outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/3,8\">",
"       3,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the A-HeFT trial studied a proprietary fixed-dose combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    , it is likely that the same benefit can be achieved using separate or generic formulations of these drugs.",
"   </p>",
"   <p>",
"    An observational study evaluated the impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    following hospital admission for acute decompensated heart failure with cardiac index &le;2.2",
"    <span class=\"nowrap\">",
"     L/min/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/9\">",
"     9",
"    </a>",
"    ]. All 239 patients were prescribed an ACE inhibitor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARB therapy at discharge, and about two-thirds were on a beta-blocker. Hydralazine plus isosorbide dinitrate was prescribed to 142 patients at discharge at the discretion of the treating physician. Patients in the hydralazine plus nitrate group had lower cardiac index (1.7 versus 1.9",
"    <span class=\"nowrap\">",
"     L/min/m2)",
"    </span>",
"    on admission and showed greater improvement in cardiac index and systemic vascular resistance compared to controls. During follow-up (median of 26.3 months), patients receiving hydralazine plus nitrate had a lower rate of all-cause mortality (34 versus 41 percent) and all-cause",
"    <span class=\"nowrap\">",
"     mortality/HF",
"    </span>",
"    hospitalization (70 versus 80 percent), irrespective of race, although there was a trend toward greater significance in African-American patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Unresolved issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus nitrate therapy in patients with NYHA class II HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) is limited. Also, it is not clear whether hydralazine plus nitrate therapy is beneficial in patients treated with both an ACE inhibitor and an ARB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Racial subgroups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also unanswered is whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus nitrate has differing effects in various ethnic populations. In subgroup analyses, this combination of agents produced a significant mortality benefit in blacks but not whites in the V-HeFT trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/5\">",
"     5",
"    </a>",
"    ]. However, tests for interaction between race and treatment produced nonsignificant results. Potential reasons for differences in benefit between the racial subgroups include chance, genetic differences that may impact drug effects (eg, blacks may have lower nitric oxide bioavailability than whites) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], and differences in the cause of HF (the primary cause was hypertension in 39 percent of patients in A-HeFT, compared to 7 percent of patients in the CHARM-Added and CHARM-Alternative trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OUR RECOMMENDATIONS AND MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations are based on the evidence discussed above (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Evidence of benefit'",
"    </a>",
"    above). The strength of the evidence for benefit is somewhat stronger in blacks than in other groups. For black patients with persistent NYHA class III to IV HF and LVEF &lt;40 percent despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), aldosterone antagonist (if indicated), and diuretics, we recommend the addition of the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and an oral nitrate. For select non-black patients with left ventricular ejection fraction &lt;40, particularly those with low output syndromes, hypertension, or mitral regurgitation with persistent symptoms despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), and aldosterone antagonist (if indicated another diuretics, we suggest the addition of the combination of hydralazine and an oral nitrate).",
"   </p>",
"   <p>",
"    We suggest treatment with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus nitrate in patients with HF and reduced LVEF who are unable to take either an ACE inhibitor or an ARB due to drug intolerance (including hyperkalemia), hypotension, or renal insufficiency. ARB intolerance can be presumed in patients who develop hyperkalemia or renal insufficiency on ACE inhibitor therapy.",
"   </p>",
"   <p>",
"    The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines with 2009 update include the following recommendations for use of combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and nitrate therapy (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      plus a nitrate is recommended to improve outcomes for patients self-described as African American with moderate to severe symptoms on optimal therapy with ACE inhibitors, beta blockers and diuretics.",
"     </li>",
"     <li>",
"      It is reasonable to add the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      plus a nitrate in patients with persistent HF symptoms who are already taking an ACE inhibitor and a beta-blocker.",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and a nitrate might be reasonable in patients who cannot take an ACE inhibitor or ARB due to drug intolerance, hypotension, or renal insufficiency (class IIb).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2009 Heart Failure Society of America (HFSA) guidelines include the following recommendations for use of the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and an oral nitrate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and an oral nitrate is recommended as part of standard therapy in addition to beta-blockers and ACE inhibitors for African-American patients with LV systolic dysfunction with NYHA class III or IV HF (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      ), as well as those with NYHA II HF (evidence for the later being weaker).",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and an oral nitrate may be considered in non-African-American patients with LV systolic dysfunction who remain symptomatic despite optimized standard therapy.",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and an oral nitrate may be considered in patients intolerant of ACE inhibitors or ARBs. The guidelines noted that patients intolerant of ACE inhibitors due to hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs so the combination of hydralazine and an oral nitrate should be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2008 European Society of Cardiology (ESC) guidelines include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23942/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      should be considered in patients with persistent symptoms despite treatment with an ACEI, beta-blocker, and an ARB or aldosterone antagonist. The guidelines note that the evidence is strongest in patients of African-American descent.",
"     </li>",
"     <li>",
"      It is reasonable to use a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      in symptomatic patients with an LVEF &le;40 percent as an alternative to an ACEI or ARB if there is intolerance to both of these medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Starting doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    25 mg three times daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    20 mg three times daily are recommended. Uptitration of dose should be considered every 2 to 4 weeks. The dose should not be increased if symptomatic hypotension develops. The target dose is hydralazine 75 mg three times daily and isosorbide dinitrate (40 mg three times daily). Although direct evidence of efficacy is lacking,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    (40 to 120 mg daily) may be used in place of isosorbide dinitrate to improve compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential adverse effects include hypotension. If symptomatic hypotension occurs, reduction in hypotensive agents is recommended but ACE inhibitor, beta-blocker, ARB, and aldosterone antagonist therapy should be continued if possible.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     Hydralazine",
"    </a>",
"    can cause a drug-induced lupus-like syndrome including arthralgias, myalgias, joint swelling,",
"    <span class=\"nowrap\">",
"     pericarditis/pleuritis,",
"    </span>",
"    rash, or fever. Such clinical manifestations should trigger an evaluation and if appropriate treatment including discontinuation of",
"    <span class=\"nowrap\">",
"     hydralazine/nitrate",
"    </span>",
"    if drug-induced lupus is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For black patients with persistent NYHA class III to IV HF and LVEF &lt;40 percent despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), aldosterone antagonist (if indicated), and diuretics, we recommend the addition of the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and an oral nitrate (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The strength of the evidence for benefit is somewhat stronger in African Americans than in other groups. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evidence of benefit'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Our recommendations and major society guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For select non-black patients with left ventricular ejection fraction &lt;40, particularly those with low output syndromes, hypertension, or mitral regurgitation with persistent symptoms despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), and aldosterone antagonist (if indicated), and diuretics (if indicated), we suggest the addition of the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and an oral nitrate (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evidence of benefit'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Our recommendations and major society guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      plus nitrate in patients with HF and reduced LVEF who are unable to take either an ACE inhibitor or an ARB due to drug intolerance (including hyperkalemia), hypotension, or renal insufficiency (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). ARB intolerance can be presumed in patients who develop hyperkalemia or renal insufficiency on ACE inhibitor therapy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/1\">",
"      Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/2\">",
"      Taylor AL, Ziesche S, Yancy CW, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007; 115:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/3\">",
"      Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/4\">",
"      Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/5\">",
"      Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/6\">",
"      Loeb HS, Johnson G, Henrick A, et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87:VI78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/7\">",
"      Anand IS, Tam SW, Rector TS, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007; 49:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/8\">",
"      Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/9\">",
"      Mullens W, Abrahams Z, Francis GS, et al. Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol 2009; 103:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/10\">",
"      Bloche MG. Race-based therapeutics. N Engl J Med 2004; 351:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/11\">",
"      Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation 2004; 109:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/12\">",
"      Stein CM, Lang CC, Nelson R, et al. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther 1997; 62:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/13\">",
"      Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/14\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/15\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/16\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23942/abstract/17\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3492 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23942=[""].join("\n");
var outline_f23_24_23942=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVIDENCE OF BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      V-HeFT trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      In addition to ACE inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Unresolved issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Racial subgroups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OUR RECOMMENDATIONS AND MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3492|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 1\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_24_23943="Aeromonas infections";
var content_f23_24_23943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aeromonas infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23943/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23943/contributors\">",
"     J Glenn Morris, Jr, MD, MPH&amp;TM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23943/contributors\">",
"     Amy Horneman, PhD, MS, SM (ASCP)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23943/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23943/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23943/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23943/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/24/23943/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Aeromonas consists of gram-negative rods widely distributed in freshwater, estuarine, and marine environments [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Aeromonas species grow at a range of temperatures, although they are isolated with increasing frequency during warmer months (May through October in the Northern hemisphere). Aeromonas species cause a wide spectrum of disease syndromes among warm- and cold-blooded animals, including fish, reptiles, amphibians, mammals, and humans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Aeromonas was re-categorized from the family Vibrionaceae to the family Aeromonadaceae in the mid-1980s, when phylogenetic evidence from molecular studies became available to support this distinction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genus Aeromonas has been divided into two major groups [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motile, mesophilic species, including eight that can cause disease in humans (",
"      <a class=\"graphic graphic_table graphicRef70536 \" href=\"UTD.htm?4/48/4876\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Non-motile, psychrophilic species that generally cause disease only in fish.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aeromonas species are oxidase positive and ferment glucose. The organisms grow at a range of temperatures from 0 to 42&ordm;C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENICITY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observations have raised questions about the role of Aeromonas as a gastrointestinal pathogen. Stool isolation rates among individuals with diarrhea are variable, ranging from &lt;1 to &gt;60 percent. In addition, Aeromonas is a common isolate from asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. There has been only one major outbreak in which Aeromonas has been implicated as the etiologic agent of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/10\">",
"     10",
"    </a>",
"    ]. Efforts to induce illness in volunteers with selected Aeromonas strains were unsuccessful in one trial, although selection of strains may not have been optimal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, it is likely that certain strains of Aeromonas cause diarrheal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ]. Several minor outbreaks of traveler's diarrhea in adults have occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/14\">",
"     14",
"    </a>",
"    ]. One large study identified Aeromonas spp as a cause of traveler's diarrhea in 18 (2 percent) of 863 patients in Spain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/15\">",
"     15",
"    </a>",
"    ]. Another study of 3500 stool samples from patients hospitalized for diarrhea in India found 164 (4.7 percent) were positive for Aeromonas spp [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not possible to predict whether a particular Aeromonas strain is capable of inducing diarrheal illness. Possible virulence factors of Aeromonas species include toxins (cytotoxic and cytotonic), proteases, hemolysins, lipases, adhesins, agglutinins, pili, enterotoxins, various enzymes, and outer membrane arrays, such as an S-layer and capsule. Other factors that may contribute to virulence include VacB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/17\">",
"     17",
"    </a>",
"    ], enolase [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/18\">",
"     18",
"    </a>",
"    ], and the presence of a Type VI secretion system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/19-26\">",
"     19-26",
"    </a>",
"    ]. It is uncertain how many aeromonads contain these putative virulence factors. In addition to the presence of virulence factors in the organism, the host immune response to infection influences the severity of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesophilic aeromonads have been isolated from various aquatic environments worldwide, including [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fresh water",
"     </li>",
"     <li>",
"      Estuarine (brackish) water",
"     </li>",
"     <li>",
"      Surface water, especially recreational",
"     </li>",
"     <li>",
"      Drinking water, including treated, well, and bottled",
"     </li>",
"     <li>",
"      Polluted waters",
"     </li>",
"     <li>",
"      Waste water effluent sludge [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aeromonads are not generally considered marine organisms, but can be found in marine systems that interface with fresh waters and can survive at all but the most extreme salt concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/27\">",
"     27",
"    </a>",
"    ]. Usually they are not part of the groundwater bacterial population, which is generally poor in nutrients.",
"   </p>",
"   <p>",
"    In nutrient-rich waters, Aeromonas species can grow to large numbers and generally peak in the warmer temperatures of the summer months in temperate freshwater lakes and chlorinated drinking water [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Aeromonas species appear to tolerate polluted environments, including chemical pollution, although they are not considered to be of fecal origin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/28\">",
"     28",
"    </a>",
"    ]. The organism has also been isolated from retail produce sources and meat products [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of infection can be reduced by caution in the setting of natural water sources, including minimizing the risk of traumatic wounds and avoiding oral ingestion, particularly during warmer summer months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrheal disease is the most common manifestation of Aeromonas infection. The organism has also been associated with a variety of extraintestinal presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/4,8,12,35-37\">",
"     4,8,12,35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aeromonas spp are associated with a range of diarrheal presentations including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute, secretory diarrhea, often accompanied by vomiting",
"     </li>",
"     <li>",
"      Acute, dysenteric diarrhea with blood and mucus",
"     </li>",
"     <li>",
"      Chronic diarrhea, lasting more than 10 days",
"     </li>",
"     <li>",
"      Choleric diarrhea with \"rice-water\" stools",
"     </li>",
"     <li>",
"      Traveler's diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been two reports of A. hydrophila enterocolitis associated with the hemolytic uremic syndrome (HUS) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Wound infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aeromonas can cause mild to severe wound infections. Infection typically occurs on the extremities following traumatic aquatic injury. Such wound infections affect men three times more commonly than women. The most typical presentation is cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/41\">",
"     41",
"    </a>",
"    ], although myonecrosis (with and without gas production), rhabdomyolysis, and lesions mimicking ecthyma gangrenosum have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A. hydrophila, A. veronii, and A. schubertii are the species most commonly isolated from wound infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/4,8,20,46\">",
"     4,8,20,46",
"    </a>",
"    ]. Aeromonas was a common wound isolate among tsunami victims in southeast Asia in 2004, and elevated numbers of Aeromonas spp were recorded in floodwater samples in New Orleans following Hurricane Katrina in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Additionally, several reports have documented aeromonad necrotizing fasciitis associated with species other than A. hydrophila, such as A. veronii biovar sobria, A. schubertii, and A. caviae [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious wound infections and sepsis have been reported following the medicinal use of leeches. Aeromonads reside in the gut of the leech Hirudo medicinalis, where they assist in the enzymatic digestion of the blood ingested by the leech [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Patients undergoing leech therapy often receive systemic chemoprophylaxis to prevent such infection.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    -treated leeches have been shown to eradicate aeromonads from leeches, and this may offer an alternative to chemoprophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis with Aeromonas species is strongly associated with infection with Aeromonas veronii biovar sobria (formerly identified in the clinical literature as Aeromonas). These patients present with the classic signs and symptoms of gram-negative sepsis. Patients typically have fever and gastrointestinal symptoms including abdominal pain, nausea, vomiting, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/4,55\">",
"     4,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sepsis tends to occur in older patients with hematologic malignancy, serious hepatobiliary disease, other immunocompromising conditions, or traumatic injuries. Pediatric case reports of sepsis due to A. hydrophila have been reported, including one case of a patient with diarrhea and pneumonia and one case of acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not always possible to identify the source of the organism in cases of sepsis; in such cases, it is reasonable to surmise that it was acquired from the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Miscellaneous extraintestinal sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aeromonas spp have been implicated in cases of ocular infections, osteomyelitis, meningitis, respiratory infections following \"near drowning,\" pelvic abscesses, otitis, cystitis, endocarditis, peritonitis, cholecystitis and joint infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/4,8,20,58-60\">",
"     4,8,20,58-60",
"    </a>",
"    ]. Necrotizing fasciitis and folliculitis due to A. hydrophila strain have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aeromonads are not routinely identified in most microbiology laboratories as part of the normal protocol for isolating stool pathogens. For cases in which Aeromonas is suspected, the laboratory must be advised to look for this organism. Automated identification systems can readily identify most true Aeromonas isolates to the level of A. hydrophila group or A.",
"    <span class=\"nowrap\">",
"     hydrophila/A.",
"    </span>",
"    caviae. However, these identifications are often incomplete or erroneous due to insufficient discriminatory markers to detect interspecies differences [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aeromonads grow quite readily on most media used for both routine cultures and stool cultures. Hemolysis is variable on blood agar media; most species display beta hemolysis. Although aeromonads grow on nearly all enteric media, they often are overlooked on MacConkey agar because A. caviae is lactose-positive just like E. coli.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     Ampicillin",
"    </a>",
"    -containing medium should not be used to suppress normal enteric flora, since a substantial portion of A. caviae isolates and all A. trota isolates are sensitive to ampicillin and therefore will not grow on such a medium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. This is especially important in light of reports implicating A. trota in pancreatic abscess and septic shock with cirrhosis, and A. caviae in cystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aeromonas spp are oxidase-positive, polar flagellated, glucose-fermenting, facultatively anaerobic, gram-negative rods that are resistant to the vibriostatic agent",
"    <span class=\"nowrap\">",
"     O/129",
"    </span>",
"    and unable to grow in 6.5 percent NaCl. The presumptive identification of an isolate involves the initial separation from other oxidase-positive genera such as Vibrio and Plesiomonas to avoid misidentification. This can be accomplished with simple tests such as",
"    <span class=\"nowrap\">",
"     O/129",
"    </span>",
"    susceptibility, tolerance to various NaCl broth concentrations, and the ability to ferment inositol [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimicrobial resistance markers and susceptibility studies should be determined by the standard agar dilution methods; disk diffusion and Vitek systems may not be reliable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antimicrobial susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies have demonstrated differences in antimicrobial susceptibility between species, highlighting the importance of both species identification and susceptibility testing for all isolates, particularly in the setting of serious infection. Most Aeromonas species produce an inducible chromosomal beta-lactamase, which may not be detected by rapid commercial susceptibility systems [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/72\">",
"     72",
"    </a>",
"    ]. Aeromonads produce beta-lactamases from three different classes; a class C cephalosporinase, a class D penicillinase, and a class B metallo-beta-lactamase (MBL) of the &ldquo;CphA&rdquo; type [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most Aeromonas strains are resistant to penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , carbenicillin, and ticarcillin; most are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX), fluoroquinolones, second and third generation cephalosporins, aminoglycosides, carbapenems,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , and tetracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/8,58,73-78\">",
"     8,58,73-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regional resistance patterns have been described, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in antimicrobial resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      , TMP-SMX, some extended-spectrum cephalosporins, and aminoglycosides has been observed among some isolates in Taiwan (compared with isolates from the United States and Australia) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antimicrobial resistance to nalidixic acid has been observed in Spain; a surveillance study of 43 strains reported that 26 percent of A. caviae, 20 percent of A. hydrophila, and 88 percent of A. veronii biotype sobria were resistant to nalidixic acid. Although still susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , these strains had a mutation in the A subunit of DNA gyrase and could easily develop a second mutation resulting in resistance to ciprofloxacin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other MBLs (VIM and IMP) in strains of A. hydrophila and A. caviae have been detected, encoded on an integron and a plasmid, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/80,81\">",
"       80,81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of Aeromonas-associated diarrhea are self-limited and can be managed with supportive therapy, including oral and intravenous rehydration. Based on anecdotal data, antibiotics may be of value in patients with severe diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/74\">",
"     74",
"    </a>",
"    ]. Antibiotic therapy is also indicated in the setting of wound infection and bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/75\">",
"     75",
"    </a>",
"    ]. Given emerging antimicrobial resistance, antimicrobial susceptibility testing of isolates is essential. Pending species identification and susceptibility testing, initial empiric therapy of suspected Aeromonas spp infections with a fluoroquinolone, third generation cephalosporin, or TMP-SMX would provide reasonable antimicrobial coverage.",
"   </p>",
"   <p>",
"    If the infection is acquired following travel to Taiwan or Spain, TMP-SMX should not be the empiric choice for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23943/abstract/75,79\">",
"     75,79",
"    </a>",
"    ]. In addition, therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    or first generation cephalosporins is",
"    <strong>",
"     NOT",
"    </strong>",
"    appropriate. All species of clinical aeromonads are resistant to ampicillin except for A. trota and sometimes A. caviae. A. veronii biovar sobria (formerly A. sobria) is uniformly resistant to first generation cephalosporins, but in vitro testing suggests that it is susceptible to third and fourth generation cephalosporins. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Antimicrobial susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are no clinical trial data to guide the duration of therapy; therefore, treatment should be guided by clinical response. Reasonable courses of therapy include three days of therapy for treatment of diarrhea, 7 to 10 days of therapy for treatment of wound infections, and two weeks of therapy for treatment of bacteremia. The course of therapy may need to be adjusted depending on individual circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544000\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genus Aeromonas consists of gram-negative rods widely distributed in freshwater, estuarine, and marine environments. Aeromonas species have been isolated with increasing frequency during warmer months. The organisms cause a wide spectrum of disease syndromes among warm and cold-blooded animals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diarrheal disease is the most common manifestation of Aeromonas infection. The organism has also been associated with a variety of extraintestinal presentations, including wound infections and bacteremia. Necrotizing fasciitis has also been reported with species such as A. veronii biovar sobria, A. schubertii, and A. caviae. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aeromonads are not routinely identified in most microbiology laboratories as part of the normal protocol for isolating stool pathogens. For cases in which Aeromonas is suspected, the laboratory must be advised to look for this organism. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical studies have demonstrated differences in antimicrobial susceptibility between species, highlighting the importance of both species identification and susceptibility testing for all isolates, particularly in the setting of serious infection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antimicrobial susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pending species identification and susceptibility testing, we suggest initial empiric therapy of suspected Aeromonas infections (severe diarrhea, wound infections, bacteremia) with a fluoroquinolone, third generation cephalosporin, or TMP-SMX (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Holmes P, Niccolls LM, Sartory DP. The ecology of mesophilic Aeromonas in the aquatic environment. In: The Genus: Aeromonas, First Edition, Austin B, Altwegg M, Gosling PJ, Joseph SW (Eds), John Wiley &amp; Sons, Ltd, Chicester 1996. p.127.",
"    </li>",
"    <li>",
"     Martin-Carnahan A, Joseph SW. Aeromonas. In: Bergey's Manual of Systematic Bacteriology, Second Edition, Brenner, Krieg, Staley, Garrity (Eds), Williams and Wilkins, New York 2005. Vol 2.",
"    </li>",
"    <li>",
"     Gosling PJ. Aeromonas species in diseases of animals. In: The Genus: Aeromonas, First Edition, Austin B, Altwegg M, Gosling PJ, Joseph SW (Eds), John Wiley &amp; Sons, Ltd, Chicester 1996. p.175.",
"    </li>",
"    <li>",
"     Janda JM, Abbott SL. Human pathogens. In: The Genus: Aeromonas, First Edition, Austin B, Altwegg M, Gosling PJ, Joseph SW (Eds), John Wiley &amp; Sons, Ltd, Chicester 1996. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/5\">",
"      MacDonell MT, Colwell RR. Phylogeny of the family Vibrionaceae and recommendation for two new genera: Listonella and Shewanella. Syst Appl Microbiol 1985; 6:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/6\">",
"      Colwell RR, MacDonell MR, De Ley J. Proposal to recognize the family Aeromonadaceae. Int J Syst Bacteriol 1986; 36:473.",
"     </a>",
"    </li>",
"    <li>",
"     Horneman AJ, Ali A, Abbott S. Aeromonas. In: Manual of Clinical Microbiology, Ninth Edition, Murray P (Ed), ASM Press, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/8\">",
"      Janda JM, Abbott SL. Evolving concepts regarding the genus Aeromonas: an expanding Panorama of species, disease presentations, and unanswered questions. Clin Infect Dis 1998; 27:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/9\">",
"      Janda JM, Abbott SL. The genus Aeromonas: taxonomy, pathogenicity, and infection. Clin Microbiol Rev 2010; 23:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/10\">",
"      Hofer E, Reis CM, Theophilo GN, et al. [Aeromonas associated with an acute diarrhea outbreak in S&atilde;o Bento do Una, Pernambuco]. Rev Soc Bras Med Trop 2006; 39:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/11\">",
"      Morgan DR, Johnson PC, DuPont HL, et al. Lack of correlation between known virulence properties of Aeromonas hydrophila and enteropathogenicity for humans. Infect Immun 1985; 50:62.",
"     </a>",
"    </li>",
"    <li>",
"     Joseph SW. Aeromonas gastrointestinal disease: A case study in causation?. In: The Genus: Aeromonas, First Edition, Austin B, Altwegg M, Gosling PJ, Joseph SW (Eds), John Wiley &amp; Sons, Ltd, Chichester 1996. p.311.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/13\">",
"      Figueras MJ, Aldea MJ, Fern&aacute;ndez N, et al. Aeromonas hemolytic uremic syndrome. A case and a review of the literature. Diagn Microbiol Infect Dis 2007; 58:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/14\">",
"      Galindo CL, Sha J, Fadl LL, et al. Host immune responses to aeromonas virulence factors. Curr Immunol Rev 2006; 2:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/15\">",
"      Vila J, Ruiz J, Gallardo F, et al. Aeromonas spp. and traveler's diarrhea: clinical features and antimicrobial resistance. Emerg Infect Dis 2003; 9:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/16\">",
"      Sinha S, Shimada T, Ramamurthy T, et al. Prevalence, serotype distribution, antibiotic susceptibility and genetic profiles of mesophilic Aeromonas species isolated from hospitalized diarrhoeal cases in Kolkata, India. J Med Microbiol 2004; 53:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/17\">",
"      Erova TE, Kosykh VG, Fadl AA, et al. Cold shock exoribonuclease R (VacB) is involved in Aeromonas hydrophila pathogenesis. J Bacteriol 2008; 190:3467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/18\">",
"      Sha J, Erova TE, Alyea RA, et al. Surface-expressed enolase contributes to the pathogenesis of clinical isolate SSU of Aeromonas hydrophila. J Bacteriol 2009; 191:3095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/19\">",
"      Cahill MM. Virulence factors in motile Aeromonas species. J Appl Bacteriol 1990; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/20\">",
"      Janda JM. Recent advances in the study of the taxonomy, pathogenicity, and infectious syndromes associated with the genus Aeromonas. Clin Microbiol Rev 1991; 4:397.",
"     </a>",
"    </li>",
"    <li>",
"     Gosling PJ. Pathogenic mechanisms. In: The Genus: Aeromonas, First Edition, Austin B, Altwegg M, Gosling PJ, Joseph SW (Eds), John Wiley &amp; Sons, Ltd, Chichester 1996. p.245.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/22\">",
"      Sha J, Kozlova EV, Fadl AA, et al. Molecular characterization of a glucose-inhibited division gene, gidA, that regulates cytotoxic enterotoxin of Aeromonas hydrophila. Infect Immun 2004; 72:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/23\">",
"      Kirov SM. Bacteria that express lateral flagella enable dissection of the multifunctional roles of flagella in pathogenesis. FEMS Microbiol Lett 2003; 224:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/24\">",
"      Seshadri R, Joseph SW, Chopra AK, et al. Genome sequence of Aeromonas hydrophila ATCC 7966T: jack of all trades. J Bacteriol 2006; 188:8272.",
"     </a>",
"    </li>",
"    <li>",
"     Erova TE, Sha J, Horneman AJ, et al. Identification of a new hemolysin from a diarrheal isolate SSU of Aeromonas hydrophila. FEMS Microbiology Letters.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/26\">",
"      Suarez G, Sierra JC, Sha J, et al. Molecular characterization of a functional type VI secretion system from a clinical isolate of Aeromonas hydrophila. Microb Pathog 2008; 44:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/27\">",
"      Hazen TC, Fliermans CB, Hirsch RP, Esch GW. Prevalence and distribution of Aeromonas hydrophila in the United States. Appl Environ Microbiol 1978; 36:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/28\">",
"      Seidler RJ, Allen DA, Lockman H, et al. Isolation, enumeration, and characterization of Aeromonas from polluted waters encountered in diving operations. Appl Environ Microbiol 1980; 39:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/29\">",
"      Kaper JB, Lockman H, Colwell RR, Joseph SW. Aeromonas hydrophila: ecology and toxigenicity of isolates from an estuary. J Appl Bacteriol 1981; 50:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/30\">",
"      van der Kooij D. Properties of aeromonads and their occurrence and hygienic significance in drinking water. Zentralbl Bakteriol Mikrobiol Hyg B 1988; 187:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/31\">",
"      Monfort P, Baleux B. Distribution and survival of motile Aeromonas spp. in brackish water receiving sewage treatment effluent. Appl Environ Microbiol 1991; 57:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/32\">",
"      Burke V, Robinson J, Gracey M, et al. Isolation of Aeromonas spp. from an unchlorinated domestic water supply. Appl Environ Microbiol 1984; 48:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/33\">",
"      Burke V, Robinson J, Gracey M, et al. Isolation of Aeromonas hydrophila from a metropolitan water supply: seasonal correlation with clinical isolates. Appl Environ Microbiol 1984; 48:361.",
"     </a>",
"    </li>",
"    <li>",
"     Palumbo SA. The Aeromonas hydrophila group in food. In: The Genus: Aeromonas, First Edition, Austin B, Altwegg M, Gosling PJ, Joseph SW (Eds), John Wiley &amp; Sons, Ltd, Chichester 1996. p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/35\">",
"      Kelly KA, Koehler JM, Ashdown LR. Spectrum of extraintestinal disease due to Aeromonas species in tropical Queensland, Australia. Clin Infect Dis 1993; 16:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/36\">",
"      Figueras MJ. Clinical relevance of Aeromonas. Rev Med Microbiol 2005; 16:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/37\">",
"      Parker JL, Shaw JG. Aeromonas spp. clinical microbiology and disease. J Infect 2011; 62:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/38\">",
"      Robson WL, Leung AK, Trevenen CL. Haemolytic-uraemic syndrome associated with Aeromonas hydrophila enterocolitis. Pediatr Nephrol 1992; 6:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/39\">",
"      Bogdanovi R, Cobelji M, Markovi M, et al. Haemolytic-uraemic syndrome associated with Aeromonas hydrophila enterocolitis. Pediatr Nephrol 1991; 5:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/40\">",
"      Figueras MJ, Horneman AJ, Martinez-Murcia A, Guarro J. Controversial data on the association of Aeromonas with diarrhoea in a recent Hong Kong study. J Med Microbiol 2007; 56:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/41\">",
"      Hanson PG, Standridge J, Jarrett F, Maki DG. Freshwater wound infection due to Aeromonas hydrophila. JAMA 1977; 238:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/42\">",
"      Tena D, Gonz&aacute;lez-Praetorius A, P&eacute;rez-Pomata MT, Bisquert J. [Rapidly progressive myonecrosis by Aeromonas veronii biotype sobria]. An Med Interna 2006; 23:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/43\">",
"      Adamski J, Koivuranta M, Lepp&auml;nen E. Fatal case of myonecrosis and septicaemia caused by Aeromonas hydrophila in Finland. Scand J Infect Dis 2006; 38:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/44\">",
"      Easow JM, Tuladhar R. Aeromonas hydrophila wound infection following a tiger bite in Nepal. Southeast Asian J Trop Med Public Health 2007; 38:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/45\">",
"      Tena D, Aspiroz C, Figueras MJ, et al. Surgical site infection due to Aeromonas species: report of nine cases and literature review. Scand J Infect Dis 2009; 41:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/46\">",
"      Vally H, Whittle A, Cameron S, et al. Outbreak of Aeromonas hydrophila wound infections associated with mud football. Clin Infect Dis 2004; 38:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/47\">",
"      Maegele M, Gregor S, Steinhausen E, et al. The long-distance tertiary air transfer and care of tsunami victims: injury pattern and microbiological and psychological aspects. Crit Care Med 2005; 33:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/48\">",
"      Presley SM, Rainwater TR, Austin GP, et al. Assessment of pathogens and toxicants in New Orleans, LA following Hurricane Katrina. Environ Sci Technol 2006; 40:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/49\">",
"      Park SY, Jeong WK, Kim MJ, et al. Necrotising fasciitis in both calves caused by Aeromonas caviae following aesthetic liposuction. J Plast Reconstr Aesthet Surg 2010; 63:e695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/50\">",
"      Kao TL, Kao ML. A fatal case of necrotizing Aeromonas schubertii fasciitis after penetrating injury. Am J Emerg Med 2012; 30:258.e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/51\">",
"      Snower DP, Ruef C, Kuritza AP, Edberg SC. Aeromonas hydrophila infection associated with the use of medicinal leeches. J Clin Microbiol 1989; 27:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/52\">",
"      Graf J. Symbiosis of Aeromonas veronii biovar sobria and Hirudo medicinalis, the medicinal leech: a novel model for digestive tract associations. Infect Immun 1999; 67:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/53\">",
"      Sartor C, Limouzin-Perotti F, Legr&eacute; R, et al. Nosocomial Infections with Aeromonas hydrophila from Leeches. Clin Infect Dis 2002; 35:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/54\">",
"      Mumcuoglu KY, Huberman L, Cohen R, et al. Elimination of symbiotic Aeromonas spp. from the intestinal tract of the medicinal leech, Hirudo medicinalis, using ciprofloxacin feeding. Clin Microbiol Infect 2010; 16:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/55\">",
"      Tulsidas H, Ong YY, Chan KC. Aeromonas hydrophila bacteraemia and portal pyaemia. Singapore Med J 2008; 49:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/56\">",
"      Rodr&iacute;guez CN, Campos R, Pastran B, et al. Sepsis due to extended-spectrum beta-lactamase-producing Aeromonas hydrophila in a pediatric patient with diarrhea and pneumonia. Clin Infect Dis 2005; 41:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/57\">",
"      Filler G, Ehrich JH, Strauch E, Beutin L. Acute renal failure in an infant associated with cytotoxic Aeromonas sobria isolated from patient's stool and from aquarium water as suspected source of infection. J Clin Microbiol 2000; 38:469.",
"     </a>",
"    </li>",
"    <li>",
"     Altwegg M. Aeromonas. In: Manual of Clinical Microbiology, Seventh Edition, Murray PR, Baron EJ, Pfaller MA, et al (Eds), ASM Press, Washington, DC 1999. p.507.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/59\">",
"      Ouderkirk JP, Bekhor D, Turett GS, Murali R. Aeromonas meningitis complicating medicinal leech therapy. Clin Infect Dis 2004; 38:e36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/60\">",
"      Choi JP, Lee SO, Kwon HH, et al. Clinical significance of spontaneous Aeromonas bacterial peritonitis in cirrhotic patients: a matched case-control study. Clin Infect Dis 2008; 47:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/61\">",
"      Fosse T, Giraud-Morin C, Madinier I, et al. Aeromonas hydrophila with plasmid-borne class A extended-spectrum beta-lactamase TEM-24 and three chromosomal class B, C, and D beta-lactamases, isolated from a patient with necrotizing fasciitis. Antimicrob Agents Chemother 2004; 48:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/62\">",
"      Monaghan SF, Anjaria D, Mohr A, Livingston DH. Necrotizing fasciitis and sepsis caused by Aeromonas hydrophila after crush injury of the lower extremity. Surg Infect (Larchmt) 2008; 9:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/63\">",
"      Mulholland A, Yong-Gee S. A possible new cause of spa bath folliculitis: Aeromonas hydrophila. Australas J Dermatol 2008; 49:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/64\">",
"      Abbott SL, Seli LS, Catino M Jr, et al. Misidentification of unusual Aeromonas species as members of the genus Vibrio: a continuing problem. J Clin Microbiol 1998; 36:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/65\">",
"      Israil AM, Balotescu MC, Alexandru I, Dobre G. [Discordancies between classical and API 20E microtest biochemical identification of Vibrio and Aeromonas strains]. Bacteriol Virusol Parazitol Epidemiol 2003; 48:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/66\">",
"      Soler L, Marco F, Vila J, et al. Evaluation of two miniaturized systems, MicroScan W/A and BBL Crystal E/NF, for identification of clinical isolates of Aeromonas spp. J Clin Microbiol 2003; 41:5732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/67\">",
"      Carnahan AM, Chakraborty T, Fanning GR, et al. Aeromonas trota sp. nov., an ampicillin-susceptible species isolated from clinical specimens. J Clin Microbiol 1991; 29:1206.",
"     </a>",
"    </li>",
"    <li>",
"     Carnahan AM, Andrews G. Vibrio, Aeromonas, Plesiomonas and Campylobacter species. In: Textbook of Diagnostic Microbiology, Second Edition, Mahon, Manuselis (Eds), WB Saunders Co, Philadelphia 2000. p.524.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/69\">",
"      De Gascun CF, Rajan L, O'Neill E, et al. Pancreatic abscess due to Aeromonas hydrophila. J Infect 2007; 54:e59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/70\">",
"      Lai CC, Ding LW, Hsueh PR. Wound infection and septic shock due to Aeromonas trota in a patient with liver cirrhosis. Clin Infect Dis 2007; 44:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/71\">",
"      Al-Benwan K, Abbott S, Janda JM, et al. Cystitis caused by Aeromonas caviae. J Clin Microbiol 2007; 45:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/72\">",
"      Schadow KH, Giger DK, Sanders CC. Failure of the Vitek AutoMicrobic system to detect beta-lactam resistance in Aeromonas species. Am J Clin Pathol 1993; 100:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/73\">",
"      Motyl MR, McKinley G, Janda JM. In vitro susceptibilities of Aeromonas hydrophila, Aeromonas sobria, and Aeromonas caviae to 22 antimicrobial agents. Antimicrob Agents Chemother 1985; 28:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/74\">",
"      Overman TL, Janda JM. Antimicrobial susceptibility patterns of Aeromonas jandaei, A. schubertii, A. trota, and A. veronii biotype veronii. J Clin Microbiol 1999; 37:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/75\">",
"      Vila J, Marco F, Soler L, et al. In vitro antimicrobial susceptibility of clinical isolates of Aeromonas caviae, Aeromonas hydrophila and Aeromonas veronii biotype sobria. J Antimicrob Chemother 2002; 49:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/76\">",
"      Cattoir V, Poirel L, Aubert C, et al. Unexpected occurrence of plasmid-mediated quinolone resistance determinants in environmental Aeromonas spp. Emerg Infect Dis 2008; 14:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/77\">",
"      S&aacute;nchez-C&eacute;spedes J, Figueras MJ, Aspiroz C, et al. Development of imipenem resistance in an Aeromonas veronii biovar sobria clinical isolate recovered from a patient with cholangitis. J Med Microbiol 2009; 58:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/78\">",
"      Aravena-Rom&aacute;n M, Inglis TJ, Henderson B, et al. Antimicrobial susceptibilities of Aeromonas strains isolated from clinical and environmental sources to 26 antimicrobial agents. Antimicrob Agents Chemother 2012; 56:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/79\">",
"      Ko WC, Yu KW, Liu CY, et al. Increasing antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan. Antimicrob Agents Chemother 1996; 40:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/80\">",
"      Libisch B, Giske CG, Kov&aacute;cs B, et al. Identification of the first VIM metallo-beta-lactamase-producing multiresistant Aeromonas hydrophila strain. J Clin Microbiol 2008; 46:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23943/abstract/81\">",
"      Neuwirth C, Siebor E, Robin F, Bonnet R. First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. Antimicrob Agents Chemother 2007; 51:4486.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3138 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23943=[""].join("\n");
var outline_f23_24_23943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H544000\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENICITY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Wound infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Miscellaneous extraintestinal sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antimicrobial susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544000\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3138\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3138|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/48/4876\" title=\"table 1\">",
"      Clinical Aeromonas spp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_24_23944="Terminology and evaluation of abnormal uterine bleeding in premenopausal women";
var content_f23_24_23944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23944/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23944/contributors\">",
"     Anne Kathryn Goodman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23944/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23944/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23944/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23944/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/24/23944/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal uterine bleeding (AUB) is responsible for as many as one-third of all outpatient gynecologic visits, with the majority of cases just after menarche or in the perimenopausal period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It can be caused by a wide variety of local and systemic disease or related to drugs (",
"    <a class=\"graphic graphic_table graphicRef74527 \" href=\"UTD.htm?25/45/26334\">",
"     table 1",
"    </a>",
"    ). However, most cases are related to pregnancy, structural uterine pathology (eg, fibroids, polyps, adenomyosis), anovulation, a disorder of hemostasis, or neoplasia. Trauma and infection are less common.",
"   </p>",
"   <p>",
"    The terminology and evaluation of premenopausal women with AUB will be reviewed here. The evaluation and management of postmenopausal bleeding and abnormal bleeding in adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL UTERINE BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal menstrual cycle results from a complex feedback system involving the hypothalamus, pituitary, ovary, and uterus. In a normal ovulatory cycle, the endometrium proliferates from estrogen stimulation, then undergoes secretory changes when exposed to progesterone, and ultimately desquamates upon withdrawal of ovarian steroid support (",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 1",
"    </a>",
"    ). Cessation of bleeding depends, in part, on clot formation, but also on uterine factors, such as vasoconstriction and uterine contraction, which is regulated by local prostaglandins.",
"   </p>",
"   <p>",
"    The normal menstrual cycle length may be defined as varying from 24 to 35 days, lasting from two to seven days, and flowing less than 80 mL per cycle (average normal amount of menstrual blood loss is 30 to 40 mL per cycle). Bleeding outside of these parameters is abnormal; however, there are variations in criteria for what constitutes \"normal\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/3\">",
"     3",
"    </a>",
"    ]. There is relatively little cycle interval variability among women between the ages of 20 and 40. By comparison, there is significantly more cycle variability for the first five to seven years after menarche and for the last ten years before complete cessation of menses (",
"    <a class=\"graphic graphic_figure graphicRef79925 \" href=\"UTD.htm?0/27/446\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Predictable cyclic menses almost always reflect regular ovulation, while cycles that fall out of this range or that vary in length by more than 10 days from one cycle to the next are likely to be anovulatory. Clinical signs of ovulation include breast tenderness, bloating or pelvic discomfort, mood changes, and thin vaginal discharge at mid-cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A confusing, inconsistent, and overlapping array of terms has evolved to describe abnormal frequency, duration, or volume of uterine bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/3\">",
"     3",
"    </a>",
"    ]. For this reason, the general term \"abnormal uterine bleeding\" is often used instead of the terms described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dysfunctional uterine bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term dysfunctional uterine bleeding has classically been used to describe excessive noncyclic endometrial bleeding unrelated to anatomical lesions of the uterus or to systemic disease; thus, it is a diagnosis of exclusion. It is more useful to think of dysfunctional uterine bleeding as anovulatory bleeding, since this is the primary cause. Anovulation may be related to a systemic medical disease or may be due to a variety of factors which affect the hypothalamic pituitary axis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Menorrhagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menorrhagia refers to excessive or prolonged menstrual bleeding. It is technically defined as blood loss greater than 80 mL per cycle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    menstrual periods lasting longer than seven days. However, both patients and clinicians are unreliable in their ability to predict the amount of blood loss and measurement of actual blood loss is not practical in a clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In ovulatory women, menorrhagia is typically due to an anatomic lesion (eg, fibroid) or systemic disease (eg, hemostatic defect) in ovulatory women. Anovulation is also a common cause of menorrhagia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Amenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amenorrhea refers to absence of bleeding for at least three usual cycle lengths [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Oligomenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligomenorrhea refers to bleeding that occurs at an interval greater than 35 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Polymenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymenorrhea refers to regular bleeding that occurs at an interval less than 24 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Metrorrhagia and menometrorrhagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metrorrhagia refers to light bleeding from the uterus at irregular intervals. Menometrorrhagia refers to heavy bleeding from the uterus at irregular intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intermenstrual bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermenstrual bleeding refers to bleeding that occurs between menses or between expected hormone withdrawal bleeds in women using some forms of hormonal contraception or postmenopausal hormone therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Premenstrual spotting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenstrual spotting refers to light bleeding preceding regular menses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Postcoital bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postcoital spotting refers to vaginal bleeding that is noted within 24 hours of vaginal intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large randomized trials comparing different evaluation strategies on which to base a recommendation for work-up of women with AUB, and the possibility of concurrent factors should be considered. As an example, a woman with a fibroid uterus may also have a defect of hemostasis which is the primary reason for her menorrhagia or she may be bleeding from an endometrial or endocervical malignancy unrelated to the fibroid uterus. Therefore, if a possible cause of AUB is determined, but bleeding persists despite treatment, the patient should be evaluated for additional etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following information should be determined. The purpose and interpretation of the answers to these questions are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link\">",
"     \"Initial approach to the premenopausal woman with abnormal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are there symptoms of ovulation (ie, molimina): breast tenderness, pelvic pain, increased thin vaginal discharge? Absence of molimina suggests anovulatory bleeding, which is the most common cause of AUB. A key component of the evaluation of AUB is to determine whether the woman is ovulating because the etiologies and management of anovulatory and ovulatory bleeding are generally different.",
"     </li>",
"     <li>",
"      When did the bleeding start? Bleeding diathesis should be suspected in a woman with menorrhagia since menarche, as well as those who bruise easily or have mucous membrane bleeding. Anovulation often occurs in perimenarcheal and women in the menopausal transition. Women in the menopausal transition also are prone to developing polyps, adenomyosis, and fibroids.",
"     </li>",
"     <li>",
"      Were there precipitating factors, such as trauma? Bleeding related to trauma suggests a vaginal or cervical, rather than uterine, source of bleeding.",
"     </li>",
"     <li>",
"      What is the nature of the bleeding (frequency, duration, volume, relationship to activities such as coitus). The quantity of blood loss can be estimated by asking questions listed in the table (",
"      <a class=\"graphic graphic_table graphicRef69390 \" href=\"UTD.htm?14/2/14379\">",
"       table 2",
"      </a>",
"      ). Bleeding between periods is often related to a structural lesion (endometrial polyp, submucosal fibroid, cervical neoplasia). Irregular heavy periods are characteristic of anovulatory bleeding. Regular cyclic periods are typically ovulatory; heavy bleeding during regular cyclic periods suggests a bleeding diathesis, fibroid uterus, or adenomyosis.",
"     </li>",
"     <li>",
"      Are there any associated symptoms? Lower abdominal pain, fever,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vaginal discharge could indicate infection (endometritis, vaginitis). Changes in bladder or bowel function suggest a mass effect from a local neoplasm or nonuterine bleeding. Headaches, breast discharge, hot flashes, hirsutism or hair loss, acne, and symptoms of hyper- or hypo- metabolism are suggestive of an endocrinologic dysfunction (eg, thyroid disease, polycystic ovary syndrome, prolactinoma or other cranial tumor, menopausal transition, some ovarian tumors).",
"     </li>",
"     <li>",
"      Is there a personal or family history of a bleeding disorder? As an example, a disorder of hemostasis should be suspected in a woman with a history of bleeding associated with surgery, dental extraction, childbirth, or bruising (&gt;5",
"      <span class=\"nowrap\">",
"       cm)/epistaxis/bleeding",
"      </span>",
"      gums once or twice a month [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Does she have a systemic disorder and is she taking any medications? Endocrine disorders, chronic liver or renal disease, thrombocytopenia, and anticoagulants are associated with menorrhagia. Intrauterine devices and hormonal contraception commonly cause intermenstrual bleeding.",
"     </li>",
"     <li>",
"      Is she having coital relations? Pregnancy-related bleeding is a possibility.",
"     </li>",
"     <li>",
"      Has there been a change in weight, possibly associated with an eating disorder, excessive exercise, illness, or stress? This suggests anovulatory bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A woman may have strong concerns over changes in menstrual blood loss, although these changes may not be considered pathologic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Hysterectomy is frequently performed based upon perceived abnormal bleeding when, in fact, patient self-reports are inaccurate indicators of the quantity of blood lost at menses and pathologic examination of the uterus often shows no abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This was illustrated by a population based study in which one-quarter of women with normal periods considered their blood loss excessive, whereas 40 percent of those with excessive bleeding (&gt;80 mL) described their periods as light or moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/5\">",
"     5",
"    </a>",
"    ]. In another study, only one-third of women who considered their periods heavy had blood loss &gt;80 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination of the external and internal anatomy of the female genital tract is crucial in identifying anatomic causes of AUB. A diagnosis cannot be firmly established and a treatment plan should not be instituted without speculum and pelvic examinations. The focus of the evaluation is to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine if there is a bleeding site on the vulva, vagina, cervix, urethra, or anus",
"     </li>",
"     <li>",
"      Note any suspicious findings (eg, mass, laceration, ulceration, vaginal discharge, foreign body)",
"     </li>",
"     <li>",
"      Assess the size, contour, and tenderness of the uterus, which may suggest the presence of fibroids, adenomyosis, pregnancy, or infection",
"     </li>",
"     <li>",
"      Examine the adnexa for an ovarian tumor",
"     </li>",
"     <li>",
"      Evaluate for pain, which suggests infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a general examination should be performed to look for signs of systemic illness, such as fever, ecchymoses, an enlarged thyroid gland, or evidence of hyperandrogenism (hirsutism, acne, clitoromegaly, or male pattern balding). Acanthosis nigricans is often seen in women with insulin resistance and anovulation. Galactorrhea (bilateral milky nipple discharge) occurs in women with hyperprolactinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Basic laboratory evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pregnancy test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy (intrauterine or ectopic) should be ruled out with a serum or urine pregnancy test in all reproductive age women with AUB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gestational trophoblastic disease, which can present weeks to years after any pregnancy, is also associated with uterine bleeding and a positive pregnancy test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cervical cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of cervical cytology (eg, conventional or liquid based) should be performed in all women to exclude cervical cancer as the cause of AUB, as it can be difficult to determine whether bleeding is from an endocervical or endometrial source. Any visible cervical lesion should be biopsied, even if cervical cytology is negative for malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Endometrial sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;After pregnancy has been excluded, endometrial sampling should be performed in women with an increased risk of endometrial cancer or hyperplasia. The indications for endometrial sampling in women of reproductive age with abnormal uterine bleeding vary by age groups (",
"    <a class=\"graphic graphic_table graphicRef62089 \" href=\"UTD.htm?38/30/39403\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Age 45 years to menopause",
"      </strong>",
"      &ndash; In women who are ovulatory, any abnormal uterine bleeding, including intermenstrual bleeding In any woman, bleeding that is frequent (interval between the onset of bleeding episodes is less than 21 days), heavy (total volume of &gt;80 mL), or prolonged (longer than seven days).",
"     </li>",
"     <li>",
"      <strong>",
"       Younger than 45 years",
"      </strong>",
"      &ndash; Abnormal uterine bleeding that is persistent, occurs in the setting of a history of unopposed estrogen exposure (obesity, chronic anovulation) or failed medical management of the bleeding, or in women at high risk of endometrial cancer (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      therapy, Lynch syndrome).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, endometrial neoplasia should be suspected in premenopausal women who are anovulatory and have prolonged periods of amenorrhea (six or more months).",
"   </p>",
"   <p>",
"    Use of 45 years old as the threshold for increased concern regarding endometrial neoplasia is supported by evidence that the risk of endometrial hyperplasia and carcinoma is fairly low prior to age 45 years and increases with advancing age; 19 percent of cases occur in women aged 45 to 54 years compared with 6 percent in those aged 35 to 44 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. This age threshold is also consistent with American College of Obstetricians and Gynecologists (ACOG) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link&amp;anchor=H507038#H507038\">",
"     \"Classification and diagnosis of endometrial hyperplasia\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H1#H1\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideally, the biopsy should be performed at or beyond day 18 of a menstrual cycle to provide information about ovulatory status as well. An endometrial biopsy that shows secretory endometrium confirms ovulation occurred in that cycle. A proliferative endometrium in the 14 days",
"    <strong>",
"     before",
"    </strong>",
"    the subsequent menses suggests anovulation. Knowledge of the ovulatory status of the patient helps in differential diagnosis. Measuring gonadotropin levels is rarely indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial approach to the premenopausal woman with abnormal uterine bleeding\", section on 'Is bleeding anovulatory or ovulatory?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transvaginal ultrasound measurement of endometrial thickness is an alternative to endometrial sampling in postmenopausal women, but",
"    <strong>",
"     NOT",
"    </strong>",
"    in premenopausal women. In the premenopausal women, endometrial thickness is not an effective test, since there is to much variation during the menstrual cycle or other etiologies (eg, chronic anovulation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\", section on 'Premenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Additional laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional testing is selective and depends upon information obtained on history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ultrasound examination and hysteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination can be useful for further evaluating women whose findings on pelvic examination are uncertain; for looking for structural lesions in women in whom an adequate pelvic examination could not be accomplished; and for assessing the endometrium and myometrium in ovulatory women (those with predictable cyclic menses). It is not required in every woman with AUB. As an example, it may be omitted, at least in the initial evaluation, if AUB is felt to be due to a lesion observed on physical examination (endocervical polyp), anovulation, or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both transabdominal and transvaginal examinations should be performed. These studies can demonstrate subserosal and intramyometrial fibroids and thickening within the endometrial lining, but cannot reliably distinguish among polyps, submucous fibroids, adenomyosis, and neoplastic change. Ultrasound can also detect ovarian neoplasms (functional cysts or tumors), but these are rare causes of AUB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In premenopausal women, the examination should be performed on day 4, 5, or 6 of the bleeding cycle, when the endometrium is expected to be its thinnest (in reproductive age women normal endometrial thickness in the proliferative phase is 4 to 8 mm and in the secretory phase 8 to 14 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/18\">",
"     18",
"    </a>",
"    ]) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51541 \" href=\"UTD.htm?2/48/2816\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/19\">",
"     19",
"    </a>",
"    ]. This allows better visualization of pathology in the uterine cavity. Endometrial thickness has been correlated with risk of endometrial cancer in menopausal women; however, in premenopausal women, the utility of ultrasound assessment for excluding malignant or premalignant disease has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If structural abnormalities are suspected on ultrasound examination, then these abnormalities can be further evaluated by saline infusion sonography or hysteroscopy. The choice depends upon whether the patient and physician choose to increase the certainty of the diagnosis before proceeding to surgical treatment or choose to have a single, invasive procedure for diagnosis and treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saline infusion sonography &mdash; Saline infusion sonography (also called sonohysterography) is a technique in which sterile saline is instilled into the endometrial cavity and a transvaginal ultrasound examination is performed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/22\">",
"       22",
"      </a>",
"      ]. This procedure allows for careful architectural evaluation of the uterine cavity to detect small lesions (eg, polyps or small submucous fibroids) which may be missed or poorly defined by transvaginal sonography or by blind endometrial sampling (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54170 \" href=\"UTD.htm?0/28/450\">",
"       image 2",
"      </a>",
"      ). Compared to hysteroscopy, the disadvantages of saline infusion sonography are that no tissue is obtained for histological diagnosis and it does not allow concurrent therapeutic intervention (eg, polypectomy). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=see_link\">",
"       \"Saline infusion sonohysterography\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hysteroscopy &mdash; Hysteroscopy provides direct visualization of the endometrial cavity, thereby allowing targeted biopsy or excision of lesions identified during the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/23\">",
"       23",
"      </a>",
"      ]. Although considered the gold standard for diagnosis of AUB, hysteroscopy requires advanced training and is more costly and invasive than imaging modalities for endometrial assessment [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/18\">",
"       18",
"      </a>",
"      ]. It also requires anesthesia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link\">",
"       \"Overview of hysteroscopy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Thyroid function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with signs and symptoms of hypothyroidism or hyperthyroidism, serum thyroid stimulating hormone (TSH) concentration should be done as an initial screening test for thyroid disease. TSH is elevated in hypothyroidism and subnormal in hyperthyroidism. Hypothyroidism and hyperthyroidism can be characterized by oligo- or amenorrhea, or hypermenorrhea-menorrhagia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Coagulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A platelet count is obtained to look for thrombocytopenia.",
"   </p>",
"   <p>",
"    In addition, coagulation testing can be useful in women with a history suggestive of a hemostatic defect: family history of a bleeding disorder, excessive bleeding since menarche; excessive bleeding associated with surgery, dental extraction, or childbirth; or bruising &gt;5 cm, epistaxis, or bleeding gums once or twice a month. We suggest: partial thromboplastin time (PTT), prothrombin time (PT), factor VIII, and von Willebrand factor antigen and activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23944/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Hemoglobin/hematocrit",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with menorrhagia, evidence of a low",
"    <span class=\"nowrap\">",
"     hemoglobin/hematocrit",
"    </span>",
"    supports the clinical impression of excessive blood loss. However, the absence of anemia does not exclude the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Neisseria gonorrhea and Chlamydia trachomatis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for Neisseria gonorrhea and Chlamydia trachomatis should be performed if there is cervicitis, purulent vaginal discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pelvic tenderness. The vaginal discharge should also be evaluated for trichomonads. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Prolactin level",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolactin level should be measured in women who complain of oligomenorrhea or galactorrhea, which are associated with hyperprolactinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Androgen levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virilization or the new onset of hirsutism should prompt consideration of a hormonally active ovarian or adrenal tumor causing anovulation. In such women, check for elevated testosterone and DHEAS levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of history, physical examination, and laboratory evaluation are used to establish a diagnosis and guide treatment. The differential diagnosis of AUB is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link\">",
"     \"Initial approach to the premenopausal woman with abnormal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If bleeding persists after treatment, the possibility that additional etiologies are contributing to AUB should be considered and the patient should continue to be evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=see_link\">",
"       \"Patient information: Heavy periods (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"       \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"       \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"       \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal uterine bleeding can be caused by a wide variety of local and systemic disease or related to drugs (",
"      <a class=\"graphic graphic_table graphicRef74527 \" href=\"UTD.htm?25/45/26334\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The normal menstrual cycle length varies from 24 to 35 days, lasts from two to seven days, and flow is less than 80 mL per cycle. Bleeding outside of these parameters is abnormal. Predictable cyclic menses almost always reflect regular ovulation, while cycles that fall out of this range or that vary in length by more than 10 days from one cycle to the next are likely to be anovulatory. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal uterine bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All women with abnormal uterine bleeding should have a complete history and physical examination. Information should be obtained on the frequency, duration, and volume of abnormal uterine bleeding, as well as the presence of associated symptoms and precipitating factors. It is useful to determine whether the woman is ovulating because the etiologies of anovulatory and ovulatory bleeding are generally different. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A general physical examination as well as examination of the external and internal anatomy of the female genital tract via speculum and bimanual examination is directed at finding anatomic lesions or signs of systemic conditions that could be causing abnormal uterine bleeding. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pregnancy test and cervical cytology should be performed in all women. Women at risk for endometrial cancer should undergo endometrial biopsy, as well. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Basic laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound examination is most useful for looking for submucosal fibroids, endometrial polyps, adenomyosis as potential causes of abnormal uterine bleeding. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Ultrasound examination and hysteroscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional testing is selective and depends upon information obtained on history and physical examination. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Additional laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Awwad, JT, Toth, TL. Schiff, I. Abnormal uterine bleeding in the perimenopause. Int J Fertil 1993, 38:261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/2\">",
"      Wren BG. Dysfunctional uterine bleeding. Aust Fam Physician 1998; 27:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/3\">",
"      Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007; 87:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/4\">",
"      Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 1984; 149:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/5\">",
"      Hallberg L, H&ouml;gdahl AM, Nilsson L, Rybo G. Menstrual blood loss--a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/6\">",
"      Kouides PA, Conard J, Peyvandi F, et al. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertil Steril 2005; 84:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/7\">",
"      Greenberg M. The meaning of menorrhagia: an investigation into the association between the complaint of menorrhagia and depression. J Psychosom Res 1983; 27:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/8\">",
"      Hurskainen R, Aalto AM, Teperi J, et al. Psychosocial and other characteristics of women complaining of menorrhagia, with and without actual increased menstrual blood loss. BJOG 2001; 108:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/9\">",
"      Wright B, Gannon MJ, Greenberg M, et al. Psychiatric morbidity following endometrial ablation and its association with genuine menorrhagia. BJOG 2003; 110:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/10\">",
"      Grant C, Gallier L, Fahey T, et al. Management of menorrhagia in primary care-impact on referral and hysterectomy: data from the Somerset Morbidity Project. J Epidemiol Community Health 2000; 54:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/11\">",
"      Clarke A, Black N, Rowe P, et al. Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynaecol 1995; 102:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/12\">",
"      Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol 2004; 190:1216.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/corp.html (Accessed on August 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/14\">",
"      Reed SD, Newton KM, Clinton WL, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009; 200:678.e1.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/corp.html (Accessed on December 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/16\">",
"      ACOG practice bulletin no. 128: Diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol 2012; 120:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/17\">",
"      Doubilet PM. Diagnosis of abnormal uterine bleeding with imaging. Menopause 2011; 18:421.",
"     </a>",
"    </li>",
"    <li>",
"     APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/19\">",
"      Goldstein SR, Zeltser I, Horan CK, et al. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 1997; 177:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/20\">",
"      Dijkhuizen FP, Br&ouml;lmann HA, Potters AE, et al. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol 1996; 87:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/21\">",
"      Breitkopf DM, Frederickson RA, Snyder RR. Detection of benign endometrial masses by endometrial stripe measurement in premenopausal women. Obstet Gynecol 2004; 104:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/22\">",
"      Khan F, Jamaat S, Al-Jaroudi D. Saline infusion sonohysterography versus hysteroscopy for uterine cavity evaluation. Ann Saudi Med 2011; 31:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23944/abstract/23\">",
"      Bradley LD. Diagnosis of abnormal uterine bleeding with biopsy or hysteroscopy. Menopause 2011; 18:425.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5446 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23944=[""].join("\n");
var outline_f23_24_23944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL UTERINE BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dysfunctional uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Oligomenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Polymenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Metrorrhagia and menometrorrhagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intermenstrual bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Premenstrual spotting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Postcoital bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Basic laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pregnancy test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cervical cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Endometrial sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Additional laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ultrasound examination and hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Thyroid function tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Hemoglobin/hematocrit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Neisseria gonorrhea and Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Prolactin level",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Androgen levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DIFFERENTIAL DIAGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5446\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5446|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/48/2816\" title=\"diagnostic image 1\">",
"      Endometrial stripe normal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/28/450\" title=\"diagnostic image 2\">",
"      Sonogram endometrial polyp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5446|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/26/35246\" title=\"figure 1\">",
"      Hormones and menses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/27/446\" title=\"figure 2\">",
"      Menstrual interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5446|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/45/26334\" title=\"table 1\">",
"      Causes genital tract bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14379\" title=\"table 2\">",
"      Assessing menstrual blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/30/39403\" title=\"table 3\">",
"      Risk factors endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=related_link\">",
"      Definition and evaluation of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=related_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=related_link\">",
"      Patient information: Heavy periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=related_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=related_link\">",
"      Saline infusion sonohysterography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_24_23945="Nonresolving pneumonia";
var content_f23_24_23945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonresolving pneumonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23945/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23945/contributors\">",
"     David Ost, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23945/contributors\">",
"     Alan Fein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23945/contributors\">",
"     Steven H Feinsilver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23945/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23945/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/24/23945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slow or incomplete resolution of pneumonia despite treatment is a common clinical problem, estimated to be responsible for approximately 15 percent of inpatient pulmonary consultations and 8 percent of bronchoscopies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/1\">",
"     1",
"    </a>",
"    ]. There are a variety of reasons that a case of pneumonia might resolve slowly or incompletely, including those relating to the etiology of the pneumonia (misdiagnosis of the pathogen or the presence of a resistant pathogen); those relating to the host, including mechanical processes; and the development of complications from the initial infection. In addition, noninfectious etiologies of pulmonary infiltrates can mimic infectious pneumonia, thus making it appear that resolution is not following the expected course. Approximately 20 percent of presumed nonresponding community-acquired pneumonia is due to noninfectious causes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/2\">",
"     2",
"    </a>",
"    ]. Despite the frequency of this problem, there has been a paucity of studies specifically addressing this issue.",
"   </p>",
"   <p>",
"    In this review, we will use the term \"nonresolving pneumonia\" to include those cases of presumed pneumonia that progress, resolve slowly, or fail to achieve complete resolution despite what is thought to be appropriate therapy. We will first discuss those factors that normally affect the resolution of pneumonia, and we will then focus on specific causes of nonresolving pneumonia. Aspiration pneumonia, community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, and the approach to fever and pulmonary infiltrates in the immunocompromised patient are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL VERSUS DELAYED RESOLUTION OF PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal resolution of pneumonia is not easily defined and may vary depending upon the underlying cause. Patients typically note subjective improvement within three to five days of treatment; more specific clinical criteria for resolution include improvement in fever, cough, crackles, leukocytosis, arterial oxygenation (PaO2), and level of C-reactive protein (",
"    <a class=\"graphic graphic_table graphicRef74599 \" href=\"UTD.htm?3/31/3579\">",
"     table 1",
"    </a>",
"    ). However, most studies on the natural history of pneumonia have focused upon the resolution of chest radiographic abnormalities, with \"slow resolution\" often being defined as the persistence of radiographic abnormalities for greater than one month in a clinically improved host [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determining whether a patient has nonresolving or progressive pneumonia must also take into account several factors that affect the expected rate of resolution. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comorbidities &mdash; Comorbid conditions often slow the resolution of pneumonia (",
"      <a class=\"graphic graphic_table graphicRef62007 \" href=\"UTD.htm?21/14/21739\">",
"       table 2",
"      </a>",
"      ). Whereas patients without associated medical illnesses usually demonstrate clearing of radiographic infiltrates by four weeks, only 20 to 30 percent of patients with a comorbid condition will clear by four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age &mdash; Approximately 90 percent of patients younger than 50 years of age show radiographic resolution by four weeks, compared with only 30 percent of patients older than 50, even in the absence of concurrent disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severity &mdash; Radiographic resolution of severe pneumonia is estimated at 10 weeks, compared with three to four weeks for mild to moderate pneumonia.",
"     </li>",
"     <li>",
"      Infectious agent &mdash; The rate of radiographic and clinical improvement varies with the particular infectious agent causing the pneumonia. In general, resolution is more rapid with Mycoplasma pneumoniae, non-bacteremic Streptococcus pneumoniae, Chlamydophila (formerly Chlamydia) species, and Moraxella catarrhalis than with other organisms (",
"      <a class=\"graphic graphic_table graphicRef67206 \" href=\"UTD.htm?7/30/7660\">",
"       table 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INFLUENCE OF SPECIFIC BACTERIAL PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are available regarding resolution of pneumonia caused by different etiologic agents, including factors that affect the course of particular types of pneumonia. It should be noted that the empiric approach to treatment of CAP and HAP suggested by most guidelines can result in failure to treat appropriately when pneumonia is the result of less common pathogens like anaerobes and fungi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Streptococcus pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because pneumococcal pneumonia represents the most common cause of community-acquired pneumonia, it also is responsible for most cases of nonresolving pneumonia syndromes that are due to infection. In normal individuals without predisposing illness, clinical improvement is relatively rapid and precedes radiographic improvement. The maximum temperature generally decreases over the first 48 to 72 hours in patients with lobar pneumonia but may not resolve completely for several more days; however, only 6 percent of patients remain febrile beyond 20 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=see_link\">",
"     \"Pneumococcal pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for delayed resolution of auscultatory findings and fever include more severe presentation, multilobar disease, and infection with drug-resistant organisms. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Resistant bacterial pathogens'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic improvement is often much slower, with 20 to 30 percent of patients demonstrating no radiographic improvement after one week. Initial worsening of the chest radiograph is common. Risk factors for delayed radiographic resolution include bacteremia, persistent fever or leukocytosis beyond six days, advanced age, chronic obstructive pulmonary disease, alcoholism, and HIV.",
"   </p>",
"   <p>",
"    Radiographic clearing occurs by one to three months in non-bacteremic cases and three to five months in bacteremic cases. Residual radiographic abnormalities are rare in non-bacteremic cases but are present in up to 35 percent of bacteremic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Legionella infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the risk factors for development of Legionella are also risk factors for delayed resolution. These include cigarette smoking, alcoholism, age greater than 65 years, immunosuppression (especially glucocorticoid use), chronic kidney disease, and hematopoietic stem cell and solid organ transplantation. As a result, the rate of resolution for Legionella infection is usually slower than for other organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic, but not necessarily clinical, deterioration despite treatment is common, occurring in up to two-thirds of patients with Legionella, compared with 4 percent of patients with non-bacteremic pneumococcal pneumonia. In addition, after this initial deterioration, resolution is slow, with clearing beginning only after two to three weeks and approximately one-half of patients demonstrating residual abnormalities at 10 weeks. Resolution may take as long as 6 to 12 months, and residual fibrosis may be evident in up to 25 percent of patients.",
"   </p>",
"   <p>",
"    In addition to the slowly resolving or residual radiographic abnormalities, patients may experience generalized weakness and fatigue for months. Residual abnormalities on pulmonary function testing may be seen as long as two years later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mycoplasma pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycoplasma pneumoniae is a common cause of respiratory tract infection, but a rare cause of severe pneumonia. Resolution is typically rapid and faster than that with other types of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/1\">",
"     1",
"    </a>",
"    ]. Significant clinical improvement usually occurs within the first two weeks, which may in part reflect the predominantly young and otherwise healthy population affected.",
"   </p>",
"   <p>",
"    Radiographic deterioration after treatment is rare, occurring in less than 25 percent of cases. The average duration of radiographic abnormalities is two to four weeks, depending upon the use of antibiotics. Forty percent have complete radiographic resolution at four weeks and 90 percent at eight weeks. Residual radiographic abnormalities are distinctly unusual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chlamydophila pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydophila pneumoniae infection is common, with 30 to 50 percent of young adults having serologic evidence of prior infection. It is a relatively mild disease, and mortality is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/10\">",
"     10",
"    </a>",
"    ]. Prompt resolution is the rule in younger patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic deterioration is uncommon, with clearing typically occurring in less than three months. Fifty percent of chest radiographs clear within four weeks, while up to 20 percent take longer than nine weeks. Residual radiographic abnormalities persist in 10 to 20 percent of cases. Much information regarding Chlamydophila resolution is derived from observations of patients with psittacosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Haemophilus influenzae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Haemophilus influenzae is commonly considered a cause of pneumonia, especially in elderly adults, in cigarette smokers, and in patients with chronic obstructive lung disease. However, several large series following the widespread use of conjugate vaccines against H. influenzae type b in children have shown a decreasing incidence of infection and a shift to nontypeable strains compared with the more invasive type b infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=see_link\">",
"     \"Microbiology, epidemiology and treatment of Haemophilus influenzae\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history of H. influenzae infection has not been well studied, but there do not appear to be any unique features regarding its resolution. Based on the propensity for the organism to infect the immunocompromised and elderly, resolution is often slow, with many patients having prolonged hospitalization. Only 50 percent of patients return to their previous level of function by six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MISDIAGNOSIS OF NONBACTERIAL PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative pathogens in addition to the usual bacterial causes of pneumonia need to be considered in the patient who fails to respond to treatment (",
"    <a class=\"graphic graphic_table graphicRef78779 \" href=\"UTD.htm?28/11/28860\">",
"     table 4",
"    </a>",
"    ). Particularly important pathogens in this category include mycobacteria (either Mycobacterium tuberculosis or atypical mycobacteria), fungi, Nocardia, and Actinomyces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis is of significant concern, especially in elderly patients and in those who have immigrated within the past five years, those who have a history of intravenous drug use, and those who have other risk factors for the acquired immunodeficiency syndrome (AIDS).",
"   </p>",
"   <p>",
"    The clinical presentation of tuberculosis as a cause of nonresolving pneumonia is often atypical, especially in diabetics and in elderly patients, who commonly have radiographic findings in the middle or lower lung zones. Diagnosis may be difficult, as sputum is not always available and culture results take weeks after the specimen is obtained. Polymerase chain reaction testing has been approved for smear-positive specimens to allow confirmation of tuberculous disease, but its role in smear-negative cases is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both opportunistic and endemic fungal infections can mimic bacterial pneumonia. In the patient with an apparent nonresolving pneumonia, Aspergillus is a particularly important pathogen, presenting either as chronic necrotizing or as invasive aspergillosis. Patients with advanced AIDS are at increased risk of invasive aspergillosis, while patients with less advanced disease may develop tracheobronchitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82627 \" href=\"UTD.htm?18/5/18513\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although invasive aspergillosis classically occurs in neutropenic patients who have been on multiple antibiotics for several days, it is increasingly recognized in elderly patients with chronic lung disease who are on corticosteroids. Aspergillus in this setting may mimic a bacterial infection, and one series demonstrated that patients with invasive aspergillosis were treated for an average of 18 days with multiple antibiotics before the diagnosis was established [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endemic fungal infections such as histoplasmosis, coccidioidomycosis, blastomycosis, and cryptococcosis should be considered as a cause of nonresolving pneumonia in the appropriate endemic areas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74059 \" href=\"UTD.htm?36/40/37509\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/13\">",
"     13",
"    </a>",
"    ]. These include the Mississippi River valley for histoplasmosis, the southwestern United States for coccidioidomycosis, and the southeast and Midwest for blastomycosis. Each of these fungi can cause a nonspecific acute febrile illness, which may be confused with community-acquired pneumonia. Histoplasmosis has worldwide distribution and should be considered in travelers to high prevalence countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nocardia and Actinomyces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although Nocardia and Actinomyces are higher order bacteria, the clinical presentation of infection due to these organisms is more consistent with a fungal etiology. Nocardia infection presents most commonly on chest radiograph as a localized alveolar infiltrate that is usually homogeneous, nonsegmental, and cavitary. Infection due to Actinomyces has a similar appearance, but with a propensity to extend across fissures and invade the chest wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=see_link\">",
"     \"Treatment of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RESISTANT BACTERIAL PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a resistant pathogen is an important consideration for any pneumonia that is not responding appropriately to antibiotic therapy. Although penicillin-resistant Streptococcus pneumoniae (pneumococcus) is the organism of most concern, multidrug-resistant Haemophilus influenzae and Pseudomonas aeruginosa, as well as methicillin-resistant Staphylococcus aureus, are now increasingly recognized in the community setting as possible causes of a nonresolving or recurrent pneumonia.",
"   </p>",
"   <p>",
"    In some surveys, up to 80 percent of pneumococci demonstrate intermediate or high-level resistance depending on geography and strain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/14\">",
"     14",
"    </a>",
"    ]. A surveillance study has shown no significant increase in nonsusceptibility between 1999 and 2007 in the United Kingdom and Ireland [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among isolates from invasive pneumococcal disease, 21 to 25 percent demonstrate penicillin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/14\">",
"     14",
"    </a>",
"    ]. The suspicion of penicillin-resistant S. pneumoniae should be especially high in the following situations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Close exposure to young children; the rates of carriage and infection due to penicillin-resistant pneumococci are highest in children under the age of five years",
"     </li>",
"     <li>",
"      Prior treatment with a beta-lactam antibiotic (within the past six months)",
"     </li>",
"     <li>",
"      Previous pneumonia within the past year",
"     </li>",
"     <li>",
"      Hospitalization within the past three months",
"     </li>",
"     <li>",
"      Hospital-acquired (nosocomial) infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate treatment of infection due to penicillin-resistant Streptococcus pneumoniae is discussed elsewhere, but generally results in outcomes comparable with that in penicillin-sensitive cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HOST FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of host factors may be associated with delayed resolution of pneumonia, including alcoholism, older age, and the presence of comorbid diseases such as diabetes and chronic obstructive lung disease. In addition, disorders of immune function, particularly AIDS and syndromes associated with deficient humoral immunity, can be associated with delayed resolution of pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acquired immunodeficiency syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although unrecognized Pneumocystis jirovecii (formerly P. carinii) pneumonia remains an important diagnostic consideration in patients with AIDS, the most common initial lower respiratory tract infection in this patient population remains bacterial pneumonia. Overall, up to 5 percent of patients with community-acquired pneumonia have HIV infection, but in highly endemic areas for AIDS, this number may approach 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/17\">",
"     17",
"    </a>",
"    ]. Consequently, it is important to consider the possibility of underlying HIV infection in patients with nonresolving or progressive pneumonia. The Infectious Disease Society of America recommends routine testing for HIV infection in patients with community-acquired pneumonia between the ages of 15 and 54 occurring in hospitals in which the rate of newly diagnosed HIV infection exceeds one case per 1000 discharges. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15449?source=see_link\">",
"     \"Bacterial pulmonary infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Primary humoral immune deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to identify primary humoral immune deficiency as an underlying risk factor for pneumonia because of the effect of treatment with intravenous immune globulin (IVIG) on the incidence and resolution of pneumonia. Specific disorders commonly associated with hypogammaglobulinemia include X-linked agammaglobulinemia, common variable immune deficiency, and selective IgG subset deficiency. The most common pathogens in these patients include Streptococcus pneumoniae and Haemophilus influenzae, with Mycoplasma pneumoniae and Pneumocystis jirovecii being less common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DEVELOPMENT OF COMPLICATIONS FROM THE INITIAL PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sequestered foci of infection may prevent adequate concentrations of antibiotic agents from reaching the site of infection. The two main forms of sequestered focus preventing adequate resolution of pneumonia are empyema and lung abscess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Empyema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empyema is now a rare complication of community-acquired pneumonia (CAP). This was illustrated in a review of 3675 patients with CAP in which empyema was diagnosed by the attending physician in 1.3 percent and by strict laboratory criteria in 0.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/18\">",
"     18",
"    </a>",
"    ]. The patients with empyema were more likely to be younger and to be illicit drug users. The most common cultured pathogen was Streptococcus milleri, suggesting a role for aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/41/34456?source=see_link&amp;anchor=H10#H10\">",
"     \"Infections due to the Streptococcus anginosus group\", section on 'Thoracic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of a possible empyema is initially facilitated by imaging techniques such as computed tomography (CT) and ultrasound. In a patient with nonresolving pneumonia, demonstration of any significant amount of pleural fluid should prompt consideration of a diagnostic thoracentesis to rule out empyema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lung abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predisposing factors that should raise the suspicion of abscess formation include alcoholism, seizures, poor oral hygiene, and previous aspiration. Chest radiography typically demonstrates an air-liquid level, but chest CT is more sensitive and can confirm the diagnosis in difficult cases. Most patients with lung abscess do well with conservative management and a prolonged course of antibiotics. However, several factors are associated with increased abscess-related mortality and may warrant a more aggressive approach. These include age-related factors (pediatric or elderly populations), large cavity size, longer duration of symptoms prior to therapy, lower lobe location, association with malignant disease, and the presence of multiple abscesses. The development of infection in preexisting bullae may be mistaken for lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24729?source=see_link\">",
"     \"Lung abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NONINFECTIOUS ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of noninfectious etiologies of pulmonary infiltrates can mimic pneumonia and therefore represent causes of presumed nonresolving pneumonia. These fall into the categories of neoplastic, inflammatory, drug-induced, and vascular disease (",
"    <a class=\"graphic graphic_table graphicRef63652 \" href=\"UTD.htm?37/21/38235\">",
"     table 5",
"    </a>",
"    ). Some of these noninfectious etiologies may also be associated with nonresolving pneumonia through other pathophysiologic mechanisms, such as endobronchial obstruction by bronchogenic carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neoplastic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplasms may be associated with nonresolving pneumonia either by compromise of the airway lumen and secondary postobstructive pneumonia or abscess, or by mimicking an infiltrative process. Bronchogenic carcinoma and carcinoid tumors are the most common cause of endobronchial obstruction leading to pneumonia, whereas bronchioloalveolar cell carcinoma and lymphoma are the most common causes of an alveolar infiltrate mimicking pneumonia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchogenic carcinoma compromises the airway lumen either through endobronchial involvement or extrinsic compression. However, the frequency of endobronchial carcinoma as a cause of nonresolving pneumonia is relatively low, ranging from 0 to 8 percent in most series [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endobronchial obstruction by a carcinoid tumor is an important predisposing factor for a postobstructive pneumonia, and should be considered as a possible etiology for endobronchial obstruction in a young or nonsmoking patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H9#H9\">",
"       \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchioloalveolar cell carcinoma may present as a focal infiltrate, often with air bronchograms, and ground glass infiltrates with a &ldquo;subsolid&rdquo; appearance, thus mimicking the radiographic appearance of pneumonia. Patients with bronchioloalveolar cell carcinoma may present with a discrepancy between the size of the infiltrate and the paucity of systemic symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lymphoma in the lung may also present with focal alveolar infiltrates with air bronchograms, mimicking the radiographic appearance of pneumonia. Lymphoma affecting the lung parenchyma may occur either as part of a systemic disease or as primary pulmonary lymphoma. Three categories of clonal lymphoid proliferation are now recognized as producing pulmonary parenchymal involvement: low grade B cell lymphoma arising from mucosal tissue (MALT), high grade B cell lymphoma, and lymphomatoid granulomatosis. Primary pulmonary lymphoma is unusual, with only 10 percent of Hodgkin lymphoma and 4 percent of non-Hodgkin lymphomas presenting with an alveolar infiltrate. As the disease progresses, lung involvement becomes more common, occurring in 38 percent of patients with Hodgkin lymphoma and 24 percent with non-Hodgkin lymphoma. Chest CT may be particularly useful in patients with suspected Hodgkin lymphoma, since mediastinal lymphadenopathy is common [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=see_link\">",
"       \"Pulmonary lymphomatoid granulomatosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Inflammatory disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous inflammatory disorders can mimic and be misdiagnosed as pneumonia. Because these disorders do not respond to antibiotics, they should be considered in the evaluation of patients with an apparently nonresolving pneumonia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic vasculitis or connective tissue disorders may cause fever, dyspnea, and pulmonary infiltrates, and therefore can be easily mistaken for pneumonia. Granulomatosis with polyangiitis (Wegener&rsquo;s) and the alveolar hemorrhage syndromes are the most frequent vasculitides to mimic pneumonia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67796 \" href=\"UTD.htm?34/47/35570\">",
"       image 3",
"      </a>",
"      ). Bronchoscopy and bronchoalveolar lavage are useful to establish the diagnosis of alveolar hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link\">",
"       \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"       \"The diffuse alveolar hemorrhage syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchiolitis obliterans organizing pneumonia",
"      <span class=\"nowrap\">",
"       (BOOP/Cryptogenic",
"      </span>",
"      organizing pneumonia) presents typically with a subacute onset, with 75 percent of patients having symptoms less than two months at the time of diagnosis. Idiopathic BOOP usually begins with a flu-like illness mimicking an atypical (community-acquired) pneumonia, with fever, malaise, fatigue, dyspnea, and dry cough. Patients may have an elevated sedimentation rate and leukocytosis. Patchy alveolar infiltrates are typically present on chest radiograph, often mimicking a pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"       \"Cryptogenic organizing pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eosinophilic pneumonias, including both chronic and acute forms, are characterized by collections of eosinophils in the interstitial and alveolar spaces [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Chronic eosinophilic pneumonia typically presents as a subacute illness with cough, fever, dyspnea, weight loss, wheezing, night sweats, and radiographic infiltrates appearing over weeks to months. Chest radiographs often demonstrate patchy, nonsegmental alveolar infiltrates that predominantly affect the periphery of the lungs, sparing the central and basilar regions. Patients typically have a rapid clinical and radiographic response to treatment with corticosteroids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=see_link\">",
"       \"Treatment of chronic eosinophilic pneumonia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Acute eosinophilic pneumonia has a more rapid onset of fever, nonproductive cough, dyspnea, and pleuritic chest pain. Chest radiograph early in the course may show only subtle reticular or ground-glass infiltrates, which can progress to bilateral diffuse alveolar disease and ARDS. As in chronic eosinophilic pneumonia, response to corticosteroids is often dramatic. Data suggest significant clinical overlap between eosinophilic pneumonia syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=see_link\">",
"       \"Idiopathic acute eosinophilic pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute interstitial pneumonia is a rare, idiopathic form of diffuse alveolar damage, thus corresponding to a clinical picture compatible with idiopathic acute respiratory distress syndrome (ARDS) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Patients typically present after a prodromal period of up to 14 days with the onset of fever, cough, and dyspnea. Chest radiographs usually demonstrate bilateral airspace disease, and chest CT characteristically shows patchy or diffuse areas of ground-glass attenuation. The effectiveness of corticosteroids is not clear, and mortality is approximately 70 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=see_link\">",
"       \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary alveolar proteinosis (PAP) is a rare diffuse lung disease characterized by the abnormal accumulation of lipoproteinaceous fluid in the distal airspaces [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/27\">",
"       27",
"      </a>",
"      ]. Patients typically present with the insidious onset of dyspnea, fatigue, weight loss, and low-grade fever. Chest radiographs often demonstrate nonspecific central alveolar opacities in the lower and mid-lung zones with sparing of the areas adjacent to the diaphragm and heart. High-resolution CT commonly has a \"crazy paving\" appearance, characterized by a ground glass pattern with thickening of the intralobular and interlobular septa to produce polygonal shapes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"       \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sarcoidosis may be confused with a nonresolving pneumonia when patients have pulmonary parenchymal disease without intrathoracic adenopathy and in the absence of clinically apparent extrapulmonary involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Drug-induced lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced lung disease can be confused with an infectious pneumonia, and a careful evaluation of medication history should be done in patients with an apparent nonresolving pneumonia to rule out a drug-related etiology.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    toxicity is a particularly important mimic of nonresolving pneumonia, as it may have an acute presentation with focal alveolar infiltrates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=see_link\">",
"     \"Amiodarone pulmonary toxicity\"",
"    </a>",
"    .) Other drugs of concern include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    &nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    &nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27462?source=see_link\">",
"     \"Nitrofurantoin-induced pulmonary injury\"",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    &nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to traditional antineoplastic agents, many new, increasingly-used biologic modifiers are associated with significant respiratory symptoms and radiograph abnormalities. Anti-tumor necrosis factor-alpha agents have been associated with an increased risk of tuberculosis as well as other bacterial and fungal infections. These may have unusual or atypical features. Tyrosine kinase inhibitors like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , now frequently used in advanced adenocarcinoma of the lung, may be associated with interstitial lung disease and acute lung injury.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    , which is used to treat progressive renal cell carcinoma, has been associated with interstitial pneumonitis in up to one-third of patients (",
"    <a class=\"graphic graphic_table graphicRef69809 \" href=\"UTD.htm?1/31/1534\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary embolism can rarely mimic pneumonia, based on the radiographic findings of pulmonary infiltrates in up to 30 percent and pleural effusions in approximately 20 percent of cases. Infiltrates, representing areas of pulmonary infarction, may take several weeks to resolve and are easily mistaken for slowly resolving pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hydrostatic pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unusual or focal radiographic patterns of hydrostatic pulmonary edema can occasionally mimic pneumonia. Pulmonary edema can have a focal presentation limited to areas of increased perfusion, as in patients with bullous lung disease or mitral regurgitation. Because pulmonary edema appears most prominent in areas of maximal perfusion, patients with severe chronic obstructive pulmonary disease may manifest asymmetric patterns of pulmonary edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     FURTHER EVALUATION OF NONRESOLVING PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation of patients with an apparent nonresolving pneumonia generally centers around more detailed imaging studies or obtaining material for microbiologic and pathologic analysis (",
"    <a class=\"graphic graphic_algorithm graphicRef52895 \" href=\"UTD.htm?10/15/10480\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest CT, particularly high resolution chest CT, is the primary radiographic tool for assessing treatment failure of a presumed pneumonia. Compared with conventional chest radiography, high resolution chest CT allows superior detection of parenchymal abnormalities, including emphysema, airspace disease, interstitial disease, and nodules. Such findings may narrow the differential diagnosis or suggest new possibilities not previously under consideration. Chest CT also detects sequestered foci of infection, such as lung abscess and empyema, and helps direct biopsy procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative ease and low risk of fiberoptic bronchoscopy make this the primary diagnostic procedure to obtain specimens from patients with a wide spectrum of possible infectious and noninfectious etiologies of nonresolving or progressive pneumonia. However, despite the frequency of its use for this indication, there are few studies that document the diagnostic yield of fiberoptic bronchoscopy for nonresolving pneumonia.",
"   </p>",
"   <p>",
"    Objective data suggest that fiberoptic bronchoscopy with bronchoalveolar lavage and transbronchial biopsy can successfully diagnose approximately 90 percent of patients who eventually have a specific diagnosis established. It is most likely to be useful in younger, nonsmoking patients with multilobar involvement and prolonged disease, whereas elderly patients, smokers, and those with immunodeficiency are more likely to have a nondiagnostic bronchoscopy and to have a slowly resolving pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/19\">",
"     19",
"    </a>",
"    ]. Bronchoscopy is particularly useful to exclude mycobacteria or fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/29\">",
"     29",
"    </a>",
"    ]. Development of endobronchial ultrasound has improved the value of fiberoptic bronchoscopy and should be considered as an alternative to mediastinoscopy when mediastinal lymph nodes are enlarged (",
"    <a class=\"graphic graphic_algorithm graphicRef52895 \" href=\"UTD.htm?10/15/10480\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Thoracoscopic or open lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors need to be considered when deciding to proceed to a more invasive biopsy procedure, such as thoracoscopic or open lung biopsy. A previous nondiagnostic bronchoscopy, concern about the specific patient's risk or ability to tolerate bronchoscopy, or the need for obtaining larger specimens of tissue for certain diagnoses under serious concern, may all support the need for proceeding to thoracoscopic or open lung biopsy (",
"    <a class=\"graphic graphic_algorithm graphicRef52895 \" href=\"UTD.htm?10/15/10480\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of treatment failure in pneumonia begins with a careful history, physical examination, and review of the medical record. Whether or not the rate of resolution is within the range of expected norms, taking into account the patient's underlying host factors, comorbidities, severity of illness, and suspected pathogen must be established. In stable or slowly improving pneumonia, especially in the presence of comorbidities or host factors that are known to delay the resolution of pneumonia, careful observation with or without therapy is warranted for four to eight weeks. If there is no resolution or progression of disease, a more aggressive diagnostic approach is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23945/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If further evaluation is necessary, it should include a chest CT to look for sequestered areas of infection or for findings that suggest an alternative diagnosis. When pneumonia fails to resolve or when there is clinical progression, fiberoptic bronchoscopy should be considered. Patients with a negative bronchoscopic examination have a good chance of merely having a slowly resolving pneumonia, particularly if they are smokers or over age 55. Diseases not readily or typically diagnosed with fiberoptic bronchoscopy include pulmonary vasculitis syndromes, bronchiolitis obliterans organizing pneumonia, and diffuse alveolar damage of various etiologies. With a worsening chest radiograph and progressive symptoms accompanied by a negative bronchoscopy, further evaluation with thoracoscopic or open lung biopsy may be necessary (",
"    <a class=\"graphic graphic_algorithm graphicRef52895 \" href=\"UTD.htm?10/15/10480\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231465\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slow or incomplete resolution of pneumonia despite treatment is a common clinical problem, estimated to be responsible for approximately 15 percent of inpatient pulmonary consultations and 8 percent of bronchoscopies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal resolution of pneumonia is not easily defined and may vary depending upon the underlying cause. Patients typically note subjective improvement within three to five days of treatment; more specific clinical criteria for resolution include improvement in fever, cough, crackles, leukocytosis, arterial oxygenation (PaO2), and level of C-reactive protein (",
"      <a class=\"graphic graphic_table graphicRef74599 \" href=\"UTD.htm?3/31/3579\">",
"       table 1",
"      </a>",
"      ). Determining whether a patient has nonresolving or progressive pneumonia must also take into account several factors that affect the expected rate of resolution, including comorbidities, age, severity, and etiology (",
"      <a class=\"graphic graphic_table graphicRef62007 \" href=\"UTD.htm?21/14/21739\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67206 \" href=\"UTD.htm?7/30/7660\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78779 \" href=\"UTD.htm?28/11/28860\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal versus delayed resolution of pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data are available regarding resolution of pneumonia caused by different etiologic agents, including factors that affect the course of particular types of pneumonia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Influence of specific bacterial pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative pathogens, in addition to the usual bacterial causes of pneumonia, need to be considered in the patient who fails to respond to treatment (",
"      <a class=\"graphic graphic_table graphicRef78779 \" href=\"UTD.htm?28/11/28860\">",
"       table 4",
"      </a>",
"      ). Particularly important pathogens in this category include mycobacteria (either Mycobacterium tuberculosis or atypical mycobacteria), fungi, Nocardia, and Actinomyces. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Misdiagnosis of nonbacterial pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of a resistant pathogen is an important consideration for any pneumonia that is not responding appropriately to antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Resistant bacterial pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of host factors may be associated with delayed resolution of pneumonia, including alcoholism, older age, and the presence of comorbid diseases such as diabetes and chronic obstructive lung disease. In addition, disorders of immune function, particularly AIDS and syndromes associated with deficient humoral immunity, can be associated with delayed resolution of pneumonia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Host factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sequestered foci of infection may prevent adequate concentrations of antibiotic agents from reaching the site of infection. The two main forms of sequestered focus preventing adequate resolution of pneumonia are empyema and lung abscess. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Development of complications from the initial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of noninfectious etiologies of pulmonary infiltrates can mimic pneumonia and therefore represent causes of presumed nonresolving pneumonia. These fall into the categories of neoplastic, inflammatory, drug-induced, and vascular disease (",
"      <a class=\"graphic graphic_table graphicRef63652 \" href=\"UTD.htm?37/21/38235\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Noninfectious etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation of patients with an apparent nonresolving pneumonia generally centers around more detailed imaging studies or obtaining material for microbiologic and pathologic analysis (",
"      <a class=\"graphic graphic_algorithm graphicRef52895 \" href=\"UTD.htm?10/15/10480\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Further evaluation of nonresolving pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/1\">",
"      Marrie TJ. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch Intern Med 1993; 153:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/2\">",
"      Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162:154.",
"     </a>",
"    </li>",
"    <li>",
"     Fein, AM, Feinsilver, S, Niederman, MS. Slow resolving pneumonia in the elderly. In: Respiratory Infections in the Elderly, Niederman, MS (Ed), Raven Press, New York 1991. p.293.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/4\">",
"      Jay SJ, Johanson WG Jr, Pierce AK. The radiographic resolution of Streptococcus pneumoniae pneumonia. N Engl J Med 1975; 293:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/5\">",
"      Macfarlane JT, Miller AC, Roderick Smith WH, et al. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis. Thorax 1984; 39:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/6\">",
"      Fein AM. Pneumonia in the elderly: overview of diagnostic and therapeutic approaches. Clin Infect Dis 1999; 28:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/7\">",
"      Fein AM, Feinsilver SH, Niederman MS, et al. \"When the pneumonia doesn't get better\". Clin Chest Med 1987; 8:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/8\">",
"      Rodrigues J, Niederman MS, Fein AM, Pai PB. Nonresolving pneumonia in steroid-treated patients with obstructive lung disease. Am J Med 1992; 93:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/9\">",
"      Coletta FS, Fein AM. Radiological manifestations of Legionella/Legionella-like organisms. Semin Respir Infect 1998; 13:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/10\">",
"      Grayston JT. Chlamydia pneumoniae, strain TWAR pneumonia. Annu Rev Med 1992; 43:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/11\">",
"      Farley MM, Stephens DS, Brachman PS Jr, et al. Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med 1992; 116:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/12\">",
"      Heath PT, Booy R, Azzopardi HJ, et al. Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatr Infect Dis J 2001; 20:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/13\">",
"      Saubolle MA. Fungal pneumonias. Semin Respir Infect 2000; 15:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/14\">",
"      Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens--a global perspective. Semin Respir Infect 2000; 15:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/15\">",
"      Farrell DJ, Felmingham D, Shackcloth J, et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J Antimicrob Chemother 2008; 62 Suppl 2:ii87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/16\">",
"      Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/17\">",
"      Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995; 152:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/18\">",
"      Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. Am J Med 2006; 119:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/19\">",
"      Feinsilver SH, Fein AM, Niederman MS, et al. Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest 1990; 98:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/20\">",
"      Dumont P, Gasser B, Roug&eacute; C, et al. Bronchoalveolar carcinoma: histopathologic study of evolution in a series of 105 surgically treated patients. Chest 1998; 113:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/21\">",
"      Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J 2002; 20:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/22\">",
"      Ebara H, Ikezoe J, Johkoh T, et al. Chronic eosinophilic pneumonia: evolution of chest radiograms and CT features. J Comput Assist Tomogr 1994; 18:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/23\">",
"      Allen JN, Pacht ER, Gadek JE, Davis WB. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 1989; 321:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/24\">",
"      Philit F, Etienne-Mastro&iuml;anni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002; 166:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/25\">",
"      Primack SL, Hartman TE, Ikezoe J, et al. Acute interstitial pneumonia: radiographic and CT findings in nine patients. Radiology 1993; 188:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/26\">",
"      Olson J, Colby TV, Elliott CG. Hamman-Rich syndrome revisited. Mayo Clin Proc 1990; 65:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/27\">",
"      Shah PL, Hansell D, Lawson PR, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000; 55:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/28\">",
"      White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/29\">",
"      Grossman RF, Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Executive summary. Chest 2000; 117:177S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23945/abstract/30\">",
"      Kuru T, Lynch JP 3rd. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999; 20:623.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6992 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23945=[""].join("\n");
var outline_f23_24_23945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H231465\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL VERSUS DELAYED RESOLUTION OF PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INFLUENCE OF SPECIFIC BACTERIAL PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Streptococcus pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mycoplasma pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chlamydophila pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MISDIAGNOSIS OF NONBACTERIAL PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fungi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nocardia and Actinomyces",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RESISTANT BACTERIAL PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HOST FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acquired immunodeficiency syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Primary humoral immune deficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DEVELOPMENT OF COMPLICATIONS FROM THE INITIAL PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Empyema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lung abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NONINFECTIOUS ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neoplastic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Inflammatory disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Drug-induced lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hydrostatic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      FURTHER EVALUATION OF NONRESOLVING PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Thoracoscopic or open lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H231465\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/6992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6992|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/15/10480\" title=\"algorithm 1\">",
"      Nonresolving pneumonia approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6992|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/5/18513\" title=\"diagnostic image 1\">",
"      Invasive aspergillosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/40/37509\" title=\"diagnostic image 2\">",
"      Cavitary Cryptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/47/35570\" title=\"diagnostic image 3\">",
"      Alveolar hemorrhage CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6992|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/31/3579\" title=\"table 1\">",
"      Duration of pneumonia findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/14/21739\" title=\"table 2\">",
"      Comorbidities and pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/30/7660\" title=\"table 3\">",
"      Bacterial flora and resolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/11/28860\" title=\"table 4\">",
"      Unusual pathogens for pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/21/38235\" title=\"table 5\">",
"      Noninfectious pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/31/1534\" title=\"table 6\">",
"      Immunomodulatory agents pulmonary diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=related_link\">",
"      Amiodarone pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15449?source=related_link\">",
"      Bacterial pulmonary infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=related_link\">",
"      Clinical manifestations and diagnosis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=related_link\">",
"      Idiopathic acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/41/34456?source=related_link\">",
"      Infections due to the Streptococcus anginosus group",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24729?source=related_link\">",
"      Lung abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=related_link\">",
"      Microbiology, epidemiology and treatment of Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27462?source=related_link\">",
"      Nitrofurantoin-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=related_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=related_link\">",
"      Pulmonary lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=related_link\">",
"      Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=related_link\">",
"      Treatment of chronic eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=related_link\">",
"      Treatment of nocardiosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_24_23946="Peripheral nerve tumors";
var content_f23_24_23946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peripheral nerve tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23946/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23946/contributors\">",
"     James M Gilchrist, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23946/contributors\">",
"     John E Donahue, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23946/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23946/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23946/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/24/23946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/24/23946/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/24/23946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30352918\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerve tumors are uncommon and many neurologists will see only a handful in their careers, unless they have a practice enriched in patients with neurofibromatosis.",
"   </p>",
"   <p>",
"    This topic review will focus on various benign and malignant neoplasms and benign non-neoplastic tumors of the peripheral nerve. The neurofibromatoses are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20712?source=see_link\">",
"     \"Neurofibromatosis type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11731?source=see_link\">",
"     \"Overview of schwannomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nerve sheath tumors affecting the spinal cord are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28694?source=see_link\">",
"     \"Intradural nerve sheath tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30352971\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of peripheral nerve tumors are caused by direct nerve invasion, involvement of surrounding tissues, or mass effect [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/1\">",
"     1",
"    </a>",
"    ]. There are no specific clinical presentations unique or even especially suggestive of a particular nerve tumor, with the exception of neurofibromatosis type 1 and neurofibromatosis type 2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20712?source=see_link\">",
"     \"Neurofibromatosis type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients present for evaluation of peripheral nerve tumors because of a soft tissue mass, pain, or focal neurologic findings, approximately in that order of frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/2\">",
"     2",
"    </a>",
"    ]. The duration and progression of symptoms or signs is important as most benign tumors have a longer duration and a slow rate of progression, while malignant tumors tend to progress rapidly in size, amount of pain, and neurologic deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Any mass changing its clinical character should be taken seriously, as that is one of the few clinical clues to its potentially malignant nature. In particular, rapidly expanding soft tissue masses are very suspicious for the presence of a malignant peripheral nerve sheath tumor and should be evaluated promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/3\">",
"     3",
"    </a>",
"    ]. A careful family history is important in the assessment of an underlying neurogenetic disorder, such as neurofibromatosis.",
"   </p>",
"   <p>",
"    On examination, peripheral nerve tumors tend to be mobile perpendicular to the axis of the peripheral nerve but fixed along the axis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/4\">",
"     4",
"    </a>",
"    ]. Ganglion cysts, lipomas, and lipofibromatous hamartomas are usually easily compressible, while neoplastic tumors are often firm in texture. Pain will occur in the region of the tumor and any nerve the tumor involves, but pain may not be specific enough to discern the particular involved nerve. Neurologic deficits of sensory and motor function correspond to the nerve in which the tumor originates or which it is compressing, and as such will often be most useful in localizing the tumor. Obtaining a Tinel sign over a nerve or tumor may also assist in localization to a particular nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant minority of peripheral nerve tumors are associated with either neurofibromatosis (NF) type 1 or type 2. Schwannomatosis is now considered to be a third variety of NF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11731?source=see_link\">",
"     \"Overview of schwannomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353014\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of laboratory evaluation of the patient with a peripheral nerve tumor is to determine the type and location. Imaging is the most useful modality. Electrodiagnostic testing can help to localize involvement of specific nerves or portions of a plexus but is nonspecific for differentiating peripheral nerve tumors. Surgical biopsy is important for tumors that are deep or potentially malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing for NF1 or NF2 is available but is expensive and not helpful in the evaluation of peripheral nerve tumors, as the diagnostic criteria for both diseases are clinical and most solitary neurofibromas and schwannomas occur in patients without NF1 or NF2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353033\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging is the most valuable tool for evaluation of peripheral nerve tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Many tumors are first identified by imaging done for symptoms of pain, sensory loss, or weakness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI is the most helpful imaging modality, especially in denoting the presence of a mass, determining whether the mass is intrinsic or extrinsic to the nerve, and delineating involvement of adjacent structures [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"       7",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58553 \" href=\"UTD.htm?6/6/6241\">",
"       image 1",
"      </a>",
"      ). The MRI is less helpful in determining the pathology of the tumor as there are no pathognomonic signal characteristics for any type of tumor. Although not definitive, MRI can sometimes be helpful in determining the malignant nature of a tumor. Rapid expansion of a known tumor, inhomogeneous enhancement, hemorrhage, necrosis, and heterogeneous signal suggest, but do not confirm, the presence of a malignant nerve sheath tumor. Large tumors exceeding 5 cm, ill-defined margins, invasion of fat planes, and edema around the tumor all raise the possibility of malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"       7",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56406 \" href=\"UTD.htm?38/27/39347\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      CT scan is not the best imaging method as many tumors have signal densities similar to muscle and so are not well defined. However, CT can be useful in demonstrating bony remodeling adjacent to the tumor, such as spinal neural foramina [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fluorodeoxyglucose positron emission tomography (PET) scanning has shown some promise in distinguishing malignant peripheral nerve sheath tumors (MPNSTs) from benign tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metastatic cancer to peripheral nerve is not common but in that scenario, CT, MRI, and PET scanning take on the additional importance of determining the primary tumor and staging the cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353054\">",
"    <span class=\"h2\">",
"     Electrodiagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic studies with electromyography and nerve conduction testing is not particularly helpful in the evaluation of peripheral nerve tumors, beyond indicating which nerve, nerves, or portions of a plexus may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6\">",
"     6",
"    </a>",
"    ]. There are no specific electrodiagnostic findings for any peripheral nerve tumors and no distinction can be made between benign or malignant tumors. However, electrodiagnostic testing may provide some indication of the function of a particular nerve and as such, may propel the patient and surgeon towards or against surgery.",
"   </p>",
"   <p>",
"    More value may arise from intraoperative electrophysiologic monitoring to assist the surgeon in determining what is or is not functional neural tissue. A non-functional nerve found preoperatively needs to be verified intraoperatively but might allow the surgeon freer access to removal of the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353061\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical biopsy is important in the evaluation of tumors, especially those that are deep or thought to be malignant, as pathology will determine further surgical options. According to an international consensus statement on malignant peripheral nerve sheath tumors (MPNSTs) in neurofibromatosis, all patients with pain, enlargement of a soft tissue mass, change in texture, or advancement of neurologic deficit should have biopsy to assess for malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pathologist with expertise in peripheral nerve tumors is obviously important, as the differentiation between schwannoma and neurofibroma is key (eg, schwannomas are seen in NF2, neurofibromas are seen in NF1; neurofibromas can undergo malignant transformation, schwannomas do not) and the determination of malignancy can be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353077\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for peripheral nerve tumors is largely based on surgical removal. Not all patients with a peripheral nerve tumor will need surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9\">",
"     9",
"    </a>",
"    ]. Some may best be treated conservatively with observation, such as the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic schwannomas or other tumors with no characteristics suspicious for malignancy",
"     </li>",
"     <li>",
"      Subcutaneous neurofibromas, dermal neurofibromas, plexiform neurofibromas with low suspicion for malignancy",
"     </li>",
"     <li>",
"      Non-neoplastic tumors",
"     </li>",
"     <li>",
"      Tumors causing minimal symptoms in the elderly, medically impaired, or debilitated patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with tumors that do require treatment, surgery is the primary tool. Disfigurement, bleeding, pain, neurologic deficit, and suspicion for malignancy are the prime indications for surgical removal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. For benign tumors, removal of the tumor with minimization of residual neurologic deficit is the goal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9\">",
"     9",
"    </a>",
"    ], though that can be impossible given the location of the tumor and intertwining with nerve fascicles, especially if the tumor is nonencapsulated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of malignant peripheral nerve sheath tumors is discussed below. (See",
"    <a class=\"local\" href=\"#H30353525\">",
"     'Treatment of MPNSTs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353164\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nomenclature of peripheral nerve tumors is confusing, as tumors often have more than one name, different tumors are called the same name and some tumor cell types are not yet definitively characterized.",
"   </p>",
"   <p>",
"    It is no surprise then that there is currently no widely accepted, overarching classification scheme for peripheral nerve tumors. Most authors utilize a system based on the presence or absence of neoplasia, whether the neoplasia is benign or malignant, and the presumed cellular origin of the underlying neoplasia, ie, nerve sheath origin or not (",
"    <a class=\"graphic graphic_table graphicRef60755 \" href=\"UTD.htm?36/55/37756\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353175\">",
"    <span class=\"h1\">",
"     BENIGN NON-NEOPLASTIC NERVE TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The category of benign non-neoplastic nerve tumors includes neuroma, ganglion cyst, intraneural heterotopic ossification, sarcoid granuloma, inflammatory pseudotumor of nerve, leprosy, hypertrophic neuropathy, lipofibromatous hamartoma, and neuromuscular choristoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353182\">",
"    <span class=\"h2\">",
"     Neuroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromas belong to a class of tumors best called reactive [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9\">",
"     9",
"    </a>",
"    ]. Traumatic neuromas occur after nerve injury causing interrupted axons (neurotmesis). Regenerating axons lack an endoneurial tube to follow, which results in a mass of disorganized axons that is often quite painful and tender (",
"    <a class=\"graphic graphic_picture graphicRef55239 \" href=\"UTD.htm?34/10/34984\">",
"     picture 1",
"    </a>",
"    ). Neuromas tend to be small and firm in texture, and require excision for cure and diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Morton neuroma is a subject of controversy regarding its nomenclature, pathology, and appropriate treatment. Abnormalities ascribed to Morton neuroma are typically located between the metatarsals of the third and fourth toes or at the bifurcation of the fourth plantar digital nerve. The lesions look like a traumatic neuroma grossly, and are comprised of degenerated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      demyelinated axons, vascular hyalinization, and fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Clinical manifestations can include pain and tenderness [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9\">",
"       9",
"      </a>",
"      ], but similar lesions are common in patients who are asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/14\">",
"       14",
"      </a>",
"      ]. Surgical removal is advocated by some authors for those who fail conservative measures [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/15,16\">",
"       15,16",
"      </a>",
"      ], but data are limited regarding the effectiveness of surgical and nonsurgical interventions for Morton neuroma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Palisaded encapsulated neuromas are small, firm, nonpigmented, painless nodules found in proximity to mucocutaneous junctions, usually in the face. They are benign but may be mistaken for a basal cell carcinoma. Surgical removal is curative.",
"     </li>",
"     <li>",
"      Mucosal neuromas are associated with multiple endocrine neoplasia type IIb, which is inherited as an autosomal dominant trait due to a single mutation in the RET proto-oncogene [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9,18\">",
"       9,18",
"      </a>",
"      ]. Mucosal neuromas present as diffusely enlarged lips, tongue nodules, and thickened eyelids, either diffusely or nodular, usually in the first or second decade. Pathologically, mucosal neuromas are comprised by markedly enlarged nerve fibers. There is no specific treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353205\">",
"    <span class=\"h2\">",
"     Ganglion cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ganglion cysts are non-neural benign cystic tumors that usually occur in proximity to joints or tendons. They develop from chronic local mechanical irritation in perineural tissue or extend from joints to enter the epineurium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9\">",
"     9",
"    </a>",
"    ]. The common peroneal nerve is frequently affected, as are the hands and wrists. A mucous cyst is a ganglion occurring at the distal interphalangeal joint, usually in patients between 40 and 70 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ganglion cysts are more common in women than men. Pain and neurologic deficits of sensation and strength in the territory of the affected nerve are typical presenting manifestations, arising from either intra- or extraneural compression. Asymptomatic cysts found on MRI are frequent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69811 \" href=\"UTD.htm?24/32/25090\">",
"     image 3",
"    </a>",
"    ). Surgical removal or aspiration is indicated if symptoms and signs warrant, but intrafascicular dissection and neurolysis in cysts with intraneural involvement may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353217\">",
"    <span class=\"h2\">",
"     Intraneural heterotopic ossification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterotopic ossification of peripheral nerve has been reported rarely and resembles myositis ossificans pathologically with a central fibroblastic core, an intermediate zone of osteoid production, and a peripheral zone of ossification. Like myositis ossificans, it is thought to occur secondary to local trauma. Pain, paresthesias, and weakness in the distribution of the affected nerve are the presenting complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9,20\">",
"     9,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353224\">",
"    <span class=\"h2\">",
"     Sarcoid granuloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoid granulomas can involve cranial and peripheral nerves, which appear firm and thickened. This can be a focal or multifocal process, causing pain, sensory loss, paresthesias, and weakness. The diagnosis may require nerve biopsy. The mainstay of treatment is glucocorticoids, as with systemic sarcoidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353253\">",
"    <span class=\"h2\">",
"     Inflammatory pseudotumor of nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory pseudotumor of nerve is another rare disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9,21\">",
"     9,21",
"    </a>",
"    ]. The swelling is composed of chronic inflammatory (mostly T lymphocytes) and reactive mesenchymal cells, resulting in segmental fusiform or nodular enlargement. The infiltrate is usually limited to the epineurium. Sensorimotor deficits in the territory of the affected nerve lead to evaluation, and surgery is usually done because of the deficits and the presumed diagnosis of nerve sheath tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353260\">",
"    <span class=\"h2\">",
"     Leprosy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leprous neuropathy results from infection with Mycobacterium leprae and is a common cause of neuropathy in underdeveloped countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=see_link&amp;anchor=H1708854#H1708854\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\", section on 'Neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leprosy has a tuberculoid and lepromatous form, dependent on each patient's immune response. Tuberculoid leprosy involves cutaneous and subcutaneous nerves, with extensive destruction of nerve fibers secondary to the inflammatory response engendered by the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9\">",
"     9",
"    </a>",
"    ]. Nerves are often enlarged due to the inflammation and from cold abscesses and fibrosis within the nerve. This is less likely in lepromatous leprosy, which results from hematogenous dissemination.",
"   </p>",
"   <p>",
"    The treatment of leprosy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23305?source=see_link&amp;anchor=H310298018#H310298018\">",
"     \"Treatment and prevention of leprosy\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23305?source=see_link&amp;anchor=H310298033#H310298033\">",
"     \"Treatment and prevention of leprosy\", section on 'Therapeutic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353301\">",
"    <span class=\"h2\">",
"     Hypertrophic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two forms of hypertrophic neuropathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized hypertrophic neuropathy is a rare condition resulting in onion bulb-like Schwann cell hypertrophy from repeated demyelination and remyelination [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9,22\">",
"       9,22",
"      </a>",
"      ]. The fusiform enlargement of the nerve is focal and separable from the hypertrophic neuropathies (Charcot-Marie-Tooth disease, Dejerine-Sottas disease, hereditary neuropathy with liability to pressure palsy, and chronic inflammatory demyelinating polyneuropathy) only by the lack of a diffuse polyneuropathy.",
"     </li>",
"     <li>",
"      Hypertrophic inflammatory neuropathy, another rare condition, often involves the brachial plexus with focal fusiform swelling of a nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9,23\">",
"       9,23",
"      </a>",
"      ]. Like hypertrophic neuropathy, it is endoneurial in origin with onion bulb-like hyperplasia around axons, but differs in having extensive edema, localized inflammatory infiltrates, and fibrosis. The diagnosis requires tissue, so biopsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      excision is often required to differentiate this entity from a neoplastic lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353314\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipofibromatous hamartoma is another unusual condition, most commonly involving the median nerve in children or young adults, and at times associated with macrodactyly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/9\">",
"     9",
"    </a>",
"    ]. These tumors involve the epineurium with fibrosis and fat, and sometimes other tissues such as muscle. Lipomas of the nerve may be hard to differentiate but are often encapsulated and contain only adipose tissue. Patients present with either a mass, enlarged fingers, or neurologic symptoms due to compression of the nerve. Neurologic symptoms are most likely if the distal median nerve is involved in the carpal tunnel. Treatment is by surgical excision, which may be limited to debulking or carpal tunnel release [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32822?source=see_link\">",
"     \"Surgery for carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuromuscular choristoma, also known as neuromuscular hamartoma or benign triton tumor, is a peripheral nerve tumor made of well-differentiated muscle. It usually affects large nerves in children and is solitary. In a study that reviewed 19 cases, nearly a third involved the sciatic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/24\">",
"     24",
"    </a>",
"    ]. Most presented with pain and foot deformities such as talipes or atrophy, but minimal neurologic deficits. The brachial plexus is also commonly involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353333\">",
"    <span class=\"h1\">",
"     BENIGN NEOPLASMS OF NON-NEURAL SHEATH ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors, also known as aggressive fibromatosis, uncommonly can affect the nerve, usually by secondary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]. These are neoplastic tumors often comprised of well-differentiated, firm masses of fibrous tissue. They are infiltrative and frequently recurrent. Muscle and muscle fascia is the usual site of origin. Up to 10 to 15 percent of patients with familial adenomatous polyposis will have desmoid tumors. They often present as painful masses most commonly affecting proximal and truncal areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Focal sensorimotor deficits are common when desmoid tumors involve nerves. Total resection is difficult and may require sacrifice of the nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/25\">",
"     25",
"    </a>",
"    ], but as the brachial plexus is a common site of involvement, total resection may not be appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353352\">",
"    <span class=\"h1\">",
"     BENIGN NERVE SHEATH NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The category of benign nerve sheath neoplasms includes neurofibroma, schwannoma, perineurioma, cellular and mixed-type neurothekeoma, nerve sheath myxoma, ganglioneuroma, and hemangioblastoma.",
"   </p>",
"   <p>",
"    Nerve sheath tumors affecting the spinal cord are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28694?source=see_link\">",
"     \"Intradural nerve sheath tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353371\">",
"    <span class=\"h2\">",
"     Neurofibroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromas are tumors composed of a mix of Schwann cells, perineurial-like cells, and fibroblasts, interspersed with nerve fibers, wire-like strands of collagen, and myxoid matrix (",
"    <a class=\"graphic graphic_picture graphicRef62448 \" href=\"UTD.htm?17/56/18310\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. The majority is solitary (up to 90 percent) and not associated with neurofibromatosis type 1 (NF1). The patient is often young, between 20 and 30 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ]. Neurofibromas are pathologically and genetically different from schwannomas, but there is no pathological difference between neurofibromas from patients without and with neurofibromatosis type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/27\">",
"     27",
"    </a>",
"    ]. The neoplastic cell of origin is the Schwann cell and the presence of intratumor nerve fibers is a cardinal feature that helps distinguish neurofibromas from schwannomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurofibromas are usually classified by location and appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous, or dermal, neurofibromas are small, nodular tumors of the skin and subcutaneous tissue, arising from small cutaneous nerves, which may cause local pain or bleeding but do not cause neurologic deficits. In NF1, they are by far the most common form of tumor.",
"     </li>",
"     <li>",
"      Intraneural neurofibromas are deeper, focal, well-circumscribed, fusiform lesions involving nerve roots, nerve trunks, nerve plexuses, or peripheral nerves. The nerve enters the mass at one end, exits at the other, and is intermixed with tumor components through the length of the mass. These tumors usually present as a mass, with local or radicular pain, or with sensorimotor neurologic symptoms and signs [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/10\">",
"       10",
"      </a>",
"      ]. Tumors within the epineurium will be encapsulated, but most extend beyond the epineurium and though circumscribed, they are not encapsulated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two types (cutaneous and intraneural) could be considered discrete tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/10\">",
"     10",
"    </a>",
"    ], and they comprise 90 percent of neurofibromas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plexiform neurofibroma, a third type, is non-discrete (",
"      <a class=\"graphic graphic_picture graphicRef68166 \" href=\"UTD.htm?14/45/15056\">",
"       picture 3",
"      </a>",
"      ). These are multinodular elongated masses affecting large nerves that may appear as a tangle of thick strands or as a ropy mass, like a \"bag of worms\" [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26\">",
"       26",
"      </a>",
"      ]. These are nearly pathognomonic for NF1 but rarely can be seen as solitary lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Massive soft tissue neurofibromas are large, diffuse masses causing regional or single-limb enlargement (formerly known as elephantiasis) seen in NF1 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Solitary intraneural neurofibromas account for about two-thirds of neurofibromas removed at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/28\">",
"     28",
"    </a>",
"    ], with the others being associated with NF type 1.",
"   </p>",
"   <p>",
"    Multiple neurofibromas are nearly diagnostic of NF1 (",
"    <a class=\"graphic graphic_table graphicRef63696 \" href=\"UTD.htm?10/44/10955\">",
"     table 2",
"    </a>",
"    ). They can be found affecting virtually any nerve or plexus; they affect a young patient population (20 to 30 years of age); and for an unknown reason, they occur more frequently on the right side than the left [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/27\">",
"     27",
"    </a>",
"    ]. Solitary neurofibromas rarely degrade to malignancy, but discrete neurofibromas in NF1 can and do become malignant, and plexiform neurofibromas carry a substantial risk of becoming malignant. (See",
"    <a class=\"local\" href=\"#H30353503\">",
"     'Malignant peripheral nerve sheath tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Imaging can be helpful in localizing the mass, as well as determining its extent and any involvement of extraneural tissues. On CT, intraneural neurofibromas are well-demarcated masses that are hypodense to muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ]. Contrast enhancement is minimal, if any. On MRI, neurofibromas show a low signal intensity on T1-weighted images and high signal intensity on T2-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ]. They enhance frequently, and usually heterogeneously. On T2 images, the tumors will often show a characteristic central hypodense region, called the target sign, which is presumed due to dense collagen and fibrous tissue in the center (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66568 \" href=\"UTD.htm?17/51/18229\">",
"     image 4",
"    </a>",
"    ). This pattern is very suggestive of neurofibroma but has been reported in schwannoma and in malignant peripheral nerve sheath tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ]. CT and MRI of plexiform neurofibromas show large multilobulated and conglomerated masses, comprised of numerous neurofibromas, extending along nerves and nerve branches [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of solitary intraneural neurofibromas is dependent on symptoms and signs. Cutaneous neurofibromas should not be removed, whether the patient has NF1 or not, unless there is a reason such as pain, bleeding, interference with function, or disfigurement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Solitary intraneural neurofibromas can be managed by observation if the patient is asymptomatic. For patients with pain, progressive neurologic deficits, or in whom the diagnosis is uncertain, surgical resection becomes necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. Solitary intraneural neurofibromas suspicious for malignancy should either be resected, or first biopsied and then resected if malignant.",
"   </p>",
"   <p>",
"    For patients with solitary or multiple intraneural neurofibromas or plexiform neurofibromas requiring treatment, surgical resection with preservation of neurologic function is the goal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/11\">",
"     11",
"    </a>",
"    ]. However, this is more likely to be accomplished in patients with solitary neurofibromas than patients with NF1. The greater likelihood of pain and neurologic deficits in patients with NF1 is due in part to the occurrence of plexiform neurofibromas in NF1 and to the need to attempt total resection in NF1 tumors because of the risk of malignant deterioration. In a series reporting surgical excision of 123 neurofibromas in 121 patients without NF1, stable or improved motor function and good pain resolution were observed in 90 and 88 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/5\">",
"     5",
"    </a>",
"    ]. The same series reported 59 patients with NF1 who had 80 tumors removed; stable or improved motor function and improved pain were observed in 83 and 74 percent respectively, but new or worse pain occurred in 16 percent.",
"   </p>",
"   <p>",
"    The location of the tumor also has great bearing on the operative outcome. Tumors in the brachial plexus are associated with a relatively high proportion of postoperative morbidity. Removal of neurofibromas involving the brachial plexus in patients without NF1 who had no neurologic deficits resulted in some degree of postoperative weakness in 8 of 31 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly, in patients with NF1 who had no preoperative weakness, significant postoperative weakness was found in 3 of 11 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NF1 is an autosomal dominantly inherited trait with full penetrance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link&amp;anchor=H2#H2\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353409\">",
"    <span class=\"h2\">",
"     Schwannoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schwannomas (also called neurilemmomas) are encapsulated tumors made entirely of benign neoplastic Schwann cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. They are the most common tumor of peripheral nerves. They do not transform to malignancy, with the exception of atypical types mentioned below [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Schwannomas grow from peripheral nerves or nerve roots in an eccentric fashion with the nerve itself usually incorporated into the capsule. In large schwannomas, nerve fibers can be difficult to find [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vestibular schwannomas (also called acoustic neuromas) account for 80 to 90 percent of cerebellopontine angle tumors in adults and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Schwannomas show a biphasic architecture of Antoni A (dense) and B (loose) patterns, as well as nuclear palisading (Verocay bodies) and a fibrous capsule containing the parent nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26\">",
"     26",
"    </a>",
"    ]. Neoplastic Schwann cells typically show spindle shaped nuclei (",
"    <a class=\"graphic graphic_picture graphicRef55266 \" href=\"UTD.htm?35/53/36691\">",
"     picture 4",
"    </a>",
"    ). Pathologic variants include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellular schwannomas are predominantly Antoni A tissue without Verocay bodies.",
"     </li>",
"     <li>",
"      Melanotic schwannomas show dense melanin pigmentation but are otherwise typical. Psammomatous melanotic schwannomas are a subtype of melanotic schwannoma with psammoma bodies, which are round, laminated bodies of calcium. Melanotic schwannomas, unlike other schwannomas, can become malignant.",
"     </li>",
"     <li>",
"      Plexiform schwannomas are rare, usually occurring along nerve plexuses as conglomerations of multiple schwannomas, and can be sporadic, or associated with neurofibromatosis type 2 (NF2) or schwannomatosis. Unlike plexiform neurofibromas, they do not become malignant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Longstanding schwannomas can show degenerative changes, such as marked nuclear pleomorphism, widespread blood vessel hyalinization, signs of remote hemorrhage, focal necrosis, and calcifications. At one time, these were called \"ancient schwannomas,\" and some still refer to them as such [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ]. These tumors are not clinically distinctive, and many pathologists do not consider them a specific variant of schwannoma.",
"   </p>",
"   <p>",
"    Sporadic schwannomas affect patients of all ages, reaching a peak between 20 and 50, with no predilection to either sex or any race [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ]. Many schwannomas are discovered incidentally as solitary tumors on flexor surfaces in middle-aged people [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6\">",
"     6",
"    </a>",
"    ]. The vast majority of schwannomas occur sporadically and singly but they also are seen, usually as multiple schwannomas, as part of NF2, schwannomatosis, Carney complex, and as part of a syndrome with nevi and vaginal leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/30\">",
"     30",
"    </a>",
"    ]. Schwannomas do not occur in neurofibromatosis type 1 (NF1).",
"   </p>",
"   <p>",
"    Most patients are asymptomatic, but dysesthesia (often elicited by palpation), radicular-type pain, sensory loss, and weakness can occur, usually from impingement on adjacent neural structures such as the brachial plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The imaging of schwannomas is similar to neurofibromas and often the two tumors cannot be distinguished (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58553 \" href=\"UTD.htm?6/6/6241\">",
"     image 1",
"    </a>",
"    ). On CT, schwannomas are hypodense to muscle, and they enhance with contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ]. On MRI with T1-weighted imaging, schwannomas have an intermediate signal intensity similar to muscle. They show a very bright signal on T2-weighted imaging, though cystic lesions will have a low signal intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ]. They enhance uniformly and frequently (70 percent) show a low intensity rim consistent with a capsule. Fusiform shape and a target sign can be seen in both schwannomas and neurofibromas. When it can be identified, an eccentrically placed nerve suggests schwannoma, and a heterogeneous appearance with cystic degeneration is more common with schwannoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though schwannomas are the most common peripheral nerve tumor, the proportion with symptoms and signs necessitating surgical removal is approximately one-half of that seen neurofibromas. One series of 351 benign nerve sheath tumors included 124 schwannomas of the upper or lower limbs, of which 44 percent of the schwannomas removed involved the brachial plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/28\">",
"     28",
"    </a>",
"    ]. Prognosis after surgery is somewhat better than for neurofibromas: in patients with full strength before surgical removal of a schwannoma of the brachial plexus, 88 percent maintained normal strength, while 90 percent of those with weakness were either unchanged or improved after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353444\">",
"    <span class=\"h2\">",
"     Perineurioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perineuriomas are tumors comprised of perineurial cells. They are classified as two forms: intraneural, which are rare, or the more common extraneural soft tissue perineurioma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/32\">",
"     32",
"    </a>",
"    ]. At one time, intraneural perineuriomas were thought to be the same as localized hypertrophic neuropathy, but the presence of pseudo-onion bulbing (intraneural form only) and clonal monosomy of chromosome 22 (both intraneural and extraneural forms) has indicated a true neoplastic origin of perineuriomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, intraneural perineuriomas mimic schwannomas, appearing as fusiform masses along the course of large nerves, usually affecting individuals in the second and third decades. Weakness, sensory loss, and a mass are the presenting complaints and findings. On the other hand, soft tissue extraneural perineuriomas typically affect middle-aged adults, with a slight female preponderance, and no neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraneural perineuriomas can be distinguished pathologically from schwannomas by pseudo-onion bulbing and by immunohistochemistry [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26,32\">",
"     26,32",
"    </a>",
"    ]. Pseudo-onion bulbs consist of concentrically arranged perineurial cells surrounding an axon, in contrast to true onion-bulbs seen in hypertrophic neuropathies, which are composed of Schwann cells. Using immunohistochemistry, perineurial cells (and perineuriomas) are positive for epithelial membrane antigen (EMA) and claudin-1, a membrane protein of the tight junction. They are negative for S100, a family of calcium-binding proteins and neurofilaments. Schwann cells (and schwannomas) are negative for EMA and positive for S100 and neurofilaments [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6,32\">",
"     6,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of perineuriomas consists of surgical excision if the tumor is causing neurologic compromise or pain. Since axons course through the tumor, residual nerve dysfunction may occur. Recurrence is unlikely. However, perineuriomas can be the source of a malignant peripheral nerve sheath tumor (MPNST). In one study, perineurial origin of MPNST was found for 5 of 23 (13 percent) tumors, only one of which was associated with a nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/29\">",
"     29",
"    </a>",
"    ]. There has been no association with neurofibromatosis. MPNSTs of perineurial cell origin may have a better prognosis than those from Schwann cell origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353451\">",
"    <span class=\"h2\">",
"     Neurothekeoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurothekeomas are superficial tumors of variable pathology, which may encompass a spectrum of disease.",
"   </p>",
"   <p>",
"    The terminology is evolving, and the name \"neurothekeoma\" may over time disappear from usage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/35\">",
"     35",
"    </a>",
"    ]. Neurothekeomas were originally called \"nerve sheath myxoma\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/36\">",
"     36",
"    </a>",
"    ], but in a later series, 53 tumors with similar pathology were termed \"neurothekeoma\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/37\">",
"     37",
"    </a>",
"    ]. Neurothekeomas had been classified as myxoid, cellular, or mixed-type (",
"    <a class=\"graphic graphic_picture graphicRef76260 \" href=\"UTD.htm?35/33/36373\">",
"     picture 5",
"    </a>",
"    ). However, those classified as myxoid most likely represent nerve sheath myxomas, and nerve sheath myxomas are no longer considered a type of neurothekeoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30353458\">",
"     'Nerve sheath myxoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, the term \"neurothekeoma\" should probably be reserved for use in the cellular or mixed-type tumors.",
"   </p>",
"   <p>",
"    Neurothekeomas presumably arise from small cutaneous nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In contrast to nerve sheath myxomas, neurothekeomas have a predilection to occur in the head, neck, and shoulders, but also in limbs. They tend to affect females more than males, usually in the second and early third decades of life, with a mean age at presentation of 15 to 21 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurothekeomas occur in the dermis and are composed of spindle and epithelial cells arranged in a fascicular or concentric whorl pattern. There is no well-defined encapsulation. Unlike nerve sheath myxomas, the cellular neurothekeomas have negative S100 staining, indicating they are not of Schwann cell origin. They are also negative for EMA, indicating they are not of perineurial cell origin either [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/39\">",
"     39",
"    </a>",
"    ], which raises the issue of whether cellular or mixed-type neurothekeomas are of nerve sheath origin.",
"   </p>",
"   <p>",
"    Treatment is by surgical excision, usually because the tumor is believed to be something else, such as a schwannoma. Recurrence is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353458\">",
"    <span class=\"h2\">",
"     Nerve sheath myxoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior descriptions of neurothekeomas have included myxomas, largely due to ill-defined pathologic criteria and unclear determination of the specific cell of origin. This has been better clarified in recent years, and nerve sheath myxoma has been established as a benign neoplasia separate from neurothekeoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/35\">",
"     35",
"    </a>",
"    ]. Regardless, the two tumor types unfortunately remain conflated in many contexts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/1,40\">",
"     1,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30353451\">",
"     'Neurothekeoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nerve sheath myxomas are uncommon, being significantly rarer than neurothekeomas. They are superficial, multinodular and solitary tumors, usually growing slowly over several years. The most common locations are finger, knee, lower leg and ankle, and forearm and hand, in that order. They affect men and women equally, with a mean age of presentation in the forth decade. They usually present as a mass and are painful in less than 25 percent of cases. No apparent nerve is associated with the tumor and neurologic deficits are not described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tumor involves the dermis or subdermis, with abundant myxoid matrix and a peripheral fibrous border. Schwann cells are the predominant cell by appearance and by immunohistochemical staining: these tumors are universally positive for S100 and GFAP, consistent with a Schwann cell origin, and only slightly positive for EMA, an indicator of perineurial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/35\">",
"     35",
"    </a>",
"    ]. Only scattered axons are seen. All these features raise the possibility that nerve sheath myxomas are related to schwannomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is by surgical resection, to include the capsule and a margin of normal tissue. The tumors can be up to 4.5 centimeters in diameter. Surprisingly, the rate of recurrence is nearly 50 percent, sometimes with multiple tumors. Neither the first, nor recurrent, tumors show evidence for malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353465\">",
"    <span class=\"h2\">",
"     Ganglioneuroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ganglioneuromas are rare, slow growing, large tumors that arise from sympathetic ganglion cells. They are in the neuroblastoma group but consist of mature ganglion cells and as such are benign. The cell of origin is derived from embryonic neural crest cells and ganglioneuromas are thought to represent the final stage of maturation from neuroblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/41\">",
"     41",
"    </a>",
"    ]. They are large tumors, with an average size of 7 centimeters, and they are encapsulated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ganglioneuromas tend to occur more frequently in females, with 60 percent occurring before age 20. They occur anywhere along the sympathetic chain, with common locations being the mediastinum, retroperitoneum, and adrenal glands. They are asymptomatic except for local mass effect, such as causing constipation when located in the pelvis, or radicular pain if presacral.",
"   </p>",
"   <p>",
"    Histopathology reveals large, mature ganglion cells (neurons), axons, satellite cells, Schwann cells, and fibrous stroma (",
"    <a class=\"graphic graphic_picture graphicRef77698 \" href=\"UTD.htm?12/30/12775\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26\">",
"     26",
"    </a>",
"    ]. The Schwann cells are not neoplastic but associate with the neurons though they do not elaborate any myelin. This separates them from schwannomas and neurofibromas in which the Schwann cells are neoplastic. Immunohistochemistry shows strong staining of the ganglion cells for neurofilaments, and strong staining of Schwann cells by S100 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is surgical excision, though given the large size, care must be taken for adjoining structures and nerves. The capsule may itself be adherent to important structures and total excision, though desirable, may not be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/41\">",
"     41",
"    </a>",
"    ]. Postoperative autonomic dysfunction otherwise seems uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353472\">",
"    <span class=\"h2\">",
"     Hemangioblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangioblastomas most commonly occur in the brain or spinal cord and only rarely are seen outside the central nervous system involving proximal nerve roots, and even rarer, peripheral nerves. Hemangioblastoma within the central nervous system is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=see_link\">",
"     \"Hemangioblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemangioblastomas in the central nervous system are commonly associated with Von Hippel-Lindau syndrome, but less than half of peripheral nervous system hemangioblastomas are associated with Von Hippel-Lindau. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The literature on peripheral nerve hemangioblastomas consists of only a few cases, one of which was in a patient with Von Hippel-Lindau [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients present with progressive neurologic deficits. Imaging with MR reveals diffuse enhancement, except for frequent cystic components, and large associated blood vessels. Angiography will also show large associated blood vessels, confirming the vascular nature of the tumor.",
"   </p>",
"   <p>",
"    The pathology of peripheral hemangioblastomas is similar to that of central hemangioblastomas with neoplastic large vacuolated stromal cells within a rich non-neoplastic capillary network and interspersed large-caliber blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/42\">",
"     42",
"    </a>",
"    ]. Cysts are common. The tumors arise from the epineurium and appear exophytic from the nerve. They have well-defined margins.",
"   </p>",
"   <p>",
"    Treatment is surgical removal. If the vascular nature of the tumor is not suspected beforehand, the tumor may bleed extensively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353503\">",
"    <span class=\"h1\">",
"     MALIGNANT PERIPHERAL NERVE SHEATH TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant peripheral nerve sheath tumors (MPNST) are an uncommon but devastating tumor of peripheral nerve, representing only about 10 percent of tumors encountered by a peripheral nerve surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/43\">",
"     43",
"    </a>",
"    ]. The incidence of MPNSTs in the general population is 0.001 percent.",
"   </p>",
"   <p>",
"    MPNSTs, which are classified as malignant soft tissue sarcomas, can arise from pre-existing plexiform neurofibromas or perineuriomas, or normal nerves. They do not arise from schwannomas. MPNSTs also occur as secondary neoplasms 10 to 20 years after radiation therapy, accounting for up to 10 percent of MPNSTs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/4\">",
"     4",
"    </a>",
"    ]. From 22 to 50 percent of MPNSTs occur in patients with neurofibromatosis type 1 (NF1), the rest being sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/2,43,44\">",
"     2,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of developing a MPNST in a patient with NF1 is between 8 and 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/45\">",
"     45",
"    </a>",
"    ], with most, if not all, arising from pre-existing plexiform neurofibromas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/46\">",
"     46",
"    </a>",
"    ]. In patients with NF1, the presence of an internal plexiform neurofibroma is associated with a 20-fold increased risk of developing a MPNST compared with the risk in those lacking an internal plexiform neurofibroma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/46\">",
"     46",
"    </a>",
"    ]. MPNSTs tend to present at an earlier age in patients with NF1 (third or fourth decade of life, versus seventh decade in patients who do not have NF1) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MPNSTs are most commonly found on the extremities and trunk, and less often on the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/47\">",
"     47",
"    </a>",
"    ]. The clinical picture is characterized by rapid change, whether in pain, size of tumor mass, or progression of neurologic deficit, especially when occurring in a pre-existing peripheral nerve tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/2\">",
"     2",
"    </a>",
"    ]. In particular, change in tumor size is most predictive of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/3\">",
"     3",
"    </a>",
"    ]. Major nerve trunks (eg, the brachial plexus) are frequent sites of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/43\">",
"     43",
"    </a>",
"    ], but a nerve of origin is often not evident [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of malignant versus benign tumor requires biopsy, which should be open and involve multiple sections of the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6,43\">",
"     6,43",
"    </a>",
"    ]. Conventional radiographic imaging may help but cannot reliably differentiate between malignant and benign. Large tumor size (&gt;5 cm), heterogeneity, ill-defined margins, invasion of fat planes, and surrounding edema all suggest MPNST [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"     7",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56406 \" href=\"UTD.htm?38/27/39347\">",
"     image 2",
"    </a>",
"    ). At least some data suggest that PET imaging can be helpful in distinguishing an MPNST from a neurofibroma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227163#H12227163\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'PET and PET/CT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic imaging (typically chest imaging to evaluate for pulmonary metastases) is also important as part of a metastatic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227170#H12227170\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Evaluation for metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By gross inspection, MPNSTs tend to be large, firm tumors, containing areas of necrosis and hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26\">",
"     26",
"    </a>",
"    ]. Microscopically, most MPNSTs are highly cellular, comprised of spindle cells reminiscent of Schwann cells. The cells are mitotically active (",
"    <a class=\"graphic graphic_picture graphicRef54780 \" href=\"UTD.htm?0/58/935\">",
"     picture 7",
"    </a>",
"    ). The cells are weakly S100 positive, consistent with dedifferentiation from Schwann cells. Variations include malignant triton tumor (malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation), a highly malignant tumor containing embryonic striated muscle components [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all NF1-associated MPNSTs and most sporadic MPNSTs, both NF1 alleles are lost. However, homozygous loss of NF1 is not sufficient to generate a MPNST and additional genetic hits are necessary, such as mutations in p53 and deletions in CDKN2A29. Positive p53 staining is very common in MPNSTs and intense immunoreactivity to p53 may be an indicator of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/26,50\">",
"     26,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353525\">",
"    <span class=\"h2\">",
"     Treatment of MPNSTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPNSTs are staged and treated as malignant soft tissue sarcomas. Because of their rarity and the frequent need for multimodal treatment, the evaluation and management of MPNSTs ideally should be carried out in a center with expertise in the treatment of sarcomas, including surgical, orthopedic, medical, and radiation oncology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link&amp;anchor=H7794442#H7794442\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\", section on 'Importance of multidisciplinary evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For limb primaries, surgical resection alone with a sufficient wide margin to achieve a potentially curative operation may require amputation of the limb proximal to the tumor, or disarticulation of a shoulder or hip, with sacrifice of nerves, nerve trunks, and adjacent soft-tissue structures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6,43,51\">",
"     6,43,51",
"    </a>",
"    ]. Nerve grafting is not appropriate due to the proximal nature of the remaining nerve, the use of adjuvant radiation therapy and the natural history of MPNSTs. At other sites (eg, the head and neck), wide excision may be impossible due to the constraints of the local anatomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link&amp;anchor=H31#H31\">",
"     \"Head and neck sarcomas\", section on 'Other adult soft tissue sarcomas'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link&amp;anchor=H11#H11\">",
"     \"Head and neck sarcomas\", section on 'Surgical principles'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H3#H3\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the rarity of these tumors has precluded any definitive efficacy trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/4\">",
"     4",
"    </a>",
"    ], as with other adult-type soft tissue sarcomas, adjunctive radiation therapy (RT) can provide an opportunity for limb salvage, and also improve local control where the attainment of wide excision margins by surgery alone is difficult. Adjunctive RT may be administered preoperatively or postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H5#H5\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Limb salvage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H4#H4\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Benefit of RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H10#H10\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Preoperative versus postoperative RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of locally advanced or locally recurrent tumors is challenging. Initial RT or chemoradiotherapy may permit some initially unresectable tumors to undergo later limb-sparing surgery. Where available, isolated limb perfusion, isolated limb infusion, or regional hyperthermia with systemic chemotherapy represent potentially limb-preserving options, but expertise is limited, and these procedures are not in widespread use in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Chemotherapy treatment for advanced disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1395552\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even with aggressive surgical and radiation treatment, the prognosis is not good. Poor prognostic signs include tumors exceeding 5 cm in size, higher tumor grade, association with neurofibromatosis type 1 (NF1), older age, distant metastases at the time of diagnosis, and inability to achieve tumor-free margins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/2,6,47,52,53\">",
"     2,6,47,52,53",
"    </a>",
"    ]. In various studies, five-year survival ranged from 34 to 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/2,6,43,47,52,53\">",
"     2,6,43,47,52,53",
"    </a>",
"    ]. The variable outcomes among these reports may be due in part to differences in treatment protocols and to the proportion of NF1-associated MPNSTs, which often present at a later stage with larger tumors than sporadic MPNSTs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/54\">",
"     54",
"    </a>",
"    ]. A survival meta-analysis of 28 studies published from 1963 through 2011 demonstrated worse survival for NF-1-assoicated tumors compared with sporadic tumors (hazard ratio [HR] 1.39, 95% CI 1.10-1.72); however, in an analysis limited to series published since 2001, the pooled HR was smaller and no longer significant (HR 1.19, 95% CI 0.85-1.66), suggesting that observed differences in outcome between NF-1 and sporadic tumors may be lessening over time [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest studies evaluating MPNSTs was a single-center retrospective review of 175 cases seen over a 25-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/47\">",
"     47",
"    </a>",
"    ]. The median age was 44, and one-third of MPNSTs arose in the setting of NF1. The extremities were the most common site (45 percent) followed by the trunk (34 percent) and head and neck (19 percent). At presentation, 84 percent had locoregional disease, while 16 percent had distant metastases. A complete (R0) resection was accomplished in 69 percent of cases, and the majority had adjuvant treatment with radiation therapy, chemotherapy, or both. At a median follow-up of 74 months, the local recurrence rate was 22 percent, and the 5 and 10-year disease-specific survival rates were 60 and 45 percent, respectively. On multivariate analysis, higher tumor grade, size &ge;5 cm, truncal location and local recurrence were associated with a significantly worse prognosis. Patients with NF-1 presented with larger tumors (median 9.9 versus 6.6 cm for sporadic tumors), and there was a statistically nonsignificant trend toward worse 5-year disease-specific survival (54 versus 75 percent for sporadic cases).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353537\">",
"    <span class=\"h1\">",
"     MALIGNANT NON-NEURAL SHEATH TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral nervous system is often involved in patients with cancer, most commonly as a result of chemotherapy or radiation therapy. However, peripheral nerves can also be involved by compression or infiltration from solid tumors (by extension or metastases) and lymphomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353551\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers can involve the peripheral nervous system by compression from primary or metastatic tumor, by",
"    <span class=\"nowrap\">",
"     extension/infiltration",
"    </span>",
"    of the tumor into the nerve, by metastatic invasion of the nerve, or by spread along the nerve (perineural extension). Proximal nerve roots and trunks (plexi) are most commonly involved, but distal, large nerves can also be compromised.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the cervical plexus, lymph node metastases from head and neck cancers, lymphoma, and adenocarcinomas of the breast and lung are the most common sources of involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/55\">",
"       55",
"      </a>",
"      ], leading to pain in the throat, neck, or scalp, with effects on speech, swallowing, and breathing (phrenic nerve), as well as abnormal sensation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of cancer pain syndromes\", section on 'Plexopathies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The brachial plexus may be involved in up to 1 percent of all patients with cancer, with breast and lung cancer most common [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/55\">",
"       55",
"      </a>",
"      ]. The lower trunk is most commonly involved due to its proximity to axillary lymph nodes and the upper lobe of the lung. Pain is the usual presentation, and helps differentiate cancerous from radiation-induced plexopathy. Sensorimotor deficits of the arm, usually in the C8-T1 myotomes and dermatomes, Horner's syndrome and a supraclavicular or axillary mass can be present on exam. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H21#H21\">",
"       \"Brachial plexus syndromes\", section on 'Neoplastic and radiation-induced brachial plexopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The lumbosacral plexus is involved about as frequently as the brachial plexus (0.71 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/56\">",
"       56",
"      </a>",
"      ], usually from direct extension from pelvic and abdominal cancers such as cervical, colon, and bladder, or metastatic disease from lymphoma, breast, and prostate. Insidious pain is present in over 90 percent of patients, and like the brachial plexus, can precede neurologic symptoms by several months. Sensory abnormalities, weakness, edema, and changes in limb temperature (\"hot foot sign\") are frequent on examination [",
"      <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/55\">",
"       55",
"      </a>",
"      ]. Involvement is usually unilateral, whereas radiation-induced lumbosacral plexopathy is often bilateral. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link&amp;anchor=H13#H13\">",
"       \"Lumbosacral plexus syndromes\", section on 'Neoplastic invasion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Involvement of individual peripheral nerves is uncommon (especially if cranial nerves are not included), and arises in most instances from compression. It is distinctly rare for peripheral nerves to develop intraneural metastases, with only a few descriptions in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/57\">",
"     57",
"    </a>",
"    ]. Another rare manner in which peripheral nerves may be involved is perineural spread, in which neoplastic cells migrate along the endoneurial tubes, with no extension beyond the perineurium. This is in contrast to intraneural metastases that arrive hematogenously, and infiltrate from the epineurium inward [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/58\">",
"     58",
"    </a>",
"    ]. This has been described in squamous cell carcinoma of the head and neck, malignant melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/58\">",
"     58",
"    </a>",
"    ] and prostate cancer. Symptoms are relevant to the involved nerve, including local mass, pain, and sensorimotor deficits. The course of perineural spread is unusually long, often years, before diagnosis.",
"   </p>",
"   <p>",
"    MRI is the most useful imaging test as it can best differentiate between mass, neural structures, and other soft tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H21#H21\">",
"     \"Brachial plexus syndromes\", section on 'Neoplastic and radiation-induced brachial plexopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link&amp;anchor=H13#H13\">",
"     \"Lumbosacral plexus syndromes\", section on 'Neoplastic invasion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30353654\">",
"    <span class=\"h2\">",
"     Neurolymphomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurolymphomatosis is the term for systemic lymphoma that has invaded the peripheral nervous system. Neurolymphomatosis is uncommon, with a review from 2003 finding fewer than 75 reported cases, including 25 that came from one institution [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Although usually of B-cell origin, peripheral nerve invasion has been reported with primary central nervous system (CNS) lymphoma of T-cell origin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/61\">",
"     61",
"    </a>",
"    ] and with S&eacute;zary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary lymphoma arising from peripheral nerve is rare, most being of B-cell origin and affecting the sciatic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/6,63,64\">",
"     6,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurolymphomatosis often presents with pain, involving either one or more peripheral nerves, nerve roots, or cranial nerves, though painless involvement is not uncommon. MRI shows enlarged nerves that enhance, and biopsy shows infiltrative lymphoma. Meningeal involvement detected by MRI or cerebrospinal fluid analysis is common, though many of the cases were diagnosed only at postmortem. The prognosis is similar to primary CNS lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/24/23946/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial evaluation of the patient with suspected non-Hodgkin lymphoma must establish the extent and sites of disease. The treatment approach and prognosis are strongly dependent upon this information. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26257?source=see_link\">",
"       \"Patient information: Neurofibromatosis type 1 (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2289415\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms and signs of peripheral nerve tumors are caused by direct nerve invasion, involvement of surrounding tissues, or mass effect. There are no specific clinical presentations unique or even especially suggestive of a particular nerve tumor, with the exception of the clinical signs of neurofibromatosis 1 or 2. (See",
"      <a class=\"local\" href=\"#H30352971\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of laboratory evaluation of the patient with a peripheral nerve tumor is to determine the type and location. Imaging, particularly with MRI, is the most useful modality. Electrodiagnostic testing can help to localize involvement of specific nerves or portions of a plexus but the findings are nonspecific for differentiating peripheral nerve tumors. Surgical biopsy is important for tumors that are deep or potentially malignant. (See",
"      <a class=\"local\" href=\"#H30353014\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for peripheral nerve tumors is largely based on surgical removal. However, some patients with asymptomatic, non-neoplastic,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      benign tumors can be treated conservatively. (See",
"      <a class=\"local\" href=\"#H30353077\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral nerve tumors can be classified according to the presence or absence of neoplasia, whether the neoplasia is benign or malignant, and the presumed cellular origin of the underlying neoplasia, ie, nerve sheath origin or not (",
"      <a class=\"graphic graphic_table graphicRef60755 \" href=\"UTD.htm?36/55/37756\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30353164\">",
"       'Nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The category of benign non-neoplastic nerve tumors includes neuroma, ganglion cyst, heterotopic ossification, sarcoid granuloma, inflammatory pseudotumor of nerve, leprosy, localized hypertrophic neuropathy, and miscellaneous causes. Desmoid tumors are benign neoplasms of non-neural sheath origin. (See",
"      <a class=\"local\" href=\"#H30353175\">",
"       'Benign non-neoplastic nerve tumors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30353333\">",
"       'Benign neoplasms of non-neural sheath origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumor types classified as benign nerve sheath neoplasms include neurofibroma, schwannoma, perineurioma, cellular and mixed-type neurothekeoma, nerve sheath myxoma, ganglioneuroma, and hemangioblastoma. (See",
"      <a class=\"local\" href=\"#H30353352\">",
"       'Benign nerve sheath neoplasms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignant peripheral nerve sheath tumors are an uncommon but devastating tumor of peripheral nerve. The diagnosis of malignant versus benign tumor requires biopsy, which should be open and involve multiple sections of the tumor. Surgical removal may require amputation of the limb proximal to the tumor. (See",
"      <a class=\"local\" href=\"#H30353537\">",
"       'Malignant non-neural sheath tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral nerves can also be involved by compression or infiltration from solid tumors (by extension or metastases) and lymphomas. (See",
"      <a class=\"local\" href=\"#H30353537\">",
"       'Malignant non-neural sheath tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/1\">",
"      Mrugala MM, Batchelor TT, Plotkin SR. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol 2005; 18:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/2\">",
"      Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology 2003; 61:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/3\">",
"      Valeyrie-Allanore L, Isma&iuml;li N, Bastuji-Garin S, et al. Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1. Br J Dermatol 2005; 153:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/4\">",
"      Perrin RG, Guha A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am 2004; 15:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/5\">",
"      Donner TR, Voorhies RM, Kline DG. Neural sheath tumors of major nerves. J Neurosurg 1994; 81:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/6\">",
"      Bhattacharyya AK, Perrin R, Guha A. Peripheral nerve tumors: management strategies and molecular insights. J Neurooncol 2004; 69:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/7\">",
"      Pilavaki M, Chourmouzi D, Kiziridou A, et al. Imaging of peripheral nerve sheath tumors with pathologic correlation: pictorial review. Eur J Radiol 2004; 52:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/8\">",
"      Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002; 62:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/9\">",
"      Golan JD, Jacques L. Nonneoplastic peripheral nerve tumors. Neurosurg Clin N Am 2004; 15:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/10\">",
"      Brooks DG. The neurofibromatoses: hereditary predisposition to multiple peripheral nerve tumors. Neurosurg Clin N Am 2004; 15:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/11\">",
"      Tiel R, Kline D. Peripheral nerve tumors: surgical principles, approaches, and techniques. Neurosurg Clin N Am 2004; 15:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/12\">",
"      Bourke G, Owen J, Machet D. Histological comparison of the third interdigital nerve in patients with Morton's metatarsalgia and control patients. Aust N Z J Surg 1994; 64:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/13\">",
"      Wu KK. Morton's interdigital neuroma: a clinical review of its etiology, treatment, and results. J Foot Ankle Surg 1996; 35:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/14\">",
"      Espinosa N, Schmitt JW, Saupe N, et al. Morton neuroma: MR imaging after resection--postoperative MR and histologic findings in asymptomatic and symptomatic intermetatarsal spaces. Radiology 2010; 255:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/15\">",
"      Pace A, Scammell B, Dhar S. The outcome of Morton's neurectomy in the treatment of metatarsalgia. Int Orthop 2010; 34:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/16\">",
"      Adams WR 2nd. Morton's neuroma. Clin Podiatr Med Surg 2010; 27:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/17\">",
"      Thomson CE, Gibson JN, Martin D. Interventions for the treatment of Morton's neuroma. Cochrane Database Syst Rev 2004; :CD003118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/18\">",
"      Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995; 267:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/19\">",
"      Kim DH, Murovic JA, Tiel RL, et al. A series of 146 peripheral non-neural sheath nerve tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg 2005; 102:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/20\">",
"      George DH, Scheithauer BW, Spinner RJ, et al. Heterotopic ossification of peripheral nerve (\"neuritis ossificans\"): report of two cases. Neurosurgery 2002; 51:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/21\">",
"      P&eacute;rez-L&oacute;pez C, Guti&eacute;rrez M, Isla A. Inflammatory pseudotumor of the median nerve. Case report and review of the literature. J Neurosurg 2001; 95:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/22\">",
"      Koszyca B, Jones N, Kneebone C, Blumbergs P. Localized hypertrophic neuropathy: a case report and review of the literature. Clin Neuropathol 2009; 28:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/23\">",
"      Stumpo M, Foschini MP, Poppi M, et al. Hypertrophic inflammatory neuropathy involving bilateral brachial plexus. Surg Neurol 1999; 52:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/24\">",
"      Maher CO, Spinner RJ, Giannini C, et al. Neuromuscular choristoma of the sciatic nerve. Case report. J Neurosurg 2002; 96:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/25\">",
"      Ferraresi S, Garozzo D, Bianchini E. Aggressive fibromatosis (desmoid tumor) of the radial nerve: favorable resolution. Case report. J Neurosurg 2001; 95:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/26\">",
"      Skovronsky DM, Oberholtzer JC. Pathologic classification of peripheral nerve tumors. Neurosurg Clin N Am 2004; 15:157.",
"     </a>",
"    </li>",
"    <li>",
"     Chang, SD, Kim, DH, Hudson, AR, Kline, DG. Peripheral Nerve Tumors. In: Neuromuscular Disorders in Clinical Practice, Katirji, B, Kaminski, HJ, Preston, DC, et al (Eds), Butterworth-Heinemann, Boston 2002. p.828.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/28\">",
"      Kim DH, Murovic JA, Tiel RL, Kline DG. Operative outcomes of 546 Louisiana State University Health Sciences Center peripheral nerve tumors. Neurosurg Clin N Am 2004; 15:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/29\">",
"      Hirose T, Scheithauer BW, Sano T. Perineurial malignant peripheral nerve sheath tumor (MPNST): a clinicopathologic, immunohistochemical, and ultrastructural study of seven cases. Am J Surg Pathol 1998; 22:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/30\">",
"      MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/31\">",
"      El-Sherif Y, Sarva H, Valsamis H. Clinical reasoning: an unusual lung mass causing focal weakness. Neurology 2012; 78:e4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/32\">",
"      Rankine AJ, Filion PR, Platten MA, Spagnolo DV. Perineurioma: a clinicopathological study of eight cases. Pathology 2004; 36:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/33\">",
"      Tsang WY, Chan JK, Chow LT, Tse CC. Perineurioma: an uncommon soft tissue neoplasm distinct from localized hypertrophic neuropathy and neurofibroma. Am J Surg Pathol 1992; 16:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/34\">",
"      Giannini C, Scheithauer BW, Jenkins RB, et al. Soft-tissue perineurioma. Evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature. Am J Surg Pathol 1997; 21:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/35\">",
"      Fetsch JF, Laskin WB, Miettinen M. Nerve sheath myxoma: a clinicopathologic and immunohistochemical analysis of 57 morphologically distinctive, S-100 protein- and GFAP-positive, myxoid peripheral nerve sheath tumors with a predilection for the extremities and a high local recurrence rate. Am J Surg Pathol 2005; 29:1615.",
"     </a>",
"    </li>",
"    <li>",
"     Harkin, JC, Reed, RJ. Solitary benign nerve sheath tumors. In: Atlas of Tumor Pathology: Tumors of the Peripheral Nervous System, 2, Firminger, HI (Eds), Armed Forces Institute of Pathology, Washington, DC 1959. p.60.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/37\">",
"      Gallager RL, Helwig EB. Neurothekeoma--a benign cutaneous tumor of neural origin. Am J Clin Pathol 1980; 74:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/38\">",
"      Busam KJ, Mentzel T, Colpaert C, et al. Atypical or worrisome features in cellular neurothekeoma: a study of 10 cases. Am J Surg Pathol 1998; 22:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/39\">",
"      Laskin WB, Fetsch JF, Miettinen M. The \"neurothekeoma\": immunohistochemical analysis distinguishes the true nerve sheath myxoma from its mimics. Hum Pathol 2000; 31:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/40\">",
"      Lee D, Suh YL, Han J, Kim ES. Spinal nerve sheath myxoma (neurothekeoma). Pathol Int 2006; 56:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/41\">",
"      Modha A, Paty P, Bilsky MH. Presacral ganglioneuromas. Report of five cases and review of the literature. J Neurosurg Spine 2005; 2:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/42\">",
"      Escott EJ, Kleinschmidt-DeMasters BK, Brega K, Lillehei KO. Proximal nerve root spinal hemangioblastomas: presentation of three cases, MR appearance, and literature review. Surg Neurol 2004; 61:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/43\">",
"      Kim DH, Murovic JA, Tiel RL, et al. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg 2005; 102:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/44\">",
"      Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/45\">",
"      Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/46\">",
"      Tucker T, Wolkenstein P, Revuz J, et al. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005; 65:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/47\">",
"      Stucky CC, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol 2012; 19:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/48\">",
"      Stasik CJ, Tawfik O. Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch Pathol Lab Med 2006; 130:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/49\">",
"      McConnell YJ, Giacomantonio CA. Malignant triton tumors--complete surgical resection and adjuvant radiotherapy associated with improved survival. J Surg Oncol 2012; 106:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/50\">",
"      Zhou H, Coffin CM, Perkins SL, et al. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am J Surg Pathol 2003; 27:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/51\">",
"      Porter DE, Prasad V, Foster L, et al. Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma 2009; 2009:756395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/52\">",
"      Levi AD, Ross AL, Cuartas E, et al. The surgical management of symptomatic peripheral nerve sheath tumors. Neurosurgery 2010; 66:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/53\">",
"      Kolberg M, H&oslash;land M, Agesen TH, et al. Survival meta-analyses for &gt;1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol 2013; 15:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/54\">",
"      Hagel C, Zils U, Peiper M, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol 2007; 82:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/55\">",
"      Ramchandren S, Dalmau J. Metastases to the peripheral nervous system. J Neurooncol 2005; 75:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/56\">",
"      Jaeckle KA, Young DF, Foley KM. The natural history of lumbosacral plexopathy in cancer. Neurology 1985; 35:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/57\">",
"      Grisold W, Piza-Katzer H, Jahn R, Herczeg E. Intraneural nerve metastasis with multiple mononeuropathies. J Peripher Nerv Syst 2000; 5:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/58\">",
"      Chang PC, Fischbein NJ, McCalmont TH, et al. Perineural spread of malignant melanoma of the head and neck: clinical and imaging features. AJNR Am J Neuroradiol 2004; 25:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/59\">",
"      Baehring JM, Damek D, Martin EC, et al. Neurolymphomatosis. Neuro Oncol 2003; 5:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/60\">",
"      Chamberlain MC, Fink J. Neurolymphomatosis: a rare metastatic complication of diffuse large B-Cell lymphoma. J Neurooncol 2009; 95:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/61\">",
"      Levin N, Soffer D, Grissaru S, et al. Primary T-cell CNS lymphoma presenting with leptomeningeal spread and neurolymphomatosis. J Neurooncol 2008; 90:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/62\">",
"      Bezier M, Reguia&iuml; Z, Delaby P, et al. Neurolymphomatosis associated with S&eacute;zary syndrome. Arch Dermatol 2009; 145:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/63\">",
"      Misdraji J, Ino Y, Louis DN, et al. Primary lymphoma of peripheral nerve: report of four cases. Am J Surg Pathol 2000; 24:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/64\">",
"      Shibata-Hamaguchi A, Samuraki M, Furui E, et al. B-cell neurolymphomatosis confined to the peripheral nervous system. J Neurol Sci 2007; 260:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/24/23946/abstract/65\">",
"      Baehring JM, Hochberg FH. Primary lymphoma of the nervous system. Cancer J 2006; 12:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15269 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23946=[""].join("\n");
var outline_f23_24_23946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2289415\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30352918\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30352971\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30353014\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353033\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353054\">",
"      Electrodiagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353061\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30353077\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30353164\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30353175\">",
"      BENIGN NON-NEOPLASTIC NERVE TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353182\">",
"      Neuroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353205\">",
"      Ganglion cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353217\">",
"      Intraneural heterotopic ossification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353224\">",
"      Sarcoid granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353253\">",
"      Inflammatory pseudotumor of nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353260\">",
"      Leprosy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353301\">",
"      Hypertrophic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353314\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30353333\">",
"      BENIGN NEOPLASMS OF NON-NEURAL SHEATH ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30353352\">",
"      BENIGN NERVE SHEATH NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353371\">",
"      Neurofibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353409\">",
"      Schwannoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353444\">",
"      Perineurioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353451\">",
"      Neurothekeoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353458\">",
"      Nerve sheath myxoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353465\">",
"      Ganglioneuroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353472\">",
"      Hemangioblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30353503\">",
"      MALIGNANT PERIPHERAL NERVE SHEATH TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353525\">",
"      Treatment of MPNSTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1395552\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30353537\">",
"      MALIGNANT NON-NEURAL SHEATH TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353551\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30353654\">",
"      Neurolymphomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2289415\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/15269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15269|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/6/6241\" title=\"diagnostic image 1\">",
"      MRI Schwannoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/27/39347\" title=\"diagnostic image 2\">",
"      MRI MPNST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/32/25090\" title=\"diagnostic image 3\">",
"      MRI ganglion cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/51/18229\" title=\"diagnostic image 4\">",
"      MRI neurofibromas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15269|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/10/34984\" title=\"picture 1\">",
"      Traumatic neuroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/56/18310\" title=\"picture 2\">",
"      Micrograph neurofibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/45/15056\" title=\"picture 3\">",
"      Plexiform neurofibroma 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/53/36691\" title=\"picture 4\">",
"      Micrograph schwannoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/33/36373\" title=\"picture 5\">",
"      Micrograph neurothekeoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/30/12775\" title=\"picture 6\">",
"      Micrograph ganglioneuroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/58/935\" title=\"picture 7\">",
"      Micrograph MPNST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15269|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/55/37756\" title=\"table 1\">",
"      Classification PN tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/44/10955\" title=\"table 2\">",
"      Diagnostic criteria NF1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=related_link\">",
"      Hemangioblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28694?source=related_link\">",
"      Intradural nerve sheath tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=related_link\">",
"      Lumbosacral plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20712?source=related_link\">",
"      Neurofibromatosis type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11731?source=related_link\">",
"      Overview of schwannomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26257?source=related_link\">",
"      Patient information: Neurofibromatosis type 1 (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32822?source=related_link\">",
"      Surgery for carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23305?source=related_link\">",
"      Treatment and prevention of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=related_link\">",
"      Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_24_23947="Intrauterine nutrient accretion";
var content_f23_24_23947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated daily intrauterine nutrient accretion rates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nutrient*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Unit/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium (mg)",
"       </td>",
"       <td>",
"        105",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper (mcg)",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium (mg)",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrogen (mg)",
"       </td>",
"       <td>",
"        325",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphorus (mg)",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium (meq)",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium (meq)",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc (mcg)",
"       </td>",
"       <td>",
"        240",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Values are averaged from last trimester and adjusted for body weight.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted form Widdowson EM. Importance of nutrition in development, with special reference to feeding low-birth-weight infants. In: Meeting Nutritional Goals for Low-Birth-Weight Infants, Sauls HS, Bachhuber WL, Lewis LA. (Eds), Ross Laboratories, Columbus, 1982, p. 4; and Ziegler EE, O'Donnell AM, Nelson SE, Fomon SJ, Growth 1976; 40:329.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23947=[""].join("\n");
var outline_f23_24_23947=null;
var title_f23_24_23948="Fem sex dysfunc criteria";
var content_f23_24_23948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Psychiatric Association diagnostic criteria for female sexual dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic criteria*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoactive sexual desire disorder",
"       </td>",
"       <td>",
"        <p>",
"         A. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity. The judgment of deficiency or absence is made by the clinician, taking into account factors that affect sexual functioning, such as age and the context of the person's life.",
"        </p>",
"        <p>",
"         B. The disturbance causes marked distress or interpersonal difficulty.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female sexual arousal disorder",
"       </td>",
"       <td>",
"        <p>",
"         A. Persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate lubrication-swelling response of sexual excitement.",
"        </p>",
"        <p>",
"         B. The disturbance causes marked distress or interpersonal difficulty.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female orgasmic disorder",
"       </td>",
"       <td>",
"        <p>",
"         A. Persistent or recurrent delay in, or absence of, orgasm following a normal sexual excitement phase. Women exhibit wide variability in the type or intensity of stimulation that triggers orgasm. The diagnosis of female orgasmic disorder should be based on the clinician's judgment that the woman's orgasmic capacity is less than would be reasonable for her age, sexual experience, and the adequacy of sexual stimulation she receives.",
"        </p>",
"        <p>",
"         B. The disturbance causes marked distress or interpersonal difficulty.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspareunia",
"       </td>",
"       <td>",
"        <p>",
"         A. Recurrent or persistent genital pain associated with sexual intercourse in either a male or a female.",
"        </p>",
"        <p>",
"         B. The disturbance causes marked distress or interpersonal difficulty.",
"        </p>",
"        <p>",
"         C. The disturbance is not caused exclusively by vaginismus or lack of lubrication.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginismus",
"       </td>",
"       <td>",
"        <p>",
"         A. Recurrent or persistent involuntary spasm of the musculature of the outer third of the vagina that interferes with sexual intercourse.",
"        </p>",
"        <p>",
"         B. The disturbance causes marked distress or interpersonal difficulty.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All diagnoses include the criterion that the disorder is not better accounted for by another Axis I disorder (except another sexual dysfunction) and is not due exclusively to the direct physiological effects of a substance (eg, a drug of abuse, a medication) or a general medical condition.",
"    </div>",
"    <div class=\"reference\">",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Arlington, VA 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23948=[""].join("\n");
var outline_f23_24_23948=null;
var title_f23_24_23949="Genetic syndromes associated with obesity";
var content_f23_24_23949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected genetic syndromes associated with obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Locus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Obesity onset (type)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albright hereditary osteodystrophy (Pseudohypoparathyroidism type 1a) (MIM #103580)",
"       </td>",
"       <td>",
"        20q13.2",
"       </td>",
"       <td>",
"        GNAS1",
"       </td>",
"       <td>",
"        Early (generalized)",
"       </td>",
"       <td>",
"        Short stature, short metacarpals and metatarsals, round facies, delayed dentition, +/&minus; hypocalcemia and/or subcutaneous calcium or bone deposition(osteoma cutis), precocious puberty, mild cognitive deficit",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Alstr&ouml;m (MIM #203800)",
"       </td>",
"       <td>",
"        2p13",
"       </td>",
"       <td>",
"        ALMS1",
"       </td>",
"       <td>",
"        Age 2-5 yrs (central)",
"       </td>",
"       <td>",
"        Blindness, deafness, acanthosis nigricans, chronic nephropathy, type 2 diabetes, cirrhosis, primary hypogonadims in males only, normal cognition",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"15\">",
"        Bardet-Biedl (MIM #209900)",
"       </td>",
"       <td>",
"        11q13",
"       </td>",
"       <td>",
"        BBS1",
"       </td>",
"       <td rowspan=\"15\">",
"        Age 1-2 yrs (central)",
"       </td>",
"       <td rowspan=\"15\">",
"        Mental retardation, hypotonia, retinitis pigmentosa, polydactyly, hypogonadism +/&minus; glucose intolerance, deafness, renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16q21",
"       </td>",
"       <td>",
"        BBS2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3p12-q13",
"       </td>",
"       <td>",
"        BBS3 (ARL6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15q22.3-q23",
"       </td>",
"       <td>",
"        BBS4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2q31",
"       </td>",
"       <td>",
"        BBS5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20p12",
"       </td>",
"       <td>",
"        BBS6 (MKKS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4q27",
"       </td>",
"       <td>",
"        BBS7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14q32",
"       </td>",
"       <td>",
"        BBS8 (TTC8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7p14",
"       </td>",
"       <td>",
"        BBS9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12q",
"       </td>",
"       <td>",
"        BBS10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9q33.1",
"       </td>",
"       <td>",
"        BBS11 (TRIM32)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4q27",
"       </td>",
"       <td>",
"        BBS12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17q23",
"       </td>",
"       <td>",
"        BBS13 (MKS1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12q21.3",
"       </td>",
"       <td>",
"        BBS14 (CEP290)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2p15",
"       </td>",
"       <td>",
"        BBS15 (C2ORF86)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Beckwith-Wiedemann (MIM #130650)",
"       </td>",
"       <td>",
"        11p15.5 in most cases; deregulation of imprinted genes including IGF2",
"       </td>",
"       <td>",
"        multiple",
"       </td>",
"       <td>",
"        &minus;",
"       </td>",
"       <td>",
"        Hyperinsulinemia, hypoglycemia, hemihypertrophy, intolerance of fasting",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Carpenter (MIM #201000)",
"       </td>",
"       <td>",
"        6p11",
"       </td>",
"       <td>",
"        RAB23",
"       </td>",
"       <td>",
"        (central)",
"       </td>",
"       <td>",
"        Mental retardation, short stature, brachycephaly, polydactyly, syndactyly of feet, cryptorchidism, umbilical hernia, high-arched palate, hypogonadism in males only",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cohen (MIM #216550)",
"       </td>",
"       <td>",
"        8q22",
"       </td>",
"       <td>",
"        COH1",
"       </td>",
"       <td>",
"        Mid-childhood (central)",
"       </td>",
"       <td>",
"        Mental retardation, microcephaly, small hands and feet, cryptorchidism, hypotonia and failure to thrive in infancy, prominent central incisors, long, thin fingers and toes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Prader-Willi (MIM #176270)",
"       </td>",
"       <td>",
"        15q",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Age 1-3 yrs (generalized)",
"       </td>",
"       <td>",
"        Microcephaly, short stature, hypotonia, almond- shaped eyes, high-arched palate, narrow hands and feet, delayed puberty, early failure to thrive with hyperphagia and increased weight gain by 2-3 years, mild to moderate cognitive deficit",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Pediatric Obesity. In: Pediatric Nutrition Handbook, 6th ed, Kleinman R (Ed), American Academy of Pediatrics, Elk Grove Village, IL, 2009. p.751",
"      </li>",
"      <li>",
"       Hoppin AG. Obesity. In: Pediatric Gastrointestinal Disease: Pathopsychology, Diagnosis, Management, 4th ed, Walker WA, Goulet O, Kleinman, RE, et al (Eds), BC Decker, Ontario, 2004. p.311.",
"      </li>",
"      <li>",
"       Leibel RL, Chua SC, Rosenbaum M. Obesity. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, 2001. p.3965.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23949=[""].join("\n");
var outline_f23_24_23949=null;
var title_f23_24_23950="Evaluation of hyperammonemia";
var content_f23_24_23950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for initial evaluation of hyperammonemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 478px; background-image: url(data:image/gif;base64,R0lGODlhnAHeAcQAAP///wAAAIiIiERERLu7uyIiImZmZt3d3ZmZmTMzMxEREe7u7szMzFVVVXd3d6qqqkBAQCAgIODg4KCgoNDQ0PDw8BAQEMDAwHBwcLCwsFBQUGBgYICAgAAAAAAAAAAAACH5BAAAAAAALAAAAACcAd4BAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhGEBh4iJiouMjY6PkJGSkYWVliMBhZmXnIObnp2hgJ+CpKKneKajqKypmq2wdKp/s7G2abV9ube8Y6YDBiIHAQRsAgMru73LXr/BAMPFrszUviXAwsQGyAADDgQBCQEFDAACh+Tg4AgF6OXjhwaHCQDg7QoNhw7Q4gH7AgXaJVgAIF+4BfYC4NNnDpm8QwhKKKtGscovRQSGHdAIrlyDBgwUlHPQAJyAEgX2/wU4aaDARmLqABRAhiDTRwAhCQA8sEABAgEDASQQEHMmgJoNSRigR2JixadQnGUrNkCAg2DgRACsiahAVgALHgYIRiwpAJibqtbLVCBit5/c2ood+1Vt1mPmFKCTCLUvFqnQyhIoIHKtiAQGQpYT8bUmQcRni+GNXPdk1psMiE1uC5Qg47SWMx0b9gCAgwJ8/aqeAjjaYW7g5h0wh8jA1wP9CpCVzA2tCLuZcDPcHNFgAASVDeMdgA5109XQo7boKe3rG6fRs/9w6oCpYTjYtYvXEd5O+fHoaZyXlb49kPVz4Lufn0J+HPv082N6pb//jEkABijggAQm4t+B1iCoIP8s+C3o4DQPRnhJgxJWeJ2FGJaS4YZ+UMjhh2J4COKIXYhIYigFpqjiiiy26OKLMA54YgsmznhEjQviaCMROiLY445B/OifkED6QKR+Rxa5Q5L0MakkDk66F+WTNUyZnpVUyoDleFtm+UKXq1GgwQVnAXCBBhR4GYWYZGZyZppFRhCAnHSqKQWdc8755ASKTGBnFHwm4qeSFViAiAUV/AlFoYcm+iQGiGCgaBSQHiIplRIgIsGkUGR6yKZZQhAABJxGISqpXmYQQAalQqEqq2qi2uoTss5q66245qrrrkjE6OuvwCLSX7Ay6gGmG8eCIp2xFCWr4bJ5OLuGtKtACyH/M9TSEkW2vTY77LZ7cHuGuHxIS24RUZaFxHIn1SeNDecya8Nk8IZbwjkNiFBAuzmoiwJAI+yLA7sq+Otuwd+W8MBYKKg1Ar0pQGxCvEOYIoACPsnEL5TvngCwvhvTQPDBN1B87W8DKODZChL/Zy8JAF28gMDnhPMOO9u0E8AA98ymMzmRkTBAP8F8rDEJwvnT0DmzicAVwwQvdcDP71B1yAALMNBPvsRofUi+zyFZwjAMtKUVIgyoVfPO9eiVsQNo4wX3IYuJYHKQ9xbQU0sCZFbONmeBPQBNZQkcsEodD5Cv32sfsjFmCujkFQqOsQs4CSlFBtACCwwFVFM6eZda/34W04NXZu9WhXpSCpyEgMoBlKYVMrGfcPd7edO2EjuMoaYucL8JEFZtQY/g8HFGG66vWwPAZQIC/QRwwHIYzzZ8PJEZ8IwABhyQTwIREeN9OG7tJzbmiRzAu/ECrD+a9HZP344BC+AF0Fgrlynvw86103cAHqGdNIDXjfYF4DG7EdpJFia/gD1ucZrhBub2wcDlXMUljhHKbjY3M34BzF9Gs1vCPuMZb6wueH4rCDJal5eV+QRiGTNftHJ3lJXoLgFVC953qpI03RTvN4g4SfI2lrR/SPBh6JBe1MiRmwQyZ2f1Q0T4dCLF0TVJKWA7igJ0B0C1PCQByCCA2xDQk/951A9rejlI2GbIBIep4XZ1MNfLluBGXIzQCXA0krfO94Q89sCPXADkfcC1P2zdsQmCJM8eSUdINlIjkRey1h2IRclKFmhYlpREhCB5Ik6iwpMjAqUoRPkhUnbClBtC5YR4lQRVWsKVFoIlf1hpBFkSwpab/BMuH7TLQPQyR4/MpDAzmaVf1jIWxiwkL5L5x2I+EpnONCSDorkMZvLAmpN85jSphE28bfNJ3cTdN5UUzu1Ak5u8YFOZ3tQJdboJTTNyp5ngCQs81SkU9tSTjfIZAVsEChGD6sQ/DxHQEw00AAVlBaMOgShRLDQADbXRQyMai0oF4FKisChGbaRRXnj/KgCgEsVHQ2qjkfbiVK1AqZJUyotXtcKlSoLpSWNRqyLVlJY4zalOd8rT9gzzp3/8qVAZUYahGpVYVYrkkhwZomomFVnNPBkYynnNp7YBR930JFWXqh6lKlKqX9jqV10G1aqCtRlO7WpZuZpNMoi1X1YFgnVuFFUmGAxdRTXGEfGqVhQcx2nwmasJWnYCwSLMrEKzoWve07EbENaKhogBAfqBw4HtFQZ1fCzJ+qqlgrkFKTIwLMwuC6W6Gq8dL2nsNVVbsby+4AAKeAbP8gcFzYqTrH79LFtO0pMHDA17RTRM2QSQtO7VRowKicjrHJeV5drQr6b9zTYG4JonYk0d/8eBx1jmAUQoFiSI2eOGN76rEPIOJCELURpexFI+GTb1BZ8bgQIegN2fIMIhVfwt1MKos41RjYtpE+J966GziPDsaj2LzDDMCAP77GIRR0EN7xSHEwBCjgAdmVwDggFbBkyGha9bwHg/0419JCO63bDNSjSjt84R5bk2bElqOeg5BcxGLeKTnkZ2opWgDKUohDOLCJYyMde64HLLM0mFSwMxIg9uLdNbYchQ4oATFnB1eMnYA7b45JoUQ2D+Ik2D4zox3YIlcuAroN3YwTzkKMTEOoMIXjQSv8nujAFZsfMA6lZkxBovGAYhgPa0omJM8MZugt6e9mR7krJU5SoAGP/0kBNRaDXfBRkX2wtkpwqD+Ipgvo1xjv3SiBq17Ji68CvB9cayvuC5D9XpIyCOCZC2Kn6JzBIxszkSsEU1MxAzaBHjSTYMM6awUGYj2PBciQ1dP0s3MCzm3L6sU5bJRLuDHARzMQZTGB7vemXJubSYT9PnBLlgGLLV21dS2ABUl4bcplailJ93QA1aWXUAVCEAYqjD5GiDHgv46605W2bAiiDg7XqiYvuxj6yEpHvRO0BI6DLGbrgjK08EWrPZ+udJWw2K1D500KzLudw0WhpgNN4htmgcN/dbNMjIuHPW+N4X2Nlm34k0OmLeHDWfum2OG0EPi4Y2L86Dv3uR9cn/kduO9rLAwaFVmQ4tgmIizKy91OGruXvA7PjgmgUJMLGaqe7sil2tBN05plt78MQENM3rBH9j1eWg1bTilg1YZWpkewF1HrHWmxyPo5HbYFvRdpbg2AjM32Nw13mRluZwPWuJTqDwKTv28TN4bOFhXi/EP2OxJVu8OcsO9613vCM8sG0MNI/5nHf+7imeyuW8ARC9BIXkXBTg7PdhkC3WLB3wSK8RdQ6RTZfsqEcdfMf37eW1iPgYuokLAgwgOAc8zbjxKK5EdPZFERgEh7W5vjkIo0aSX9o0cdNZAvohO+O74CKJyIiOldjifdH4f0wWoEZ27BIRKMY0JVE4QdZk/6KjP2jwVrD3bDVxAIM2aEMzG5fTFuAgcalWQ2fkfRxWGJjAEi4RDZ0hFAIgMZVTfyHYYj/GebWjFR0YY6TVd8tXXVZRNOK1aIT2aiMXg5H2DDXUFeHGeZk2Du5Xc6wwCwoXEWJEZw4TgQaGg9CDCFGmL4nQXtXWG4JGaZPRhIfwhCkmadxzfvdDP9YmckH4dNfweYJBGOUwZy9EguwmQATWbf2HExq4Q6HREOM2cyJkR+O0fMaTAILTLgAjRsqFMV9GQUrEFF0nESKnGUHRY/piiE8IWz9BgucnX84TNITlgs+meK9xNl/TXVhDfEahLinXXb53XKChHDw3DnhogP/jck5lqDC/0y5TEw4xZBS6g1oTB3FOCDpmURYtt4u/p0SIIDhXgxAwV0YHEYZCBnljxgJZ14wqkIjRKASohICHxwKqVy5fZwJpNzsr0HZvZxoFeFuvuIcoAFvtd0vdeI4HCIu3oInTInfoWI/v51VmgI2MZ3fZiHf02Ar62I5kuFbuOIT8yHjIh1R6CJAJ2ZAtMnn22FN6dwoBuVMVeY8SqS0RmZHmAY8cqUwU+ZG64JEi2VYAWZJzZJAoWQfyxE6c0JL0tJJwwE+iQJMyGQcHlVCWkJM3GQcT5Sid8JM9GQcddQpFOZRvYFKnoJRI+QYsdQpP2ZRtIFOnQJVS2Qb/NyUKWXmVXNmVXumVDvkIUhCWKfKVNJIF1FJ3ZnlifzGWyreW5WYFafmWcOmMrOGWa1eXGyeXeGl6euleZCdJnPaXcdlHHTOXjmdXhFmYimACxyN6LCBYBoOY8FWM0khXiwl5Akd57dJ4oWeXS3AeADM1Idh61piZmlk+7PU0USh1nraDDJM0AcgPiHCYfekCH7Nh61VFcwNA9xMO7CcT7rCPqJmHmABeQ0YPj7k8MuF0gLUA7TYCl0GFoKkEookaIXGJyXkW7bcTw8ASR5Q5z1icprCZP1hqnSkNx/AArYiF0mM2JAafk3mbLbA2MpgXe/GFF4iJWCMWOoiR5Jlr/9nwbqVmYinYE0NBZQDwaxJ0GRBkm42Em3j4PgRKAi9EnceQQZAxnqhZnuUjczs4fVloGlIHM0m0EVvjcAIxnxFanxO6igGhjAPBjKPRRMQZoDhQR2PVR3T5lxSyMLQVeYIZVsVpnHzZooOJo1dAmUKYmRSyjQmomFigo2MIl+uRWaS1nDfKo+oBmYyXOJYHmIv5pFkapgDKpVdApdVZl6qAXD4xNfvQHc+Xe8R3HE/TfLgXDsVXpZg5AuzVDTpzYDZGGXpaGG7aXgumRr0XNMYhPE/Ua2JKmKoAYioDWw3Qf/gmhpGmnOl5f2chRK3oiniEAk5GOF+2dI4WDJQapP+k4W2ag6kvFqSiOqZjk2rwUxOyUxU2eJ5jpw2KFjStFqmheS+kZmmp6Bs5SGdn8Xa1BhGShmiSphZww0JraqUmcGyVig+w2oZ3WGKIlm0nF2GFiUhIUzvwVodqhqyDhq0rQ2QBN4lvd23KkxnjeJHQ0aZjRJoFMRBGFw4wKmEQ4WjHCKyhyqQWx4rGqkPqihUVJ5160XQHu0XE0DkKMW3EU61rSTEGm6Qdipb0ybFO6rFISqRFqrEfS7JKeqRDilYlK7IrC5EpG5ho2qRjSpZEtS02WyxFykg7q0s967M/qyb2GrT/SLTgZLTUhLRFMrRK26NNG0pPOy45O7VUW7X/VYseTHuyKikeWTuyW6sdXfuyIcklEhK2bMm1Zct3WJu2y7S2udS2ZPu28ei2vKS20QGTcKIfeIsKe6saNukff3sKgdsXPHkghYsKh+sXQnkgi4sKjasaR3kgkYsKk+sXTHkgl4sKmasaUXkgnYsKn+sXVnkgo4sKpcu5ErKVoBu1rNu6imK1YekLsCuWRjK7CTl6r+SXMEt6zzJ3vqS7gYS7ldAjWQtJxiu8s8S7v0uzuxt47KhHq8S8wQu9uUu9wwu8W0C8nKC9rOGlLlCJ/YiyOeqcULqlzotH3tsC4Gu+O3oWI2qdizcyKnB+anpYe+en//laJTpaNkCl3Huc/xXYK/Ebc2YqnZxXv/WBvD/USl6KwAZ8mWcqvjmYefkLjjXgvwrsmejSwAVMYuU7rkJqaOMnEASxqMehG4NRfH/amwygfUljMCm8EhkqRSfMN4FxAPTbaP1ghAXGp0taAs96sFhDEsWmL8UgfrV3EF4TAPnye++ww3eKsQlYbQGhqCt3FjgTwxGxwmjjwtHTMTFcmndawwLDEQesw8WnxT4cvpjoEj0Br5gANloGqZvKncmWgQwQnQtMrUlxPGBTxtKTw586fsy3oHQ8q837rPe3ZZGGDA2wQAU4gtIWgt7xf0RsQwCDwdaLaOPHE2sYr3IcEYzsp/SQggWBx3psMP98PDJMDDI3LMiYjBpzvMbsO4XLE8RlkahZyKv6GWcn7BZhVoGsLA2AjMNnTLC6HMDHqxQ6yIX0Ezve8Doe0S7uqYXAMD7gw5q+c8ToCcKlpYhmIRf/mcuKMD3F2stRKJ/voqx9nJ6ubMbtjMzlLMVsbMvN6arqwm/daomJCGwds8oxZ6ADRHTGHM9lwTv8RstUYAqKTIIF4RMhsUUB5xmZU0HIIIn8838iPGFiJ6wlMzEixxlxWDz6bK546BP9/KAW6kEBzcmxxzSwzM2FbDvI64TEEbHFE8Ol1hwyugAvLHErCsZpVJohqi6xIQ4FTTAHjRo6rdB3qRTxh3vIBhn/ApBFwzg9lrk2EWGfBBui9Gy+Ni19OG3UP3OwMZpGA/HTZaOnQu04eMEVzbcWeprUBNzVTf3VHJq8EjwDCbCOWqe81eK7gQ2yLCvYGmnYHYK9WvC/17vJz3u/hB3Cet2+jx3ZPDBr5/vNf5S+i63AMRBwM7fEabagDHMEDnyW0lswGOYUs2Z47CvZNLAwOqjB9Ulasj0CvUk/hxHAAtnb2shrKGdi3IMy+0sEpz2QkA0Drq1AC/zRjj0Dg1OitK2NWZoyBLFls6E1syFGCarZgN0C+yJppSh0AASffYg9x8A035c1W5OLeFaoDBDFcde8KGDCOl1fS52uqz3CVqxG/2f73S1ANvK5w+hHN2qsX9hX2tlQNqIcOUDcAMHq21FqcwckRgTBAA+xZ7smjRTGOJPzgZ5TyYVBEjGBDcf933s9WCONrErmGhOGqp38xiDewYjs3SJjOr0hRBLbfrP8ZBPYMp8zGUChELw1X9Uo4WwMA3PhdETmy+N4PJc4F93zPQigzV/hgDSO4oWdAri839/h4t3sG8Qh5cgN4Czg5EHz4/OTGbF2Ej+HEulDAiHxAKxZwUlu4zDQW4442tsADiXU0Wph0T0WpACh0d/hgB094dmrjSu+2gRBbQYW5vtNHB8YwZQtWfXmrWVBbpaY0PE2PQXo57/hANxz4ZEzYv+i/npmTjmQSja96XbUNwKvk1hBRy8tp9VcVGmDBtdILrMp8KiRQbFe8Qk1kwCSXolm03JlntkvEOtOI7HoQAA93dSfvot+mkWvc3MrQTYO5NyILQQnLqXJveXMPtjlbtxZLu6WvejP3burnpIpPr3fzo3tvrzjTt+wrSzzDu/k3u/57u7nntip3dn1bu6XDvD+Lu/vDpL9YrvIJ7sOD2G1G/FDxR5yawtmu+8+Zbdoe/Ekea9sO7dxW7dw2/EkL/Im7yAZn8Ajr/IcD7Yhj/F0eyB9e5ItfyCD+0kzb7h9IvM37x+P+7XZsfJKULk6//P+sblHn/IKErpjy/QIcrr/Tw/zEaK6Uz/0rrvw2pT1/64aRA8iX9/1t0TxL7KQVI8iE6nYfZHxWWX2WD9KaT/wa3/1Fl+Qb4/2krfufsH2cX/vq8H3eR/vXk/35CENEf7BGu+yZ39KjOU0oUqu74j0jW0kho+ePLMcREObCp74bSn5k134jt8NbtfHYSQ9xNZhni33UAH4lO+IDkMwGuHLzin2gr/3hJ8DKdc5wfD6da0RiZj6fj/4cP8DSxyKvO9zOhZxwK/3cz/8JpmPOx+9z++0tu/8HRn5UF+905+X2T/5PxDuQjP7Bx/81Y/3JHBzlZUM0mAwmB3gxR2Zm7DcNU7+zW/+whBbv6E36t8w/+kOAoAoGKJ5oiYRpK3IurE803UM27m+872v437CIRGIEiROiodgIAgcnoEEwxC4HgIEQOMaEAC0gkJhugBICwxRYXtIXB1oJ3RwHSzKgTbrfW2gBBUN8ggSHiImFioyNtYIGgycFCCMbTEErEWGbXGOHQA4eRYcLCggMCisOQA+JHEBphJYohUsLCQIrIjsNki2GDo2BgsXGwsRHysTCSIpMf0iFPBOa70QGJSEgon9UiJ47XGBAVCKDFT+Zo8Y7ALsmgMvD8/X288k3+vjo2RpD9hqIgLTGl9hHlwbc6sAt1neUKkysSDAGVgAMDkcYSuPLorvWBiUt29QvpEmGf+VPHnSEAE4U9YIHHGFCgArULTgCqCAoaeHaLwYEABIhJ8AcmKGunMLDh8ARYeaSKmS39Sq9KxiDTM1AUJhUrMGAiuW2dipX8saQUvjrFq1bNsqegv3xly6de+GxTtPrt6ofU/w/WsysOBFU5GiLKxVMVzCjG04JiLKBOK4iiM/VoY5s12VlRNtHswZbejReRvZDIDgnZ4mYKQE+HVVcGnTlm0fqi3DQBIF5LZhnOP1Mm6wum0fP6LgCikoJpxIGyE7ceHkxcleL2KdaACEDqb5fi6AIJfpt2lnt7o98/qke6YRWP5FlM0E5kETT29W/5D2WP0bAyB/jwz4g4D7VVf/oGgKGsbfgY48yGAKEepF4UgW4ifhPRjWxeGG+WlYj4eNFTgiSSHaY6JbJYKIomYuPhKOjDPSWKONN+KYo44ytghjMSr66AKQeA2pX5FBAobkDkdmx6SSTrYFJW5S+khlWVaOhiWKWhqn5I9eqgcmZGLORuaFZlKFZm5qnsmmSG5qB+eHciZJZ3927oXnC3oayOcLOwIaqKA3TulnD1yKhaiQhRq6pKGKvpllo476CemEjE46ZqXoIZdpDpaG+Reomnq61qOcmjZqX6qqxOpiqZZK4KaiYhprZ3q66qoMuqolAQV7AkCBBHD6CqywcBW72LGFJQvDsrYCUEEAEEwQ/8AEEARQAZzSUmstttq2xW2112armLjelgutCBvIuAGd7Ibj7lzweiGvYvReYa+6FMj4q5z8huMvXAB7IXBhBF9hsLrYXgEBngxPixfEDmc2sbooVHvFBHhmbC1eHW+cGcgXo2BBABbwaTLKeqlsWsskn8BBABzwKTPNetlsWs4wmyBBAMPq6TPQeAltWtE8m3CBoUr/xbRpTiMdtdRTU111kINinbXWgF64tdc05vY1oSSJXbbX/zE44pC1bVcar0zy2uCcK61JXZwJhsriPmvXfR52qCKotz58E9J24T3SraDagd/t9514VxU3pYMz/neGjdOa94CLH4MUCadhzv/DZJE+nhsB7gSIdgoPBKDNDKOf8BkissteJ+UnrGBLTff9gFQboFv+ESi7b9MC7MAjk4I0M2V0vJCns+D8DtLbXvk5AyhQkaR7o5B7CZsMEhMB0yCfPO7OER8D9a8Gz/pqNf22PmDQv6g5dwyYs8IKlXghiShTXGE1AhmAS0pQFDkgQD4CAIcI1gEbBozvCgIYYAGFE8EvlG8ZgtifFjYRH50IkA7gKIMCumAUAIDjCiWISVAudbjzDW8TooCN/yqYwUOhoAFyiB06vIAAJwAEfObQwi7+55LVFGWFekiASxDihCzMRHvAilwKnCGQFYABEwgZIDdeM40BSmIFB2j/QCwUQIAB7BCFMMhGcEQQHumEIoxQEMgbXXg7FdShAJsITwIXQAv9lUMSDDQBOPwoiYlIcYqhW0E4/Dee7ghnAHIcnl9OdAJ0HMGR50gAKIS4GiJGr4u14IIBVfGJLIBBhr/JQlcqSUUU6AEL7ohOJBuCwi9qMgsHiAc6WhIbBgwyG7R0CvpqScwoDECXi+IeDDERG2WGAZm8gIEodoEAl8xREkIhXemmGUNH0pKLx7yh3EiZyeKh05OcKKItoxNL1cTEGlxkgB0CSM65TbMiaHQHeQzyvy1ER5y6JONFrCGCBrQDCm8wQBsBUEeBZtOhv7nnl2BYk9hIFA3ZEx81/8EADzmwTppc4ab58PhN4GSiPMWDpivbh0H4DXCHkxnDO06xzlBy4pbmpMwv5OlI3gBgIu9raatQYACoJBB1NimAJq0R0Fwq1CVyqKcakqKABKzQCxBUIESl+cGXElVE3XNOFsK4HJty9BweZUEaspmKZVrSpA3U5FKhSklFdnME8hlARlL4Q3Lscgo2BWXxnDqNokQ0p1z8YBmGitfE8QChq2qTMhyQRoqmZQeSTVPwKqS6HNSTk5NlJmRD97qZ3BWunSXSZzdH2QXF9XKrvQvc0vba2+a1b7PtUGs12IkU4XYGqEME28qUW9bajxHDzakM5FdSfNZguS+MLXGnm/+5V4rot2IlrQ2kS93jfrdPkLOeD1LYOqe4pAG7QCwBglkC1ehRFHqoqmnzpIP1ShUAuTiBDienHbOBjWwAHnCgekuEQobkIyrlhHvDMBTYFeCyzwXufUFSRgKwIhQliEhmt2s1uw3hml7Y5VDh8T4tNNigTlhAalwH3vrlwMTnQMADToGEGpdTgx827g8iDICQJrgXsQDlARbKXOh4BKvh1XGFLRIcBSggCiXMMYx3XN0itLXI6d0F/gC4BTtc9b2deKJL9LjkKke3D/lVqVCpfAzJVcm23A3um63sOCPRmcJ6trN1HZRnDwOaz/Vt0p/tu2dB77Y4nCutoRGd6Fr/HXrOTHb0ozsl6TsGmtI+IDCnO921TmMN05oedUVHS+pTQwhwqF61bpHL6lefOUqwnnWlr0TrW29a1bjeNWddzetf38rXwB529YRNbF5TQANKY8EFNKCwsSR72QBo9rOPPesIBADb2q6LtrOdbWv/umMaq4u4PQbuXVfAZFewALjgkm4vsPvcvMaAFzCAF3pfwd7y3rXPrjC0ufT7Z/vmNbYoJrGIDXzXGQhABvqy8IYnfNcG18vEI27xi2M84xpPFKgHfIOOA3jjW1qRahMl8hBpKRkpP7mGVl7yLrFczrZ+eVbgHPNPkZykBr45oUkTbJjz3M8+p/nOgw7pHcCm/wEHqCcGGeCSBDjWv5h1wdKZgwDzeuGWzMu10fHsg++sYelnLMEKnL7Dz3Fd5zVg4hmesAZ0uq+BE+1w1xX9gyWgYADaOIV9Bs0+HWBCe/1F5+BfXHf2GCi1elfjAapwh7fjkOg0GGQD/0EOTNb68LrOgU0v6UOjviLyap9B4E0w+Mls1vCaR1wOvuMGvi7eBFCfq3hHP4MCJKDtKYX7S1so+tXD6gctXrqLHeAF0abdjjyo+h6GOjoB7FW7dAc+4odu+6JSP/gzvz6js88Yl3Mftt5/DPiVb/LxV78F3k0K70B8w/Xbof13Rv91U+DdGp/BoPO7strvnz3m7l+r0f9f/Y1VC9QOj4UVHhmg/LnfAJqaCsQSeqkQFKmGNZiQAuSUCeXeCsBBRDyQNaxAIqmc/UVgElEgOGzBBWZgFHGgTsCEVoGgRxSbA3oWCoRHL5QSA8TTLJBCVMxC7ulXR3wZQ+nfOqzDDRnCDYJEDu7gJ/ggEpxBLgCS3jWUEbrYY9EgbfWDc8BDOKTDNRwhGIZDQlXeMNUUSyUgXilTF/rQDoYhJ6RG67iDMJEPL0RZMaVhFpKIDb7GEvJQQvRgQgDhNFVeQ4VCAkDFDIZVeDzBTsHRKFCSGAyigtUEEWoXASViHuphzhHSTKjZiO2ge2CgBfrQHGbVFawB60gfFj6BVgrBgQRiQSjW0yimYCmu0SmmlCqG3ybW3GG03wh6xi/yYg2axAHgndoBiTG20tQNY3L1ouRhVzPu4faZH9BJo6xZXzU+4zViIzUy46VxozWe3y6CYzj+B8iZzceho9iYYzu64zvCYzzK4zzSYz3a4z3iYz7q4z7yYz/64z/aWQgAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ASA: argininosuccinic aciduria; CPS: carbamyl phosphate synthetase; OTC: ormithine transcarbamylase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23950=[""].join("\n");
var outline_f23_24_23950=null;
var title_f23_24_23951="Long arm splints";
var content_f23_24_23951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long arm splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 268px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long (or posterior) arm splint is used for elbow and forearm injuries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_24_23951=[""].join("\n");
var outline_f23_24_23951=null;
      